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 Abstract 
An increasing prevalence of metabolic syndrome and obesity has been linked to the rise 
in transplant indication for cryptogenic cirrhosis and nonalcoholic fatty liver disease 
(NAFLD), creating a growing challenge to public health. NAFLD liver transplant (LT) 
candidates are listed with low priority, and their waiting mortality is high. The impact of 
community/geographic factors on donor risk models is unknown. The purpose of this 
study was to develop a parsimonious donor risk-adjusted model tailored to NAFLD 
recipients by assessing the impact of donor, recipient, transplant, and external factors on 
graft survival. The theoretical framework was the social ecological model. Secondary 
data were collected from 3,165 consecutive recipients from the Scientific Registry of 
Transplant Recipients and Community Health Scores, a proxy of community health 
disparities derived from the Robert Wood Johnson Foundation’s community health 
rankings. Data were examined using univariate and multivariate analyses. The donor risk-
adjusted model was developed using donor-only factors and supplemented with recipient 
and transplant factors, classifying donors as low, medium, and high risk. NAFLD 
residents in high-risk counties had increased likelihood of liver graft failure. Findings 
may be used to allocate high-risk donors to a subset of NAFLD with excellent outcomes, 
increasing the donor pool and decreasing mortality on the wait list.   
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Chapter 1: Introduction to the Study  
An increasing prevalence of metabolic syndrome and obesity has been linked to 
the rise in transplant indication for cryptogenic cirrhosis (CC) and nonalcoholic fatty liver 
disease (NAFLD) creating a growing challenge to public health (Fazel, Koenig, Sayiner, 
Goodman, & Younossi, 2016; Pais et al., 2016). Many NAFLD patients who develop 
cirrhosis or hepatocellular carcinoma (HCC) and CC patients are in need of a liver 
transplant (LT). Therefore, NAFLD-related end-stage liver disease including 
nonalcoholic steatohepatitis (NASH) cirrhosis will soon become a leading indication for 
LT (Mikolasevic et al., 2018). 
CC is a chronic liver disease of unknown etiology, and most CC cases are 
attributed to advanced NASH cirrhosis (Caldwell & Marchesini, 2018). The current liver 
allocation system based on the model for end-stage liver disease (MELD) does not 
accurately capture the risk of wait-list mortality of NAFLD/CC patients (Bambha & 
Biggins, 2008; Patel, Berg, & Moylan, 2016). Patients with NAFLD/CC and low MELD 
scores have slower disease progression and low priority on the LT wait list than patients 
listed for other end-stage liver diseases (Kwong, Lai, Dodge, & Roberts, 2015). Although 
patients with NAFLD/CC cirrhosis have short-term morbidity and mortality, their mid- 
and long-term posttransplant outcomes are favorable, similar to other etiologies, 
suggesting that an LT can be an excellent treatment option for NAFLD/CC (Patel et al., 
2016). 
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Organ shortage is a major problem that accounts for remarkable wait-list 
mortality (Elwir & Lake, 2016). As a result, many NAFLD/CC patients, who often have 
many comorbidities, are likely to drop out from the wait list or die while waiting for an 
LT at a higher rate compared to other etiologies (O’Leary, Landaverde, Jennings, 
Goldstein, & Davis, 2011; Pais et al., 2016). 
Transplant centers are increasing the utilization of marginal deceased donors 
including older donors, extended criteria donors, and donors after cardiac death to expand 
the donor pool (Akkina et al., 2012; Diwan, Paterno, & Shah, 2015). The main purpose of 
this study was to create and validate a novel model for donor quality score tailored to 
NAFLD/CC recipients of LT, or the donor quality-nonalcoholic fatty liver disease (DQ-
NAFLD) model, using data from the Scientific Research Transplant Registry (SRTR) as 
well as county-level data to incorporate the community health indicators (County Health 
Rankings & Roadmaps, 2018). The DQ-NAFLD model could lead to positive social 
change if used as a tool to quantify donor quality and assist the decision-making during 
an organ offer. The use of DQ-NAFLD score could be clinically relevant if used in 
donor-recipient matching to identify the highest DQ-NAFLD scores associated with 
acceptable outcomes for subsets of NAFLD/CC patients. The donor pool would increase, 
and more suboptimal donors would be allocated to NAFLD/CC patients on the wait list 
for LTs who have lower priority. Otherwise, there is a good possibility that NAFLD/CC 
patients could die while on the wait list because no liver will be offered to them.  
In Chapter 1, I provide a brief review of the study background, the statement of 
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the problem, the purpose of the study, and the research questions. This chapter also 
provides a brief introduction to the socioecological theoretical framework, the definition 
of the study variables, the scope of the study, and the assumptions and limitations. 
Finally, I describe the significance of this study and its potential contributions in 
matching the right donors, including marginal donors, to NAFLD/CC recipients, and in 
reducing the percentage of organs wasted that could be allocated to the appropriate 
NAFLD/CC recipients with excellent outcomes.  
Background 
Liver transplant surgery has become a widely accepted, curative, and life-saving 
treatment for people with end-stage liver disease. Currently in the United States, about 
14,000 patients are waiting for a liver donation, but only about 7,500 LTs are performed 
annually (United Network for Organ Sharing [UNOS], 2018). Between 2015 and 2016, 
LTs increased by 10.0%. Nevertheless, the proportion of liver recovered but not 
transplanted has reached 9.4% in 2014 (Kim et al., 2016). The disparity between liver-
organ supply and demand has resulted in a remarkable organ shortage and a large number 
of potentially preventable deaths, which is a public health crisis (UNOS, 2018). 
Strategies to improve organ-recipient matching are needed (Flores & Asrani, 2017).  
The U.S. Department of Health and Human Services Organ Procurement and 
Transplantation Network (OPTN) Final Rule contains the regulatory requirements and 
ethical principles for organ allocation. The organ allocation system must be fair and just 
and should not put any member of society in a disadvantageous position for having 
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access to available organs (UNOS, 2018). Liver allocation requires an appropriate 
balance between medical urgency and efficiency (UNOS, 2018).  
Liver allocation policies have shifted from a wait-time designation to addressing 
more urgent cases based on the calculated MELD score (Merion et al., 2005). 
Nevertheless, the MELD score designed to predict short-term wait-list mortality is a 
weak predictor of posttransplant survival, and it is insufficient to optimize the value of 
each donor’s liver (Asrani & Kim, 2011). In recent years, grounded in the principle of 
utilitarianism, investigators have developed organ allocation models seeking to maximize 
survival benefit of the whole population or aiming at saving more years of life, rather 
than more lives (Briceño, Ciria, & de la Mata, 2013). Steps taken in this direction include 
the development of the first donor risk index (Feng et al., 2006) and subsequent donor 
risk models, which seek to predict the survival of the donated liver after transplantation, 
enabling matching between the expected posttransplant life span of the liver with that of 
the recipient (Porrett, ter Horst, & Shaked, 2012; Weiss et al., 2012).  
Several models have been proposed using donor factors, recipient factors, and 
intraoperative factors to predict posttransplant survival and facilitate transplant decision-
making (Flores & Asrani, 2017). However, almost all proposed models are not widely 
used in clinical practice because they require inputs not readily available at the time of 
the evaluation of an organ offer or because they are not reliable metrics of donor 
characteristics that fail to consider essential predictors or include irrelevant factors (Blok 
et al., 2012; Braat et al., 2012; Campos-Varela, Dodge, Stock, & Terrault, 2016; 
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Dutkowski et al., 2011; Halldorson, Bakthavatsalam, Fix, Reyes, & Perkins, 2009; Hoyer 
et al., 2015; Mataya, Aronsohn, Thistlethwaite, & Friedman Ross, 2014; Northup et al., 
2015; Rana et al., 2008). Additionally, some of the risk models do not reflect current 
clinical practice as they were developed using data before the implementation of the 
MELD score allocation system.  
Clinical studies often focus on clinical and biological factors ignoring the 
importance of community conditions in risk-adjusted models. Epidemiologic factors such 
as socioeconomic status; access to quality health care; ecological, behavioral, and 
psychosocial factors; and geographic variations create disparities in posttransplant 
outcomes and prevent the current allocation systems from making organs available to the 
highest number of people (Northup et al., 2015). Understanding the epidemiologic factors 
that lead to inequalities in the liver allocation and posttransplant outcomes are of 
paramount public health importance. None of the donor risk models proposed are tailored 
to the NAFLD/CC population, and none of them considered unmeasured characteristics 
that can impact posttransplant liver allograft survival, including environmental, 
behavioral, and psychosocial aspects of the communities where transplant recipients 
reside (Nandi, Glymour, & Subramanian, 2014). Chapter 2 provides a more extensive 
review of the literature related to the NAFLD/CC patients, the current allocation system, 
and how a quantified donor quality metric can help in decision-making. This study 
complemented existing work and may assist researchers with donor risk models tailored 
to NAFLD/CC patients useful in organ allocation decision-making.  
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Statement of the Problem 
Due to the rise in obesity and diabetes mellitus type 2, NAFLD patients listed for 
LT are expected to increase steadily. Nevertheless, the MELD allocation score fails to 
capture the actual risk of death of NAFLD candidates. As a result, many of them receive 
low priority and continue to die while waiting for an LT (Asrani & O’Leary, 2015). 
Organ shortage leads to the utilization of nonoptimal donors, and donor risk models 
provide a metric to quantify donor quality and help allocate nonoptimal donors to 
appropriate recipients. On the other hand, many organs are discarded while some of them 
can be utilized with excellent results if adequately selected and matched to the 
appropriate LT candidates. Donor risk models provide the first step to match marginal 
donors to the appropriate recipients. The creation and validation of a novel model for 
donor quality score, the DQ- NAFLD, tailored to NAFLD/CC recipients of LT can fill a 
gap in the current knowledge base and be a step forward in the optimal utilization of a 
scarce resource to achieve the ultimate goal of improving liver graft survival. None of the 
previously proposed liver donor risk models has considered the impact of community risk 
factors on the performance of donor risk models (Nandi et al., 2014).  
Purpose of Study 
The primary goals of this quantitative study were to develop a parsimonious risk-
adjusted model, use this model to derive a donor quality score for NAFLD/CC LT 
recipients that will predict graft failure at 1-year post LT, and explore its relationship 
with transplant and recipient characteristics and with geographic and county health risk 
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factors. I used a quantitative method and secondary data. To be useful in clinical practice, 
the DQ-NAFLD will only include donor and recipient variables known at the time of the 
organ offer and will be built with data in the post-MELD era (see Flores & Asrani, 2017). 
An extended version of the model that includes transplant factors not available at the time 
of offer but estimable, such as cold ischemia time, will be useful for donor-recipient 
matching.  
Recipient characteristics included age, gender, biological MELD score, and body 
mass index (BMI). Donor characteristics consisted of donor age, gender, height, weight, 
BMI, cause of death, hypertension, diabetes, donor after circulatory death (DCD), 
hepatitis C virus (HCV) status, Hepatitis B surface antibody (HBsAb) status, Hepatitis B 
surface antigen (HBsAg) status, modification of diet in renal disease (MDRD) clearance, 
and donor hypernatremia. Transplant variables included ABO compatibility, size 
compatibility, and cold ischemia time. Most importantly, the study addressed distance 
from the transplant center, used to identify recipients in remote communities and in 
geographic isolation from transplant centers, and underlying community health factors 
from the location of LT recipients that are significantly associated with posttransplant 
outcomes and can bias the performance of the novel DQ- NAFLD (see Galea, Tracy, 
Hoggatt, DiMaggio, & Karpati, 2011). 
By finding a donor quality metric for NAFLD/CC recipients, this model will 
contribute to identifying NAFLD/CC LT candidates who may die while on the wait list or 
may be removed because they are too sick to be transplanted. Both groups would benefit 
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from an LT when matched appropriately. By optimizing survival benefit of NAFLD/CC 
LT candidates on the wait list, this model will attempt to increase the organ pool for 
NAFLD/CC patients, reduce wait-list mortality, improve survival outcomes, and meet the 
dual goal of fair allocation and optimum efficiency (Kamath et al., 2001). This study had 
four objectives: 
1. to develop a donor risk model tailored to NASH/CC LT recipients with 
intrinsic donor factors to improve risk stratification for liver organs;  
2. to develop an extended donor risk model tailored to NASH/CC LT recipients 
with donor, recipient, and transplant factors;  
3. to examine the modifying effect of distance from center and its interaction 
with donor risk score on liver graft failure; and 
4. to explore the modifying effect of community risk factors and their interaction 
with donor risk on liver graft failure. 
Research Questions and Hypotheses 
 The variables used to formulate the research questions and hypotheses are defined 
and operationalized in the section Study Variables and Operational Definitions of 
Chapter 3 and in Appendix A. This retrospective cohort study was conducted to answer 
the following research questions through testing of corresponding hypotheses:  
Research Question 1 
What are the relationships between posttransplant graft survival among 
NAFLD/CC recipients and a number of donor characteristics (age, gender, height, 
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weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death, 
HCV status, HBsAb status, HBsAg status, MDRD, and hypernatremia)? 
𝐻01: There is no association between posttransplant graft survival among 
NAFLD/CC recipients and a number of donor characteristics (age, gender, height, 
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death, 
HCV status, HBsAb status, HBsAg status, MDRD, and hypernatremia). 
𝐻𝑎1: There is an association between posttransplant graft survival among 
NAFLD/CC recipients and a number of donor characteristics (age, gender, height, 
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death, 
HCV status, HBsAb status, HBsAg status, MDRD, and hypernatremia). 
Research Question 2 
What are the relationships between posttransplant graft survival among 
NAFLD/CC recipients and transplant factors (cold ischemia time, ABO matching, and 
size matching)?  
𝐻02: There is no association between posttransplant graft survival among 
NAFLD/CC recipients and a number of transplant factors (cold ischemia time, ABO 
matching, and size matching). 
𝐻𝑎2: There is an association between posttransplant graft survival among 
NAFLD/CC recipients and transplant factors (cold ischemia time, ABO matching, and 
size matching). 
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Research Question 3 
What are the relationships between posttransplant graft survival among 
NAFLD/CC recipients and a number of donor factors (age, gender, height, weight, BMI, 
the cause of death, hypertension, diabetes, donor after circulatory death, HCV status, 
HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors (cold 
ischemia time, ABO matching, size matching) after adjusting for characteristics of 
recipients of LT (age, gender, BMI, biological MELD)?  
𝐻03: There is no association between posttransplant graft survival among 
NAFLD/CC recipients and a number of donor factors (age, gender, height, weight, BMI, 
the cause of death, hypertension, diabetes, donor after circulatory death, HCV status, 
HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors (cold 
ischemia time, ABO matching, size matching) after adjusting for characteristics of 
recipients of LT (age, gender, BMI, biological MELD). 
𝐻𝑎3: There is an association between posttransplant graft survival among 
NAFLD/CC recipients and a number of donor factors (age, gender, height, weight, BMI, 
the cause of death, hypertension, diabetes, donor after circulatory death, HCV status, 
HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors (cold 
ischemia time, ABO matching, size matching) after adjusting for characteristics of 
recipients of LT (age, gender, BMI, biological MELD). 
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Research Question 4 
What are the relationships between posttransplant graft survival among 
NAFLD/CC recipients and the health risk status of the county where recipients reside, as 
measured by the community health score (CHS)? 
𝐻04: There is no association between posttransplant graft survival among 
NAFLD/CC recipients and the health risk status of the county where recipient resides, as 
measured by the CHS. 
𝐻𝑎4: There is an association between posttransplant graft survival among 
NAFLD/CC recipients and the health risk status of the county where recipient resides, as 
measured by the CHS. 
Research Question 5 
What are the relationships between posttransplant graft survival among 
NAFLD/CC recipients and the distance from transplant center? 
𝐻05: There is no association between posttransplant graft survival among 
NAFLD/CC recipients and distance from center. 
𝐻𝑎5: There is an association between posttransplant graft survival among 
NAFLD/CC recipients and distance from transplant center. 
Research Question 6 
What are the relationships between posttransplant graft survival among 
NAFLD/CC recipients, DQ-NAFLD risk score, and external community factors (CHS 
and distance from the transplant center)? 
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𝐻06: There is no association between posttransplant graft survival among 
NASH/CC recipients, DQ-NAFLD risk score, and external community factors (CHS and 
distance from the transplant center). 
𝐻𝑎6: There is an association between posttransplant graft survival among 
NAFLD/CC recipients, DQ-NAFLD risk score, and external community factors (CHS 
and distance from the transplant center). 
Theoretical Framework for the Study 
Social-ecological theory recognizes that individuals are embedded in their social 
structure that interacts with individual and environmental factors. Based on 
Bronfenbrenner’s (1977) seminal work, McLeroy, Bibeau, Steckler, and Glanz (1988) 
proposed a five-level social-ecological system and examined the complex interplay 
between public policy and intrapersonal, interpersonal, institutional, and community 
factors. From this theory, it follows that there are complicated social determinants that 
increase or decrease the risk of poor posttransplant outcomes (Braveman & Gottlieb, 
2014). It is necessary to act on multiple levels to improve patient and graft survival after 
LT.  
The social-ecological model was the most appropriate framework for this study. 
The individual domain includes patient-level and biological factors. The family and 
social network levels include family members who are involved in supporting patients 
throughout their transplant journey. Health care system level comprises the clinical 
pathway to an LT, such as donor match, the transplant surgery, and quality of health care 
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provided. The community domain includes the contextual environment or the nature of 
the community where patients reside, the wait list, and organ donation policies. The 
social-ecological model provided the guiding framework for the literature review 
presented in Chapter 2. 
Nature of the Study 
The nature of the study was quantitative with secondary data. A retrospective 
cohort of consecutive NAFLD/CC adult recipients of LT who met the inclusion criteria 
was analyzed. To identify quantitative donor characteristics predictive of liver-graft 
survival after LT; the risk model associated; and the relationships with recipient, 
transplant, geographic, and community health indicators, Cox’s proportional hazard (PH) 
models as well as random survival forests, a machine learning approach appropriate to 
analyze time-to-event outcomes, were considered. This quantitative study led to the 
development of a DQ- NAFLD model that quantified the donor quality associated with 
an LT for NAFLD/CC patients.  
Definitions 
The conceptual definitions of specific terms used in this study are included in this 
section. Some of these concepts have been further defined in Chapter 2.  
 Cold ischemic time (CIT): Cold ischemic time is the amount of time, usually 
about 12–18 hours, after a donor’s liver is harvested for transplantation. CIT is defined as 
the time from cross clamping of the donor liver to removal from cold storage solution. 
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Reducing CIT improves the quality of the liver allograft. CIT can be lowered by lowering 
the logistical and transportation time (Pan et al., 2018).  
Community Health Score (CHS): Community Health Score is a composite health 
index that incorporates county-level environmental and behavioral conditions, the 
prevalence of comorbidities, and quality of health care (a surrogate of sociodemographic 
characteristics). The Study Variables and Operational Definition section in Chapter 3 and 
Appendix A provide more details about the county health indicators used in the CHS.  
Cryptogenic cirrhosis: Chronic liver disease of unknown etiology, often attributed 
to NASH cirrhosis (Caldwell & Marchesini, 2018). 
Death drain donor (DBD): Donation after brain death (DBD) represents the 
majority of deceased donors and is associated with excellent liver transplant outcomes. 
Neurological brain death is the standard criteria for organ donation that takes place after 
the irreversible loss of clinical function occurs. 
Donation after cardiac death (DCD): Non–heart-beating organ donation takes 
place after circulatory death of the donor. DCD livers are usually procured after 
withdrawal of life support and have a period of absence of blood flow before cold 
preservation, as opposed to heart beating donors who maintain organ perfusion until 
initiation of cold preservation (OPTN, 2018). Therefore, DCD donors are more 
susceptible to further ischemic injury and increased risk of graft failure than DBD donors 
(Halldorson et al., 2015).  
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Donor risk index (DRI): Donor risk index is a measurement of the donor liver 
quality developed from a predictive model of donor factors including donor age, race, 
donation after cardiac death, donor high, and use of split/partial grafts (Feng et al., 2006).  
Distance from transplant center: The distance between recipient primary 
residence zip code and transplant center zip code.  
 Expanded criteria donor (ECD): Any deceased donor age 70 years or above, or 
age 60 years with significant medical history, or a donor with a history of hepatitis B or 
hepatitis C. The patient must give informed consent to accept the liver of an ECD donor 
(Rodrigue, Hanto, & Curry, 2011). 
 Modification of diet in renal disease (MDRD): Equation that utilizes four 
variables, including age, gender, ethnicity, and serum creatinine, to estimate glomerular 
filtration rate (Levey et al., 1999).  
Model for end-stage liver disease (MELD) score: Model for end-stage liver 
disease score is used to quantify the severity of end-stage liver disease for LT and to 
prioritize liver allocation. The MELD score is a predictor of short-term wait-list mortality 
(Bernardi, Gitto, & Biselli, 2011).  
Nonalcoholic fatty liver disease (NAFLD): NAFLD is a multisystem disease 
characterized by excess fat stored in the liver, primarily associated with other comorbid 
conditions such as obesity, diabetes mellitus, cardiovascular disease, hyperlipidemia, 
metabolic syndrome, and chronic kidney disease (Mikolasevic et al., 2018). In this study, 
patients with progressive NAFLD in need of a liver transplant were considered. 
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Nonalcoholic steatohepatitis (NASH): NASH is an advanced status of NAFLD to 
steatohepatitis, a progressive fibrotic liver disease indicating liver transplant is necessary 
(Argo & Caldwell, 2009).  
Organ procurement organization (OPO): Organ procurement organization is an 
organization authorized by the Centers for Medicare and Medicaid Services (CMS) to 
procure organs for transplantation. For each OPO, CMS defines a geographic 
procurement territory within which the OPO concentrates its procurement efforts. No 
OPO is limited to or granted exclusive right to procure organs in its territory (OPTN, 
2018).  
Organ procurement and transplantation network (OPTN): Organ procurement 
and transplantation network is an organization governed by the U.S. Department of 
Health and Human Services and is formed by multiple committees to develop organ 
transplantation policies (OPTN, 2018).  
Public health service (PHS) increased risk donor: The Centers for Disease 
Control and Prevention (CDC) developed guidelines in 1994 to designate high-risk 
donors based on a category of high-risk behaviors likely to increase chance of human 
immunodeficiency virus (HIV) transmission (Rogers, Simonds, Lawton, Moseley, & 
Jones, 1994). On July 2013 the PHS increased-risk criteria were introduced as an 
extension of the CDC high-risk criteria by adding the risk of recent hepatitis B and 
hepatitis C, in addition to the risk of HIV (Seem, Lee, Umscheid, & Kuehnert, 2013). 
More details about the two criteria are provided in Appendix B. 
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Scientific Registry of Transplant Recipients (SRTR): Scientific Registry of 
Transplant Recipients is a national database that receives transplant data from many 
organizations and stores data on transplant candidates, donors, transplant recipients, and 
posttransplant follow-up data (SRTR, 2018). 
Standard criteria donor (SCD): Standard criteria donor liver comes from a 
deceased donor who is brain dead but still has a beating heart that may be supported by a 
respirator (Rodrigue et al., 2011).  
Split liver donation: Split or partial liver donation refers to the split of the liver 
organ into two segments, the left lateral segment often transplanted to child and the right 
segment transplanted to an adult, although splitting the donor between two adults is also 
performed (Vagefi, Parekh, Ascher, Roberts, & Freise, 2011).  
Transplant center: A hospital in which transplants are performed. The transplant 
surgeon of the transplant center receiving the organ offer for a surgeon’s candidate is 
responsible for ensuring the medical suitability according to the candidate’s blood type 
and subtype (OPTN, 2018).  
United Network for Organ Sharing (UNOS): United Network for Organ Sharing 
is a private, nonprofit organization that manages the nation’s organ transplant system 
under contract with the federal government (UNOS, 2018).  
Wait list: This is a computerized list of candidates who are waiting to be matched 
with specific donor organs in hopes of receiving transplants. Wait list candidates are 
registered on the list by member transplant centers (OPTN, 2018).  
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Assumptions 
Several basic assumptions were made during this investigation. During patient 
selection, environmental factors were assumed to be constant across all patients who 
resided in the same county. I assumed that all patients received clinical services of 
equivalent quality as the transplant center and center effect were not analyzed. 
Moreover, I assumed that data were accurately collected and correctly measured by 
clinical, administrative, and research staff and that lab values were not flawed. Late graft 
failures, which happen after 1-year posttransplant, were ignored. I assumed that an ideal 
donor was a standard criteria liver donor (i.e., with brain death, age less than 45 years, a 
whole non-split graft) and that the risk model could quantify donor risks for a 
heterogeneous group of nonideal donors.  
Scope and Delimitation 
In this study, only adult recipients (18 years or older) of cadaveric single-organ 
LTs were considered. Recipients of multiorgan transplants were excluded. The study 
population was limited to patients transplanted for NAFLD/CC; all other etiologies for 
LT were excluded. A cohort of patients transplanted in the most recent 5 years with at 
least 1-year follow-up in the post-MELD era was considered to develop models to predict 
graft survival within 1-year posttransplant. To develop a valid risk adjustment model, an 
adequate number of events (in this case graft failures or deaths) must have occurred in the 
development cohort to allow selection of variables for risk adjustment. A proposed 
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convention in multivariate prognostic modeling was to require at least 10-15 events per 
risk adjuster in the final model (see Harrell, Lee, & Mark, 1996).  
The SRTR technical advisory committee recommends a more conservative 
minimum of 25 events in the development data set to attempt to build a risk adjustment 
model (Snyder et al., 2016). Final decisions on which variables to include for donor risk 
adjustment were based on published data, knowledge of subject matter, and available 
data. A list of potentially appropriate variables for risk adjustment was compiled based on 
literature review, availability in SRTR, and expert opinion about the importance and 
clinical relevance of proposed data elements. All transplant centers contribute to the 
SRTR database. The large sample size ensured that the study was powered to conduct 
multivariate analyses. Therefore, inferences from SRTR studies are likely to generalize 
across the United States. However, the model is expected to present some threats to 
external validity and may not generalize with data from non-U.S. transplant centers with 
different policies and procedures (see Massie, Kucirka, & Segev, 2014).  
Limitations 
SRTR database has a significant amount of data that are missing or inaccurate. 
The aggregate nature of the community health factors can lead to model estimates that 
may be subject to ecological bias. Lost to follow-up can be a threat to internal validity. 
The retrospective nature of SRTR data can lead to confounding attributable to 
unobserved variables. Transplant centers prospectively submit their data at transplant 
milestones, reducing recall bias. Medical and social history interviews conducted with the 
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deceased donor’s close family members can be inaccurate if the persons interviewed have 
limited or inaccurate information.  
A study suffers from selection bias if individuals in the study population are not 
representative of the target population. However, the SRTR database is a comprehensive 
registry of transplant recipients, which includes consecutive organ transplants that 
occurred in the United States since October 1, 1987. Therefore, the accurate pathology-
based diagnosis paired with the inclusion of consecutive patients was likely to reduce 
selection bias. The designed inclusion criterion, which limited to NAFLD/CC adult 
recipients of LTs, optimized the external and internal validity of the study, reduced 
confounding, ensured the homogeneity of the sample population, and increased the 
likelihood of finding a true association between independent predictors, covariates, and 
outcomes. 
Significance and Social Change 
The changing patterns in patient demographics and indication for LT pointed to 
the development of a post-MELD era donor quality score tailored to NAFLD recipients. 
This study can shed some light on understanding how organ quality plays a role in 
posttransplant outcomes. Transplant physicians are inaccurate at predicting donor specific 
risks and tend to overestimate graft failure for marginal donors (Volk, Roney, & Merion, 
2013). Moreover, patients prefer an active involvement in decisions about organ 
acceptance, and although they tend not to accept marginal donors, a closer evaluation of 
the competing risk of wait-list mortality can lead patients to accept higher-risk donors 
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(Dries, Annema, Berg, Ranchor, & Porte, 2014; Volk, 2015; Volk, Tocco, Pelletier, 
Zikmund-Fisher, & Lok, 2011). The results of this research have the potential to advance 
knowledge in clinical decision-making at the point of care during an organ offer and may 
provide an objective tool for physicians and patients. 
The DQ-NAFLD objective donor quality metrics could lead to positive social 
change if used as a tool to quantify donor quality and may assist physicians and patients 
in the decision-making during an organ offer. The DQ-NAFLD score could be clinically 
relevant if used to identify high-risk donors associated with acceptable outcomes when 
matched to subsets of NAFLD/CC recipients. The donor pool could increase, and more 
suboptimal donors could be allocated to NAFLD/CC patients on the wait list who have 
lower priority to receive an LT. Otherwise, there is a good possibility that these patients 
could die while on the wait list because no liver will be offered to them.  
Summary 
NAFLD is becoming the leading indication for LT. Nevertheless, the wait-list 
mortality rate for NAFLD recipients is high compared to other indications for an LT. In 
this chapter, I introduced the subject matter and showed that the population of 
NAFLD/CC recipients could benefit from an optimized allocation of liver organs. I 
explained the lack of donor risk models that address NAFLD/CC patients and the need to 
consider community risk factors and their impact on post LT graft survival. Furthermore, 
the purpose of this study along with a justification of the need for this research and its 
theoretical framework was presented. Research questions and hypotheses were included, 
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and the delimitations, assumptions, and limitations of this study were given. Chapter 2 
provides a comprehensive literature review of the study background and research 
problem.  
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Chapter 2: Literature Review 
Mirroring obesity and type 2 diabetes prevalence, NAFLD with end-stage liver 
disease and NASH are projected to replace HCV as the leading indications for LT in the 
United States and the world (Pais et al., 2016). The number of patients with NASH listed 
for liver transplant in the United States has increased by 168% from 2003 to 2014, 
becoming the second leading etiology for liver transplantation after 2008, and still 
trending upward (Cholankeril et al., 2017). With the introduction of highly effective 
direct antiviral agents, the incidence of HCV-related decompensated cirrhosis is steadily 
decreasing. NASH patients on the transplant wait list have low priority, are often old with 
comorbidities, and have a high likelihood to die on the wait list. To fill the gap between 
the demand for LT and the supply of deceased donor organs, transplant centers are forced 
to consider using high-risk donors for transplant candidates with the longest waiting time. 
Factors such as donor age, donor cause of death, and donation after cardiac death can 
contribute to increasing the risk for graft failure that can lead to the death of the 
transplant recipient (SRTR, 2018).  
To quantify the impact of donor factors, researchers have developed organ-
specific donor risk indices to identify predictors of graft and patient survival post LT 
using various combinations of donor, transplant, and recipient characteristics and are 
actively searching to fit useful statistical risk models using objective variables that 
quantify the risk associated with donor organs. The concept of donor risk index (DRI) 
introduced by Feng et al. (2006), and the subsequent models following the development 
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of the DRI are important advances. However, they need to be updated to be considered in 
liver allocation policies and to be useful in clinical practice to guide transplant clinicians 
in the use of nonoptimal donors by accounting for the impact of geography and 
unmeasured donor characteristics. DRI could be tailored for NAFLD/CC recipients to 
reflect features unique to this population (Flores & Asrani, 2017). I performed a thorough 
literature review to gain an understanding of the current knowledge about the relationship 
between donor quality and patient characteristics in the NAFLD/CC population, and to 
identify a gap in the knowledge base about the impact of community risk factors on 
donor risk models. This review led to the development and validation of a novel donor 
quality model tailored to NAFLD/CC recipients of LT: the DQ-NAFLD. This chapter 
includes the following items: 
 the literature review strategies; 
 the theoretical framework that shaped this study and framed the research 
questions;  
 review of literature related to the source, concept, and constructs of the 
theoretical framework and how the theory has been applied in similar studies;  
 review of literature to describe the spectrum of NAFLD and NASH, including 
the donor allocation system based on the MELD score and its impact on the 
wait-list mortality of NAFLD patients;  
25 
 
 
 
 review of donor risk models previously developed, including machine 
learning approaches to donor-recipient matching models, the variables 
utilized, the similarities, the differences and the limitations of each model;  
 review of the utilization of marginal donors, including older donors and 
donation after cardiac death; and  
 review of literature that addressed the impact of community health indicators 
on post liver transplant outcomes. 
Literature Review Strategy 
A comprehensive literature review including the most recent literature and 
seminal studies on the study topic was conducted. This included the period 2002 through 
2018 by querying the following databases: MEDLINE, Science Direct, ProQuest Central, 
and PubMed. Also queried were major peer-review liver transplant journals, including 
the American Journal of Transplantation, Liver Transplantation, Journal of Hepatology, 
Journal of Gastroenterology and Hepatology, and BMC Gastroenterology. Key words (in 
combination with liver transplantation) included donor quality, donor risk index, donor 
allocation, liver transplantation, NASH, NAFLD, cryptogenic cirrhosis, wait list 
mortality, liver wait list mortality, donor allocation, MELD, marginal donors, suboptimal 
donors, DCD, donation after cardiac death, non-heart beating donors, Socio Ecological 
Model, SES, and community health indicators. The criteria for selection of peer-reviewed 
articles were (a) U.S. system of allocation (although some international studies were also 
considered for comparison purposes), (b) English language, (c) adult subjects, (d) related 
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to study concept of donor quality and variables, and (e) related to the study population. 
Titles, abstracts, and articles were reviewed, and articles that met the inclusion criteria 
were selected for review.  
Theoretical Foundation 
The theoretical framework is the backbone of planning research. Theories shape 
the way research is conducted and add structure and consistency from topic selection to 
the literature review, development of research questions, study design, and analysis plan 
(Alderson, 1998). The theoretical framework that shaped this study and framed the 
research questions was based on the social-ecological model (SEM) (McLeroy et al., 
1988). SEM is a theory-based framework that can be used to examine the complex 
interplay between individual, community, and social factors that increase or decrease the 
risk of poor posttransplant outcomes (Stilley et al., 2010). The SEM can help to 
understand the multifaceted and multilevel interactions between personal and 
environmental factors that determine behaviors and guide in identifying the social 
determinants of health, or those unfair conditions in the social environment that can 
impact access to liver donors and can increase the risk of poor post liver transplant 
outcomes.  
Figure 1 illustrates the five nested hierarchical levels of influence of the SEM. 
The individual levels include biological factors and patient behaviors. The interpersonal 
level consists of the family and social networks. The community level includes the 
distance from the transplant centers, environmental health risks, and insurance. The 
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organization level in the current study context includes the United Network for Organ 
Sharing (UNOS), the Organ Procurement and Transplant Network (OPTN) and the Organ 
Procurement Organization (OPOs). The policy level includes the donor allocation 
policies.  
 
Figure 1. The social ecological model (SEM) in the context of liver transplantation. 
 
In Figure 1, the first level identifies the patient level, including individual and 
biological factors, some of them modifiable through educational interventions. The 
family and social network level factors include family members who are involved in 
supporting patients throughout their transplant journey or the next of kin who provide 
medical and behavioral information about a donor. Health care system level comprises 
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the clinical pathway to a liver transplant, such as donor match, the transplant surgery, 
quality of health care provided, and the nature of the community where patients reside. 
Social level factors including listing and organ donation policies. 
Researchers have studied the impact of social factors on health. Braveman and 
Gottlieb (2014) suggested that healthcare is responsible for only 10-15% of preventable 
mortality. However, individual behaviors have an impact on people’s health by 40%, 
genetics by 30%, and social and environmental factors by 20%. Therefore, there is 
substantial evidence in the United States, and globally, that social determinants of health 
have a substantial impact on morbidity and mortality in the general population. In 
addition to individual factors, such as socioeconomic status, education, individual 
behavior, and social support, environmental factors, such as access to healthcare and 
healthy food options vary by region and county. 
One of the implications of heterogeneity in these risks is its potential impact on 
risk models that predict patient outcomes. Ignoring these underlying risk factors of 
transplant recipients not available from medical charts can result in biased performance 
of transplant risk models, because social determinants of health impact the outcomes 
(Schold, Phelan, & Buccini, 2017). Given a socioecological conceptual framework, a 
donor risk model that evaluates recipient and donor match and their impact on post-
transplant outcomes can be refined by adjusting for community characteristics.  
The SEM framework was used in transplant studies to identify social determinant 
of referral for kidney transplant evaluations to plan educational intervention aimed at 
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improving equity in access to kidney transplant or to analyze the sociocultural pathways 
to organ donation among American Indian adults (Fahrenwald & Stabnow, 2005). The 
social-ecological theory implies that there are complex social determinants of post-liver 
transplant outcomes (Braveman & Gottlieb, 2014). It is necessary to act on multiple 
levels to improve survival after liver transplant.  
Nonalcoholic Fatty Liver Disease 
During the past century, the world has experienced a significant decline in 
mortality and a substantial increase in life expectancy. Chronic diseases have replaced 
acute infectious diseases becoming the predominant cause of morbidity and mortality 
worldwide. NAFLD is becoming the new epidemic in chronic liver disease, which 
mimics the worldwide epidemics of obesity and type 2 diabetes. It is projected to become 
the most frequent indication for LT by 2030 (Byrne & Targher, 2015).  
NAFLD Spectrum 
NAFLD. NAFLD is a multisystem disease in which excess fat is stored in the 
liver, primarily associated with other comorbid conditions such as obesity, diabetes 
mellitus, cardiovascular disease, hyperlipidemia, metabolic syndrome, and chronic 
kidney disease (Argo & Caldwell, 2009). Patients with NAFLD are often older age, with 
obesity and other metabolic comorbidities, and at a high risk to develop cardiovascular 
complications. NAFLD affects the hepatic structure and function and can lead to 
cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Consequently, NAFLD is a 
leading cause of cirrhosis, HCC, and the need for liver transplantation. However, 
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cardiovascular disease is the primary cause of deaths among NAFLD patients (Byrne & 
Targher, 2015). 
NASH. The spectrum of NAFLD includes simple steatosis and steatohepatitis 
(NASH) which is a progressive, and fibrotic liver disease. Fatty liver accumulation or 
steatosis alone is classified as Type 1 NAFLD, steatosis and lobar inflammation as Type 
2 NAFLD, steatosis and ballooning degeneration as Type 3 NAFLD, steatosis ballooning 
degeneration and fibrosis is Type 4 NAFLD. Types 3 and 4 are defined as NASH. 
Described for the first time by Ludwig, Viggiano, Mcgill, and Oh (1980) as “a poorly 
understood and hitherto unnamed liver disease” (p. 434), NASH is a progressive fibrotic 
liver disease that can lead to HCC and end-stage liver disease. One consequence of 
NASH is the appearance of liver fibrosis, measured by a score that ranges from F0 
(absence of fibrosis) to F4 (liver cirrhosis) (Chalasani et al., 2018). NASH is diagnosed 
with a liver biopsy. 
Cryptogenic cirrhosis. Cryptogenic cirrhosis (CC) is the end stage of chronic 
liver disease in which the underlying etiology is unknown and undentified after extensive 
clinical, serological, and pathological evaluations. Powell et al. (1990) observed a gradual 
loss of steatosis in cases that progressed from NASH to cirrhosis, and Caldwell and 
Marchesini (2018) noted that metabolic risk factors were common among individuals 
with CC. This suggests that some cases of CC can be attributed to advanced NASH, 
although other causes of CC do exist. Thuluvath, Kantsevoy, Thuluvath, and Savva 
(2018) revealed that CC should not be considered the same as NASH cirrhosis. It remains 
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debatable if the two entities are essentially the same. Further investigations are required 
to identify unknown causes of cirrhosis (Caldwell & Marchesini, 2018; Thuluvath et al., 
2018). Figure 2 illustrates the NAFLD disease spectrum as revealed by biopsy results.  
 
Figure 2. NAFLD spectrum. 
Note. Source: NASH Biotech. Retrieved from 
http://www.nashbiotechs.com/newsletter.html. NAFL=Non-alcoholic fatty liver; 
NASH=Nonalcoholic steatohepatitis. 
 
Epidemiology of NAFLD and NASH 
The epidemiology and demographic characteristics of NAFLD usually constellate 
obesity and type 2 diabetes; however, a portion of NAFLD patients are lean (Younossi et 
al., 2016). NAFLD is increasingly prevalent in the U.S. and globally and is a major cause 
of advanced liver disease. Consequently, the number of liver transplants for NASH 
nationwide has increased over time. Many NAFLD patients are likely to progress to more 
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advanced liver disease. However, it is challenging to screen for NASH because invasive 
liver biopsy is needed.  
The global prevalence of NAFLD is currently estimated to be 24% (Younossi et 
al., 2016). In the United States among patients with NAFLD and in the general 
population, the prevalence of NASH is estimated to be 21%, and 3-4%, respectively 
(Younossi et al., 2016). The prevalence of NAFLD in the United States varies by 
ethnicity: highest among American Hispanics followed by Americans of European origin 
and African Americans. The ethnic disparity in the prevalence of NAFLD is not fully 
understood. The high prevalence of obesity and hypertension and the low prevalence of 
NAFLD among African Americans suggest that ethnicity may influence the association 
of metabolic syndrome with NAFLD (Smits, Ioannou, Boyko, & Utzschneider, 2013). 
Moreover, even within a specific ethnic group in the United States, there may be 
differences in the prevalence of NAFLD associated with the country of origin, which 
remain unknown (Fleischman, Budoff, Ifran Zeb, & Foster, 2014). Genetic and 
environmental factors may explain some of these differences. 
Risk Factors of NAFLD 
The progression of NAFLD from steatosis to NASH fibrosis is estimated to be 14 
years, and progression to each subsequent fibrosis stage is estimated to be seven years. 
As the stage of fibrosis increases, so does the risk of liver-related mortality. Authors of 
population-based and familial-aggregation studies, as well as twin-studies, have given 
evidence of a heritable component of NAFLD that ranges from 20 to 70 %. NAFLD 
33 
 
 
 
heritability differs among ethnicities, greater among Hispanics (33%), as compared to 
African Americans (14%) (Loomba et al., 2015; Speliotes et al., 2011). 
Epigenetic factors. Various factors contribute to the development of NAFLD, 
including genetic predisposition, environmental exposures, and lifestyle (Gerhard & 
DiStefano, 2015). Major advances have uncovered the genetic basis for the heritability of 
NAFLD. In NAFLD, genome-wide HCV association studies have identified novel loci 
associated with disease severity phenotypes and approximately seven categories of genes 
associated with NAFLD (Anstee & Day, 2015).  
Role of environmental factors. A combination of genetic predisposition and 
environmental factors contribute to the development of NAFLD. Dietary habits, activity, 
and socioeconomic factors predispose individuals to NAFLD. Patients with NAFLD tend 
to have easy access to fast food places and restaurants, and, therefore, more likely to have 
unhealthy eating habits and low physical activity levels as compared to healthy 
individuals. The role of socioeconomic factors is not well defined. Kallwitz et al. (2015) 
explored the role of environmental factors in different ethnic groups with NAFLD to 
investigate the effect of environmental factors on genetic predisposition. They studied the 
impact of dietary and lifestyle factors together with the impact of acculturation, education 
level, income and access to health care, and found that they were not independently 
associated with the risk of developing NAFLD, suggesting a joint effect between 
environmental and genetic factors (Younossi et al., 2016). 
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Historical and Logistical Aspects of Liver Allocation 
The National Transplant Act of 1984 established an organ matching and 
procurement network which prohibits the buying and selling of organs and mandates the 
maintenance of an equitable system for the allocation and distribution (Coombes & 
Trotter, 2005). The Organ Procurement and Transplantation Network (OPTN) is a system 
for donor matching and allocation, and its membership includes every transplant hospital 
program, organ procurement organization (OPO), and histocompatibility laboratory in the 
United States, certified by the United Network for Organ Sharing (UNOS). Each UNOS 
entity plays an active role in forming the policies that govern the transplant community. 
The Transplant Act also required that the OPTN, under federal contract, is managed by 
UNOS via a Board of Directors and committee members to operate the OPTN (UNOS, 
2018).  
UNOS Regions 
The system of allocation employed by UNOS divides the United States into 11 
geographical areas called UNOS regions as depicted in Figure 3.  
35 
 
 
 
 
 
 
Figure 3. UNOS regions. 
Note. Source: OPTN (n.d.) Retrieved from 
https://optn.transplant.hrsa.gov/members/regions.  
 
The states in each region are shown in Table 1. Each of these regions, initially 
established by the OPTN for administrative and representative purposes, are represented 
on the Board of Directors and each of the standing OPTN committees. The geographic 
subdivisions were never established with the purpose to provide an equal distribution of 
organs among populations of transplant centers. The division of these 11 geographic 
regions was designed to recognize existing relationships within the transplant community 
as well as the local interests of each transplant center (OPTN, 2018).  
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Table 1 
 
States in UNOS Regions 
 
Region States 
 
1 Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Eastern 
Vermont 
 
2 Delaware, District of Columbia, Maryland, New Jersey, Pennsylvania, West 
Virginia, Northern Virginia 
 
3 Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Puerto Rico 
 
4 Oklahoma, Texas 
 
5 Arizona, California, Nevada, New Mexico, Utah 
 
6 Alaska, Hawaii, Idaho, Montana, Oregon, Washington 
 
7 Illinois, Minnesota, North Dakota, South Dakota, Wisconsin 
 
8 Colorado, Iowa, Kansas, Missouri, Nebraska, Wyoming 
 
9 New York, Western Vermont 
 
10 Indiana, Michigan, Ohio 
 
11 Kentucky, North Carolina, South Carolina, Tennessee, Virginia 
 
Note. Source: OPTN (n.d.) Retrieved from 
https://optn.transplant.hrsa.gov/members/regions 
 
Donation Service Areas 
Within each UNOS region, there are variable numbers of donation service areas 
(DSAs). Each DSA is served by one of the 58 OPOs that are responsible for identifying 
potential donors and coordinating all the activity leading up to and including the organ 
procurement. Each OPO is considered the first point of contact when a potential organ 
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donor is identified in a specific DSA. The Center for Medicare Services designates these 
DSAs (Figure 4), but they vary regarding the number of transplant centers served, square 
mileage of the area, state boundaries, candidate/donor ratios, and procurement rates and 
characteristics. 
 
 
Figure 4. OPO donation service area map. 
Note. Source: Wedd, Harper, and Biggins (2013)  
 
This current allocation scheme was adopted over 20 years ago. Livers are offered 
to sicker patients within the donor area before being offered to other parts of the country. 
The variation in DSAs has raised concerns that access to deceased donors is unequal 
across DSAs leading to a regional variation in posttransplant outcomes. Yeh, Smoot, 
Schoenfeld, and Markmann (2011) analyzed organ availability in terms of transplant rate 
and MELD with exceptions using national data from 2002 to 2009. They found 
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remarkable differences across DSAs. Transplant rates varied by 20.1-fold  and average 
MELD score ranged from 23.8 to 31.2, indicating that patients in low average MELD 
DSA could reach the top of the wait list faster compared to other DSAs. As a result, high 
average MELD DSAs, which have low organ availability, were associated with high 
mortality rates. Therefore, geographic inequity in access to deceased donor livers 
suggests that the organ distribution areas need to be restructured to guarantee equity (Yeh 
et al.,  2011). 
The National Transplant Act established a system of regulation and oversight for 
the field, a data management system to track outcomes and is a mandate to review and 
continuously provide an equitable distribution of organs in the United States. UNOS is a 
regulatory entity where professional input, patient advocacy and public opinion regarding 
the field of transplantation are all considered. Although this contracting entity provides 
regulations regarding the allocation and distribution of organs, rules regarding allocation 
are adopted after exhaustive dialog and consensus among participating members. Given 
the competing interests of each member, may be difficulty to reach consensus within the 
group (UNOS, 2018).  
The disparity in supply and demand of cadaveric organs has driven much of the 
policy discussion within the life-saving liver transplantation field. The method by which 
donor organs are allocated to individuals on the wait list for transplants is a relevant topic 
for research and debate, needed to meet the dual goals of fair allocation and optimum 
efficiency.  
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The Final Rule 
Despite clinical and scientific advances within the field, perceived inequities exist 
regarding geographical disparity as well as increased mortality on the wait list for those 
awaiting a liver transplant. When liver transplants first initiated, the allocation policy was 
based on little more than total time spent on the transplant wait list. This gave 
decompensated patients with recent diagnoses of end-stage liver disease little hope for 
transplantation. Under this system, wait-list mortality and drop-out rates were high 
(OPTN, 2018).  
In 1998, these perceived inequities were addressed by the Department of Health 
and Human Services in the form of a “Final Rule” to ensure that the allocation of scarce 
organs was based on medical need and not on wait time. The Institute of Medicine 
addressed this issue of disparity and recommended a restructuring of the liver allocation 
process to deemphasize wait time and provide a more equitable distribution based on 
predictive prognosis (Coombes & Trotter, 2005). Moreover, the “Final Rule” was 
intended to place greater emphasis on acuity and less focus on keeping organs within 
local procurement areas. To achieve the goal of equitable distribution of a scarce 
resource, the Final Rule provided two recommendations to the transplant community: 
1.  an expansion of the geographical area served by each OPO to equalize access; 
and  
2. The development of an allocation system that prioritizes based on acuity and 
deemphasizes waiting time.  
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Liver Allocation Based on Acuity 
To address the recommendation regarding redirecting allocation based on acuity, 
Kamath et al. (2001) developed the MELD score in February 2002, a metric for liver 
allocation. The MELD score predicts short-term mortality and is calculated using three 
laboratory values: the total serum bilirubin, serum creatinine and the international 
normalized ratio (INR) according to Equation 1: 
MELD=3.78 ln [serum total bilirubin (mg/dL)] +11.2 ln (INR)        (1) 
+ 9.57 ln [serum creatinine (mg /dL)] +6.43 
The MELD score is used to determine priority for LT candidates, who are placed 
on a national transplant list. Donor organs are allocated first regionally, then locally and 
regionally. The utilization of the MELD score had several advantages. Easly calculated 
from widely available laboratory tests, the MELD score allocation system resulted in a 
reduction of wait-list mortality and median waiting times (Asrani & Kim, 2011). The 
MELD score is intended to reflect the severity of the candidate’s disease. However, for 
certain liver diseases, such as acutely decompensated cirrhosis, HCC, 
cholangiocarcinoma, hepatopulmonary syndrome, pulmonary hypertension, and familial 
amyloidosis, where the progressions are not weighted into the MELD scores, the 
calculated MELD score is inadequate to reflect the candidate’s medical urgency 
(Bernardi et al., 2011; Martin & O’Brien, 2015). To balance their risks of tumor 
progression or other medical conditions, the MELD score is adjusted by adding exception 
points. The MELD score, with or without exception points, determines prioritization on 
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the transplant wait list ranked by an increased risk of death. It is applicable to a majority 
of chronic liver diseases (Asrani & Kim, 2011). The MELD score allocation rule is not 
applicable to Status 1 patients, who have acute fulminant hepatic failure at high risk of 
death within a week if a liver transplant is not performed.  
Over the years, investigators have proposed numerous modifications to the 
MELD scoring system (Kalra, Wedd, & Biggins, 2016). Sharma, Schaubel, Sima, 
Merion, and Lok (2008) found that serum creatinine may have a high weight in the 
existing MELD formula and proposed a re-weighted MELD score that assigns higher 
weight to bilirubin and lower weight to creatinine and IRN. In liver transplant candidates, 
serum sodium is an independent predictor of post-transplant mortality, associated with 
mortality independent of MELD score, particularly for those with low serum sodium 
levels (Kim & Lee, 2013). Huo et al. (2007) developed the MELD to serum sodium 
(SNa) ratio (MESO) to combine both the predictive power of MELD and SNa. Several 
investigators have shown that incorporating sodium into the MELD score increases its 
predictive accuracy (Biggins et al., 2006; Biselli et al., 2010; Heuman et al., 2007). 
Kim et al. (2008) showed that using the MELD-Na score over standard MELD 
score can reduce wait-list deaths by 7%. Supported by these findings, a modified MELD 
score with added serum sodium was implemented on January 11, 2016 (Biggins et al., 
2006). The MELD-Na score is calculated through Equation 2: 
MELD-Na = MELD+1.32 x (137-Na) - [0.033 x MELD x (137-Na)]    (2) 
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Expansion of the Geographical Areas 
The first recommendation to expand all service areas for organ procurement to 
serve a population base of nine million people was met with strong opposition from much 
of the transplant community and was never adopted (Ahmad, Bryce, Cacciarelli, & 
Roberts, 2007). Several states, including Louisiana, Wisconsin, Texas, Arizona, 
Oklahoma, Tennessee, and South Carolina, passed legislation prohibiting such expansion 
based on established limitations to interstate commerce (Meckler, 1998). Investigators are 
exploring new strategies to change the distribution system and reduce geographic 
disparities. 
Regional sharing for candidates with MELD scores of 15 or greater. Until 
January 2005, the allocation of livers by acuity remained almost an exclusive locally 
driven system, whereby organs were allocated to the most acutely ill patients (Status 1 
patients). This was done locally and then regionally, and before allocation to the highest 
MELD score patients locally and regionally. Merion et al. (2005) found that survival 
benefits from the liver transplant procedure occurred for patients with MELD score above 
18, while undergoing a transplant with a MELD score below 5 yielded a probability of 
mortality that was higher than those continuing to wait for a liver transplant. They 
suggested reconsidering the liver allocation policy for low MELD candidates and adding 
survival benefit component in the liver allocation policy. As a result, a change in the liver 
allocation policy occurred when the OPTN implemented the minimum-15 rule on 
January 12, 2005 (Regional Share 15 Rule). This rule requires that organs be offered first 
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to Status 1 patients locally and then regionally, and then to patients with a minimum 
MELD score of 15 locally and then regionally. If no such recipients are identified, offers 
to patients with MELD scores less than 15 are allowed. The minimum-15 rules were 
intended to address inequities in organ distribution based on the geographical difference 
in acuity of liver disease. This organ allocation policy change resulted in a 36% decrease 
in the proportion of liver recipients with a MELD score less than 15 undergoing 
transplant but did not change the sharing outside DSAs (Bittermann, Makar, & Goldberg, 
2012; Elwir & Lake, 2016). 
Regional sharing for Status 1 candidates. On December 15, 2010, the OPTN 
implemented full regional sharing of adult donor’s livers for all Status 1 candidates. 
Previously, livers in most regions were offered to Status 1 candidates first locally, and 
then regionally. Implementation of full regional sharing has promoted timely access to 
donor livers to Status 1 candidates and decreased wait list death rate.  
Regional Share 35/National Share 15. In 2012, the Health and Human Services 
Advisory Committee on Transplantation recommended an evidence-based organ 
allocation, rather than a system based on arbitrary boundaries of OPOs or their DSAs. 
OPTN/UNOS acknowledged that there were unacceptable geographic disparities in 
access to transplantation and charged organ-specific committees to develop a policy to 
minimize geographic effects. In 2013 the liver allocation policy was modified with the 
implementation of Share 15 National and Share 35 Regional to increase regional, national 
access for highly urgent liver candidates with MELD score of 35 or higher (Washburn, 
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Pomfret, & Roberts, 2011). Regional Share 35 policy resulted in an increase in the 
number of transplants and a decrease in the number of discarded liver organs (Halazun et 
al., 2016). Additionally, the Regional Share 35 policy resulted in 30% decrease in wait-
list mortality for high MELD recipients and an increase in LT patients in the intensive 
care unit or on life-support devices (Massie et al., 2015).  
Revised Policy Exception Scores for Hepatocellular Carcinoma (HCC) 
One unintended consequence of the MELD allocation system has been an 
increase in transplanting patients with HCC. To account for their risk of tumor 
progression, they were provided with MELD exception points. Subsequent studies 
showed that HCC priority points favored HCC candidates. Therefore, the MELD 
exception policy was modified several times by decreasing such exception points in 2003 
and 2005 (Parikh & Singal, 2016). A recent revision of the OPTN liver allocation policy 
implemented in 2015 modified the maximum value and the timing of exception scores for 
HCC candidates. This created a better balance in transplant opportunities between 
candidates with HCC exceptions and those with allocation priority based on their 
calculated MELD score. The maximum HCC exception score was capped at 34 (Pais et 
al., 2016).  
Currently, a national system that provides equitable access to LT for candidates 
whose disease severity is not accurately reflected by the calculated MELD score is not 
available. There are regional agreements. Each region has a review board that adopts 
independent criteria to evaluate requests for exceptions submitted by the liver transplant 
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programs. To create greater consistency in assigning exception scores for medical 
conditions not assessed reliably by the MELD score, the Liver Committee in January 
2016 distributed a proposal to establish a national liver review board (NLRB) to replace 
the regional boards in each of the OPTN regions (OPTN, 2018). This step is still under 
evaluation. 
Weaknesses of the MELD Allocation Model 
In addition to favoring patients with HCC, the MELD allocation system has 
resulted in a disproportionate number of patients within larger OPOs who are 
transplanted at higher acuity levels than those patients in smaller OPO. Moreover, the 
MELD score is not an accurate predictor of post-transplant mortality and does not include 
donor characteristics (Habib et al., 2006). The MELD variables are subject to laboratory 
variations (Cholongitas et al., 2007; Trotter et al., 2007). Serum creatinine is inaccurate 
for cirrhotic patients and is influenced by gender, muscle mass, age, and ethnicity (Martin 
& O’Brien, 2015). The MELD score may penalize female candidates because serum 
creatinine, a function of muscle mass may underestimate the severity of liver disease in 
women who have a lower muscle mass compared to men. As a result, the MELD 
allocation system has resulted in a 12% decrease of the probability to receive a liver 
allograft, and a 15% increased mortality on the wait list (Lai et al., 2010; Myers, 
Shaheen, Aspinall, Quinn, & Burak, 2011). Though the MELD score has improved 
equity in the liver allocation process, there is still a significant mortality rate on the LT 
wait list. The MELD score may not be a reliable predictor of liver-related mortality for all 
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patients (Bambha & Biggins, 2008; Huo et al., 2007). Some candidates may have 
clinically significant complications not captured by the MELD, such as the NAFLD/CC 
patients, who may experience disproportionate rates of wait-list dropout and are thus at 
risk of death while on wait list (Kwong et al., 2015).  
The impact of MELD allocation model on NAFLD/NASH. Patients with 
NASH, cryptogenic cirrhosis and low MELD score have slower disease progression and 
are less likely to receive an LT than patients listed for other end-stage liver diseases. 
Cardiovascular comorbidities, renal complications, and older age are likely to increase 
the risk of wait-list dropouts and unfavorable short-term outcomes. For this reason, 
patients with NAFLD cirrhosis have a low priority, and they often die on transplant wait 
list. Although patients with NAFLD cirrhosis have operative difficulties and a high rate 
of postoperative complications, their long-term post-transplant outcomes are not inferior 
to patients transplanted for other etiologies (Pais et al., 2016). Patients transplanted for 
NAFLD cirrhosis have short term morbidity and mortality, but high middle- and long-
term post-transplant graft and patient survival rates (O’Leary et al., 2011). Proper 
management of NAFLD patients on the wait list can increase access to LT and decrease 
the risk of posttransplant complications. 
High Risk Donors 
Patients waiting for a liver transplant are steadily increasing. Parikh et al. (2015) 
conducted a study to project donor growth. They used a Monte Carlo simulation to 
measure the impact of several factors on population growth and liver donor utilization, 
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and they estimated population growth of 7.1% in 2025 but a lower 6.1% donor utilization 
growth. The aging of the U.S. population and the obesity epidemic indicate that potential 
LT candidates are growing at a faster rate than potential donors, widening the gap 
between donors used and waiting patients.  
Organ shortage has extended  the standard criteria and led to exploring innovative 
approaches to increase organ supply, including live donor transplants, the use of split 
livers, non-optimal donors, i.e., donors after circulatory death (DCD), high-risk death 
brain donors (DBD), and extended-risk donors (Saracino, 2018).  
Donors After Circulatory Death (DCD) 
Donation after cardiac death describes the retrieval of no–heart-beating organs for 
transplantation following confirmation of death using circulatory criteria. DCD typically 
have irreversible brain injuries with no chance for recovery, but they do not meet the 
criteria for brain death. They progress to cardiac arrest after withdrawal of life support. 
DCD livers are more susceptible to damage than DBD livers and can lead to 
posttransplant complications including ischemic-type biliary lesions complications and 
higher rates of primary nonfunctioning and graft failure (Blok et al., 2016; Saracino 
2018). 
Orman, Barritt, Wheeler, and Hayashi (2013) conducted an exploration of the 
association between donor characteristics and donor use. They observed a decreasing 
trend in donor utilization from 1988 to 2004, and then a gradual increase. The proportion 
of nonuse DCD livers increased from 9% in 2004 to 28% in 2010. With an aging 
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population, increased body mass index, and the prevalence of diabetes, the donor quality 
has worsened, leading to a significant decline in LT availability. The increasing 
proportion of discarded DCD livers indicates a reluctance to use these suboptimal 
allografts due to the recognition that outcomes will be worse. There is a critical need for 
strategies for the optimal utilization of marginal donors in subsets of LT recipients that 
would benefit a DCD donor without worsening post-transplant outcomes.  
Public Health Service Increased Risk Donors 
In 1994 CDC established criteria to define high-risk donors based on social 
behaviors that increase their risk for blood-borne diseases, including human 
immunodeficiency virus (HIV), even if these donors tested negative by serologic 
screening for infectious disease (Rogers et al., 1994). In July 2013 U.S. Public Health 
Service (PHS) published the “increased risk” guidelines that expanded the CDC “high 
risk” guidelines including the likelihood of recent hepatitis B virus (HBV) and HCV, in 
addition to HIV infection (Seem et al., 2013). The increased-risk designation refers to 
donor’s risk behaviors including men who have had sex with other men, history of drug 
abuse, prostitutes, inmates, persons with hemophilia, persons who have had sex with 
persons who engaged in high-risk behaviors, and children born from mothers with high-
risk behaviors. CDC high-risk donors before 2013 and increased-risk donors are often 
discarded as they are considered at risk of transmitting specific infection pathogen, and 
some recipients are unwilling to consider them. I have provided more details about CDC 
high-risk and PHS increased-risk criteria in Appendix B.  
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Transplant candidates should be informed if they are being offered organs from 
increased-risk donors to evaluate the risk of accepting a donor at risk of transmitting 
recent blood-born infection versus the risk of prolonging their time on the wait list 
(Kucirka et al., 2015). Therefore, PHS increased-risk donors are potentially underutilized 
and contribute to increasing wait-list time (Volk, Wilk, Wolfe, & Kaul, 2017). However, 
the absolute risk of transmission is very low, and many patients could utilize these organs 
and receive a substantial predicted survival benefit instead of prolonging their stay on the 
liver transplant wait list and increase their risk of mortality while waiting for a low-risk 
donor (Kucirka et al., 2015).  
Expanded Criteria Donors (ECD) 
Currently, the OPO defines Expanded Criteria Donor (ECD) as a donor at least 
60-year-old or a donor between 50- and 60- year-old with at least two of the following 
conditions: hypertension, serum creatinine ≥1.5, or stroke as a cause of death. ECD 
donors are not considered ideal, but they can expand the donor pool and increase the 
options for some candidates to shorten their time on the wait list (Vodkin & Kuo, 2017). 
Based on the ECD criteria donors are either classified as ECD or as non-ECD, which 
does not capture all the spectrum of donor risk. 
The Concept of the Donor Risk Index 
The liver allocation policy based on the MELD score only includes LT candidate 
characteristics and estimates the short-term risk of death while waiting for an LT. 
However, donor-recipient matching and organ acceptance are complex decisions The 
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MELD score-base prioritizes sicker patients rather than prioritizing based on achieving 
an optimal donor-recipient match or post-transplant survival. In recent years, 
investigators have emphasized the need to apply the concept of utilitarianism to the organ 
allocation system (Briceño et al., 2013). Organ allocation models seek to maximize the 
survival benefit of the entire patient population rather than of an individual patient, or to 
save more years of life, rather than more lives (Briceño et al., 2013). Relevant steps 
include the development of a donor risk model, which seek to predict the survival of the 
donated liver after transplantation, enabling “matching” between the expected post-
transplant lifespan of the liver with that of the recipient. Donor quality and recipient 
characteristics have an impact on graft survival after a solid organ transplant (Weiss et 
al., 2012).  
In their seminal paper, Feng et al. (2006) developed the first donor risk index 
(DRI), a metrics for donor quality with emphasis on the importance of donor factors for a 
successful LT. The DRI has been used in multiple studies to quantify donor quality and to 
help understand the impact of donor factors on selected recipients, including those with a 
low MELD score or HCV (Flores & Asrani, 2017). In national surveys, 46% of transplant 
specialists felt that the availability of a reliable and practical DRI would improve shared 
decision making at the time of donor offer. However, unlike the MELD score, the DRI 
has not been translated into liver allocation policy and practice. Several risk models have 
been proposed using donor, recipient, and interoperative factors to predict post-transplant 
survival to facilitate transplant decision-making (Flores & Asrani, 2017).  
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With the utilization of ECD and DCD donors, the DRI may assist in decision 
making and in evaluating organ and patient outcomes (Akkina et al., 2012). Volk, Lok, 
Pelletier, Ubel, and Hayward (2008) showed that high-risk livers or livers with high DRI 
were more likely to be used for low disease severity recipients and less likely to be used 
for Status 1 or high MELD score recipients. Less urgent candidates or low MELD 
patients were likely to receive high-risk organs leading to unfavorable posttransplant 
survival. Schaubel, Sima, Goodrich, Feng, and Merion (2008) found that high DRI 
donors had a detrimental effect on recipients in the lowest MELD category ranging from 
6 to 8, and proposed transplantation of high DRI organs for high-MELD candidates. 
Maluf, Edwards, and Kauffman (2006) analyzed the association between extended 
criteria donation and DRI>1.7 and found no interaction between DRI and MELD score, 
suggesting that high-DRI livers can be transplanted in high-MELD recipients with no 
impact. Rauchfuss et al. (2013) found that waiting time is a critical factor in high-MELD 
patients while DRI is less critical, suggesting that high-MELD patients would benefit 
from earlier transplantation with a high-DRI donor rather than waiting for an optimal 
organ. In decision making, it is preferable to use high-risk donors in patients with 
advanced MELD score rather than waiting for a low-risk donor (Amin et al., 2004). 
Donor Risk Models to Predict Posttransplant Graft Survival 
Following the development of the DRI, several risk models to predict post-
transplant survival have been developed using donor, recipient, and operative factors to 
predict post-transplant survival. Some studies have attempted to identify the most 
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relevant risk factors and to develop several statistical models designed to predict graft 
outcomes with improved predictive ability, as compared to the DRI. Other studies have 
attempted to validate the DRI or to adapt it to other country populations. I summarized 
selected models and their relative advantages and disadvantages in Tables 2 and 3.  
Table 2 
Donor Risk Models to Predict Post-Liver Transplant Graft Survival 
Risk model Risk factors 
DRI Donor: age, race, height, DCD, split liver, COD.  
Transplant: allocation, CIT 
 
ET-DRI Donor: age, DCD, split liver, latest serum GGT gamma-glutamyl  
 transpeptidase, allocation, rescue allocation. 
Transplant: CIT 
SOFT Donor: age, creatinine, COD. 
Recipient: age, BMI, previous LT, previous abdominal surgery,  
albumin, dialysis, UNOS status, MELD score, encephalopathy, PVT, 
ascites, portal bleed, life support.  
Transplant: allocation, CIT 
 
BAR Donor: age. 
Recipient: age, MELD score, previous LT, life support 
Transplant: CIT 
 
D-MELD Donor: age. 
Recipient: MELD score 
  
DQI 
 
Donor: age, COD, ICU stay, split liver, lowest MDRD creatinine 
clearance 
Notes: BAR: Balance of risk; BMI: Body mass index; COD: Cause of death; CIT: Cold ischemia time; 
DCD: Donation after cardiac death; D-MELD: Donor age Model for End-stage Liver Disease; DQI: Donor 
Quality Index; DRI: Donor Risk Index; ET-DRI: Eurotransplant donor risk index; GGT: latest serum GGT 
gamma-glutamyl transpeptidase; ICU: Intensive Care Unit; LT: Liver transplant; PVT: Portal vein 
thrombosis; SOFT: Survival outcomes following liver transplantation 
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Table 3 
Donor Risk Models. Strengths and Weaknesses 
Risk model 
 
Strengths Weaknesses 
DRI Validated in recipient subsets. 
Variables available at the time of 
transplant. 
Developed with data pre-MELD. 
Variables not all accountable at the 
time of donor offer. Race not a 
reliable predictor. 
 
ET-DRI All variables available at the time 
of transplant.  
Not all variables available at the 
time of offer, poor external 
validation. 
 
SOFT Can be used to predict wasteful 
transplants and survival benefit.  
Complex model with many 
variables not available at the time 
of offer. Predicts only short-term 
mortality. Similar predictions with 
and without donor factors. 
 
BAR Variables available at the time of 
transplant. 
Predicts only short-term mortality. 
Lacks granularity define futility 
but only 3% of transplants would 
meet the definition.  
 
DRI Validated in recipient subsets. 
Variables available at the time of 
transplant. 
Developed with data pre-MELD. 
Variables not all accountable at the 
time of donor offer. Race not a 
reliable predictor. 
 
ET-DRI All variables available at the time 
of transplant.  
Not all variables available at the 
time of offer, poor external 
validation. 
 
SOFT Can be used to predict wasteful 
transplants and survival benefit.  
Complex model with many 
variables not available at the time 
of offer. Predicts only short-term 
mortality. Similar predictions with 
and without donor factors. 
 
(table continues) 
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Risk model 
 
Strengths Weaknesses 
BAR Variables available at the time of 
transplant. 
Predicts only short-term mortality. 
Lacks granularity define futility 
but only 3% of transplants would 
meet the definition.  
 
D-MELD Very simple model to use. Penalizes older donor livers with 
high-MELD recipients. 
 
DQI Use few variables available at the 
time of offer 
Use data from French transplant 
registry. Not externally validated. 
 
Notes: BAR: Balance of risk; D-MELD: Donor age Model for End-stage Liver Disease; DQI: Donor 
Quality Index; DRI: Donor Risk Index; ET-DRI: Eurotransplant donor risk index; SOFT: Survival 
outcomes following liver transplantation.  
 
 
 
The Donor Risk Index  
Feng et al. (2006) developed the first DRI using a population of adult recipients of 
cadaveric liver transplant in the United States from 1998 to 2002 and data from SRTR. 
They identified seven donor characteristics significantly associated with liver failure, 
three of them related to donor demographics (age, race, and height), then donor cause of 
death (trauma, cerebrovascular accident, anoxia, and others), the type of death (DCD or 
non-DCD) and whole or partial/split transplant. The model also included cold ischemia 
time and sharing donor service area (local, regional and national). From the Cox 
proportional hazard model, the derived equation to estimate the DRI is presented in 
Equation 3: 
DRI = exp [(0.154 if 40≤ age <50) + (0.274 if 50≤ age <60)                     (3) 
      + (0.424 if 60≤ age <70)         
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      + (0.501 if 70 ≤ age) + (0.079 if cause of death = anoxia)  
     + (0.145 if cause of death = cerebrovascular accident)  
     + (0.184 if cause of death = other)  
    + (0.176 if race = African American) + (0.126 if race = other)  
    + (0.411 if donation after cardiac death) + (0.422 if partial/split)  
    + (0.105 if regional share) + (0.24 if national share)  
    + (0.010 x cold ischemia time)] 
Notes: The term exp implies e raised to a value, i.e., 𝑒𝑥𝑝(𝑣𝑎𝑙𝑢𝑒) = 𝑒(𝑣𝑎𝑙𝑢𝑒) 
The reference donor, or the lowest risk donor, would be a white donor with age 
under 40-year, who died of trauma, with height of 170 cm, with a whole local non-DCD 
organ with cold ischemia time of eight hours. Lowest risk donors accounted for 19% of 
LT recipients in the study population; their estimated one-year graft survival ranged 
between 87% and 89% and their estimated three-year graft survival between 80% and 
83%.  
Recipients with the highest-risk livers, i.e., with African-American donors of age 
greater than 40, who died for a cause other than trauma, with height lower than 170 cm, 
and a split or partial national DCD liver with cold ischemia time greater than eight hours, 
had an estimated 1-year graft survival between 69% and 74% and a 3-year graft survival 
between 57% and 63% (Feng et al., 2006). 
Validation of the Donor Risk Index. Subsequent studies have validated the DRI 
as an independent predictor of liver graft failure in the U.S. populations as well as in 
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populations of other countries in the post-MELD era (Hung et al., 2015; Northup et al., 
2015; Rosenberger et al., 2014). Donors with DRI of more than 1.7 have been associated 
with a significant increase in the risk of liver failure in each MELD category. 
Additionally, the DRI has also been associated with the development of post-transplant 
complications, such as hepatic artery thrombosis, biliary complications, end-stage renal 
disease (Israni et al., 2013; Stine, Argo, Pelletier, Maluf, & Northup, 2016). Some 
researchers have also looked at the economic impact of using high-risk livers on the cost 
of LT, including the cost of increasing readmissions (Axelrod, Schnitzler, Salvalaggio, 
Swindle, & Abecassis, 2007; Salvalaggio et al., 2011).  
Donor quality quantified by the DRI score is associated with progressed fibrosis 
among patients with HCV, and with survival in HCC recipients of a LT as well as for 
those who undergo re-transplantation (Macdonald, Sewell, Harper, Roberts, & Yao, 
2015; Stine et al., 2016). 
Strengths and influences on transplant practices. The DRI score has been used 
to define organs as high or low risk and enables using this classification of donor risk in 
transplant practices (Feng et al., 2006). Moreover, the DRI has been instrumental in 
identifying disparities in organ utilization. Mathur, Schaubel, Zhang, Guidinger, and 
Merion (2014) showed that Hispanics were 21% more likely to get a lower-risk organ 
compared to Caucasians. Since the implementation of Share 35, the DRI has shown the 
unintended changes in practice pattern post-Share 35. Although liver acceptance offers 
has declined significantly after Share 35, organs discarded pre–Share 35 or post–Share 35 
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had no statistically different DRIs, suggesting that changes in organ acceptance could 
lead to increasing national discard rates and organ waste (Goldberg, Levine, Karp, 
Gilroy, & Abt, 2017).  
An objective and effective scoring system that quantifies donor quality could be 
beneficial in clinical practice and risk communication. Volk et al. (2013) found that there 
is considerable variability among surgeons about their perception of donor risk and in 
their estimates of the probability of graft failure for specific clinical scenarios. A useful 
metric of donor quality could help physicians evaluate the donor risk and reduce surgeon 
bias in organ acceptance practice.  
Patients prefer an active role in decision making. Volk et al. (2011) conducted a 
study to analyze patient decision making about donor quality in LT, and they found that 
patients are biased toward acceptance of high-risk donors and would rather stay on the 
wait list then accept a low-quality donor. They found that risk tolerance was associated 
with personal beliefs and not with severity of disease, suggesting that understanding how 
the patients think about organ quality can be used in risk communication counseling 
patients about the risks and benefits of accepting a low-quality organ. They demonstrated 
that risk communication needs to be tailored to patient understanding of organ quality. 
Although patients may be initially riskaverse, this tendency can be mitigated if they can 
understand the competing risk of dying on the wait list. Therefore, donor risk models 
have the potentiality to provide a useful tool to transplant clinicians to educate patients on 
their risks and benefits so that they can make an informed decision. 
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Limitations and weaknesses of the DRI. The DRI is still not accepted in clinical 
practice as a tool for donor-recipient matching. Mataya et al. (2014) conducted a survey 
among physicians to assess LT decision making and the utilization of DRI. They found 
that 73% of physicians perceived that the DRI did not incorporate the risk of liver failure, 
while 88% felt that the variables used to develop the DRI were misleading. The DRI was 
developed by Feng et al. (2006) using pre-MELD score data and may not reflect the 
current LT practice. Moreover, the DRI includes the donor variable race that not only 
lacks biological relevance but is also not a reliable predictor of posttransplant graft failure 
and should not be included in donor risk models (Asrani et al., 2010; Flores & Asrani, 
2017). Unmeasured confounding factors may also have an impact on post LT graft 
failure.  
Eurotransplant Donor Risk Index (ET-DRI) 
Braat et al. (2012) developed a DRI tailored and adapted to the Eurotransplant 
region (ET-DRI), using cadaveric LTs from 2003 and 2007. From the Cox proportional 
hazard model, the derived six-factors ET-DRI is as shown in Equation 4: 
ET-DRI = exp [0.960 ((0.154 if 40≤age<50) + (0.274 if 50≤age<60)               (4) 
         +(0.424 if 60≤age<70) + (0.501 if 70≤age) + (0.079 if cause of death = anoxia) 
         +(0.145× if cause of death = cerebrovascular accident)  
        + (0.184 if cause of death = other) + (0.411 if donation after cardiac death) 
         +(0.422 if partial/split) + (0.105 if regional share)  
         +(0.244 if national share)) + (0.010 × (cold ischemia time−8 h))  
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         +0.06((latest lab GGT (U/L) - 50)/100) + (0.180 if rescue offer)]  
Notes: The term exp implies e raised to a value, i.e. exp(𝑣𝑎𝑙𝑢𝑒) = 𝑒(𝑣𝑎𝑙𝑢𝑒) 
External validations of the DRI and ET-DRI when adapted to the French 
transplant registry led to poor calibration and discrimination, suggesting that both models 
need further validation and adjustment before being used for donor allocation rules 
(Winter et al., 2017). A refinement of the ET-DRI that combined recipient factors, or the 
combined donor-recipient model (DRM), showed an improved predictive ability (Blok et 
al., 2015) 
Survival Outcomes Following Liver Transplantation (SOFT)  
The Survival Outcomes Following Liver Transplantation (SOFT) score developed 
by Rana et al. (2008) utilized a combination of 18 recipient, donor, and operative factors 
to predict 3-month post-transplant survival. The most significant risk factors were 
previous transplants, warm ischemia time, and the need for life support. A reduced 
version of the SOFT score that utilized only 14 risk factors available at the time of listing, 
is the pre-allocation SOFT score (P-SOFT), used to evaluate a candidate prior to liver 
allograft allocation. The SOFT score was derived from a multivariable logistic regression 
model with the coefficients converted into points. The model includes multiple risk 
factors limiting its applicability in clinical practice. Recipient and operative factors 
dominate the SOFT score (Rana et al., 2008). Sensitivities analyses have shown that 
short-term survival models with and without donor factors have similar performance. 
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Therefore, the SOFT score is not an ideal tool to assess donor risk (Flores & Asrani, 
2017).  
Balance of Risk (BAR)  
Dutkowski et al. (2011) developed a score system based on a few strong 
predictors of post-transplant mortality. The balance of risk (BAR) score was derived 
using UNOS data from 2002 to 2010 and six strong predictors of post-transplant 
behavior: recipient MELD score; cold ischemia time; recipient age; donor age; previous 
liver transplant; and life support dependence prior to transplant. A BAR score ranges 
from 0 to 27 points derived from a logistic regression model. The model reflects an 
exponential increase in 3-month mortality, and a BAR score above 18 is a marker of 
transplant futility (Dutkowski et al., 2011). However, only 3% of the LT had a BAR 
score greater than 18, or equivalently, only 3% met the definition of futile transplant 
indicating that the BAR score lacks granularity and has limited applicability in decision 
making (Flores & Asrani, 2017).  
Donor Age and Recipient Model for End-Stage Liver Disease (D-MELD) 
 The donor age and recipient model for end-stage liver disease (D-MELD), a 
combination of donor age and preoperative MELD, was proposed by (Halldorson et al., 
2009) to optimize donor-recipient matching. In this model, a cutoff of D-MELD score 
greater than 1600 predicts unfavorable outcomes. Avoiding matching organs from older 
donors with high-MELD recipients results in favorable patient and organ survival. 
However, the age of liver donors has increased in the past several years, and a few 
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researchers have studied the impact of donor age on LT, reaching contradictory 
conclusions (Lué et al., 2016). 
Donor Quality Index (DQI)  
After showing that the DRI and the ET-DRI were not validated in the French LT 
recipients, Winter et al., (2018) developed a donor quality index (DQI) using data from a 
French transplant registry. They utilized five donor variables: age; the cause of death; 
length of stay in intensive care unit; lowest MDRD creatinine clearance; and liver split. 
They adjusted the model for several recipient covariates, used only for adjustment. 
Equation 5 shows the  derived DQI: 
DQI=exp [0.28 (1 if donor age > 69 years, 0 otherwise)                    (5) 
    +0.06 (1 if COD is “other”, 0 otherwise) 
    +0.30 (1 if COD is “cerebrovascular accident (CVA)”, 0 otherwise) 
    +0.11 (1 if COD is “trauma”, 0 otherwise) 
    +0.24 (1 if ICU stay is 4 days, 0 otherwise) 
    +0.22 (1 if the lowest MDRD creatinine clearance< 60 ml/min/1.73m2, 0 otherwise) 
   +0.05 (1 if the lowest MDRD creatinine clearance, 60 ml/min/1.73m2 and 90  
    ml/min/1.73m2, 0 otherwise) 
   +0 39 (1 if split or partial liver, 0 otherwise)] 
Notes: The term exp implies e raised to a value, i.e., exp(𝑣𝑎𝑙𝑢𝑒) = 𝑒(𝑣𝑎𝑙𝑢𝑒) 
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The authors identified three risk groups based on the DQI score; a low-risk group with 1.00 
< DQI ≤ 1.58; a medium-risk group with 1.58 < DQI ≤ 2.35; and a high-risk group with 
DQI > 2.35. The derived DQI is yet to be externally validated in other populations.  
Machine Learning Algorithms for Donor-Recipient Matching 
Organ shortage has encouraged the development of donor risk models for proper 
allocation of donor organs using not only traditional statistical methods but also machine 
learning algorithms. Haydon et al. (2005) used for the first time neural network models to 
match donors to LT recipients and to identify potential recipients likely to benefit most 
from each liver offered. They used pre-MELD data and a self-organizing map, which is a 
form of neural network, to predict three and 12-month survival post-LT. Briceño et al. 
(2014) conducted a multicenter study of donor-recipient matching using data from 11 
transplant centers in Spain to investigate the utilization of artificial neural networks 
(ANNs), as a tool to predict three and 12-month graft survival post-LT. They compared 
its performance with traditional donor risk models and donor-recipient matching, such as 
the DRI, D-MELD, BAR, and SOFT scores. Using the Spanish cohort, they developed an 
ANN model, the Model for Allocation of Donor and Recipient in España (MADR-E). 
They found that the MADR-E model was able to fit complex non-linear relationships in 
donor-recipient matching, better than traditional models. 
Furthermore, the MADR-E model is designed to optimize both equity and 
efficiency by achieving the lowest rate of death on the wait list and also the optimal 
posttransplant outcomes. Using the same approach in a different cohort of LT recipients 
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from King’s College Hospital, Ayllón et al. (2018) developed an ANN model (the KCH 
model) for donor-recipient matching to predict three and 12-month graft survival. 
Compared to traditional models, the KCH model resulted in a remarkable improvement 
in 3-month and 1-year graft failure predictions.  
Lau et al. (2017) explored the use of machine learning algorithms, such as random 
forests and artificial neural networks, to predict graft failure after LT, based on donor-
recipient characteristic known before donor allocation. They analyzed LTs from 1998 to 
2013 from the Austin health database that includes the population in the states of Victoria 
and Tasmania and found that the performance of machine learning methods was 
substantially more accurate, as compared to traditional methods of matching recipients to 
donors.  
Random survival forests (RSF), tree-based ANN methods for survival data, allow 
interpreting variable importance (VI) or to calculate some marginal effect of the 
independent variable on the dependent variable and provide an excellent tool for data 
exploration. RSFs use a robust computer-based algorithm that yields to an unbiased 
assessment of variable importance, for accurate prediction, but are still considered not 
suited for substantive research due to complexity.  
ANN models are very flexible, and they can fit complex data. However, they are “black 
boxes,” and it is difficult to elicit the hierarchical contribution of each factor, or to 
anticipate how changing a specific variable will affect the model. Moreover, they may 
not perform well with new data, limiting their generalization and stability. Additionally, 
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ANN models need to be retrained with new data periodically because they can be 
susceptible to changes in transplant and allocation policies, and clinical practices. An 
optimal dynamic ANN model for organ acceptance and allocation has the potential to 
guide decision making. However, before generalizing, their performance across multiple 
populations needs to be assessed (Kwong & Asrani, 2018).  
There is a debate on weather prediction models should be developed using only 
classical statistical methods or if it is appropriate to use ANN methods. When more than 
prediction is required, i.e., relevant information about dependent and independent 
variables and more insights into the underlying structure of the data, traditional methods 
are preferred (see Harrell, 2015). 
Social Determinants of Posttransplant Survival 
Unmeasured recipient and donor characteristics could potentially confound the 
results of donor risk models. Community-level disparities remain poorly understood in 
existing risk models. Quillin et al. (2014) have studied the adjusted effect of 
socioeconomic status (SES) on access to LT and  posttransplant graft and patient survival 
in the United States. They have found that LT candidates with lower SES appear to face 
barriers to LT, and low SES recipients of LT experience less favorable posttransplant 
outcomes. They concluded that SES is an independent predictor of access to transplant 
and post-transplant survival.  
Schold et al. (2012), for the first time in transplant research, attempted to 
investigate community-level disparities. They used county health indicators publicly 
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available through the Robert Wood Johnson Foundation project and the University of 
Wisconsin Population Health Institute and evaluated the association of community health 
indicators with post kidney transplant outcomes. Twelve county-level health indicators 
were selected as proxies for community health, environmental and behavioral risks, 
social condition, or access to care, and developed a community health score (CHS). They 
found that multiple health indicators from the recipients’ residence and CHS risk 
categories were independently associated with kidney transplant outcomes.  
Ross, Patzer, Goldberg, and Lynch (2017) investigated the impact of socio-
demographic considerations on the wait list and posttransplant survival for patients with 
end-stage liver disease. They looked at the impact of the county-level socio-demographic 
risk as measured by the CHS, and the distance to listing transplant centers. They found 
that high risk-CHS candidates and remote candidates who were more than 25 miles away 
from a transplant center had greater wait-list mortality but similar mortality after LT. 
Critique of Methods 
Feng et al. (2006) for the first time introduced the concept of donor risk index, a 
parsimonious risk model that may predict the survival of the donated liver after 
transplantation, a surrogate of donor quality. The DRI has been very useful in risk 
stratification and to support matching between donors and recipients. However, it has 
several limitations. The DRI was developed using data before the MELD era, and it does 
not reflect current practice patterns. Moreover, after the incorporation of Share 35 in 
2013, the impact of DRI may be affected by unmeasured geographic variations (Flores & 
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Asrani, 2017). The DRI includes race, which is not a biologically plausible predictor of 
graft failure, but it is likely to be a surrogate of center performance (Flores & Asrani, 
2017). 
The D-MELD combines the recipient’s MELD score with the donor’s age to 
obtain a continuous variable that can identify donor-recipient matches predicted to result 
in significantly poorer short- and long-term outcomes (Halldorson et al., 2009). The D-
MELD was designed to prevent donor-recipient matches with a high risk of unfavorable 
outcomes. This allocation strategy can jeopardize very sick patients in the context of low 
organ-donation rates.  
Some studies have proposed scores to estimate graft survival, based on the 
combination of multiple variables. The SOFT, and BAR scores can identify subgroups of 
patients with poor prognoses after LT, but they use many variables, and not all of them 
are available at the time allocation is made (Dutkowski et al., 2011; Rana et al., 2008). 
The SOFT score is very complicated for clinical practice and emphasizes short term 
survival. The BAR score ranges from 0 to 27, with a threshold of 18 distinguishing low 
from high-risk LTs (Rana et al., 2008). The majority of LTs are classified as low risk 
according to the BAR score. Both scores are not reliable metrics of donor quality. 
While hepatitis C is projected to drop with advanced in direct-acting antiviral 
therapy, NAFLD/NASH is projected to become the leading indication for LT due to 
increasing obesity rates (Pais et al., 2016). Therefore, a donor risk model needs to be 
tailored for recipients transplanted for NAFLD to remain relevant.  
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Moreover, exploration of other relevant characteristics such as community risk factors 
and distance from the transplant center is crucial to understand how external factors can 
impact a donor risk model. 
Summary and Conclusion 
This chapter contains a review of the NAFLD disease spectrum, of NASH, and of 
CC. Additionally, I conducted a literature review of the epidemiology and risk factors for 
NAFLD, including epigenetic and environmental factors. A review of disease trends 
revealed a rise in LT for NAFLD/CC, which is becoming the leading indication for LT. 
Furthermore, I detailed a review of historical and logistical aspects of liver allocation. 
Finally, I discussed a description of the UNOS regions, the DSAs, and changes in donor 
allocation policies from the “Final Rule.” I reviewed the strengths and weaknesses of the 
MELD score allocation system and its impact on the NAFLD/CC patients.  
From literature review has emerged a gap projected to widen between liver donor 
supply and LT candidates on the wait list, and the need to utilize high-risk donors. I 
reviewed the concept of DRI and its usage in decision making to identify optimal and 
suboptimal donors. Finally, I completed a thorough literature review of proposed risk 
score models, including traditional statistical models and machine learning-based models, 
along with their strengths and weaknesses. Through the extensive literature review, I 
revealed that current prognostic scores for donor organ quality are not reliable and robust 
prognostic tools that can predict short-term graft survival. Geographic variations, 
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unmeasured recipient and donor characteristics, and community-level disparities can play 
a role in predicting posttransplant graft survival.  
The current study led to the creation and validation of a novel model for donor 
quality score tailored for NAFLD/CC recipients and evaluated the impact of county-level 
health indicators and geographic characteristics. The new donor risk model filled a 
critical gap in the current knowledge base and is a step forward in the optimal utilization 
of a scarce resource to achieve the ultimate goal of improving liver graft survival. In 
Chapter 3, I presented research methodologies used in the study, including the study 
design, the study population and sample, data acquisition, and statistical analyses.   
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Chapter 3: Research Method 
The number of advanced NAFLD candidates on the liver transplants wait list is 
rapidly growing. Advanced NAFLD and CC candidates experience remarkably high 
mortality on the wait list due to persistent organ shortage and low wait-list priority. For 
NASH/CC patients in need of liver transplantation, the policies defining the priority of 
donor liver allocation are of ultimate importance. Use of marginal donors may improve 
donor allocation in these patients. 
The purpose of this study was to develop parsimonious risk adjustment models to 
quantify donor quality for advanced NAFLD and CC liver transplant recipients and to 
explore the association between derived donor quality score and distance from the 
transplant center, county health indicators, and communities where recipients of liver 
transplant reside. The donor quality score can be used to explore appropriate 
donor/recipient matching for risk stratification and to carefully select grafts from 
nonoptimal donors that can lead to satisfactory outcomes, reducing the number of donors 
turned down and reducing wait-list mortality. Moreover, geographic variations in liver 
allocation are a recurrent topic in transplant debates, reflecting concerns about health 
inequalities. A consideration of community-based health measures from the location 
where liver transplant recipients reside in risk-adjusted models and distance from the 
transplant center can be used to understand the interrelated causes of disparities to 
support policies or interventions to mitigate them.  
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In Chapter 2, I reviewed existing donor risk models along with their strengths and 
weaknesses and found that none of the donor risk models from the literature was tailored 
to NAFLD/CC recipients of liver transplant or adjusted for geographic or social 
environmental factors. The impact of community health factors on transplant risk-adjust 
models has been understudied. Chapter 3 includes a brief discussion of the targeted 
population, sampling procedures, sample size and power analysis, data collection, data 
cleaning, statistical analysis procedures, and techniques. Threats to internal and external 
validity are also presented. The chapter concludes with a discussion of ethical 
considerations, a summary of critical points, and a transition to the next chapter. 
Research Design and Rationale 
I used a quantitative correlational design (see Campbell & Stanley, 1963), more 
specifically a retrospective and longitudinal cohort study design of consecutive 
NAFLD/CC liver transplant recipients. This observational design allowed me to explore 
the expected relationship among variables, but it could not be used to make causal 
inferences. Because of the lack of randomization, there is always a possibility that the 
association between dependent and independent variables may be explained by other 
variables, the so-called unmeasured confounders that can be known or unknown.  
A pivotal point in this study was that a combination of donor, recipient, 
transplant, geographic, and social factors explained the hazard of liver graft failure in 
NAFLD/CC recipients of a liver transplant. Therefore, to quantify the impact of donor 
factors on graft survival, the donor quality was adjusted for recipient characteristic, and 
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the impact of geographic and social factors was explored. The research questions 
addressed whether graft failure or death occurred and whether donor factors played a 
role. A retrospective population-based longitudinal cohort study design is appropriate 
when the dependent variable of interest is a time-to-event outcome. This study was 
quantitative and included transplant population-based registry data collected at transplant 
milestones and publicly available county-level data. These data sources were consistent 
with exploring donor risk factors of liver graft failure in the study population.  
Sampling Population 
The sampling population included all available adult NAFLD/CC patients on the 
transplant registry who underwent cadaveric liver transplant between July 1, 2013, and 
December 31, 2016. Multiorgan transplants were not included. Status 1 patients at risk of 
imminent death at listing were excluded. All recipients in the study population were 
transplanted after the implementation of the Share 35 allocation policy, on June 18, 2013, 
to minimize the impact of changes in allocation policy.  
Sampling Procedures 
The SRTR database included all recipients of LT since 1987 in the United States. 
An appropriate sampling strategy for this study was consecutive sampling, which is the 
best nonprobability sampling strategy because it includes all subjects who meet the 
inclusion criteria (Portney & Watkins, 2009). Consecutive sampling is very reliable and 
likely to represent the target population (Portney & Watkins, 2009).  
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Secondary Data Collection  
Secondary data are data already available and collected for other purposes. 
Secondary data available from the SRTR database and the County Health Ranking & 
Roadmaps were used and adapted to answer the study research questions. 
The SRTR Database 
Every liver transplant performed in the United States since 1987 is included in the 
SRTR database. SRTR receives data from the OPTN database, which is managed through 
a federal contract by the United Network for Organ Sharing (UNOS). SRTR data comes 
from multiple sources, including transplant centers, organ procurement organizations, and 
histocompatibility laboratories.  
SRTR data provide access to broad, comprehensive information on all donors, 
wait-listed candidates, and transplant recipients in the United States, submitted by the 
members of the OPTN (SRTR, 2018). Mandated reporting of every solid organ transplant 
information performed in the United States allows inclusion in the study of each 
transplant performed in the United States that meets the inclusion criteria. SRTR data 
have been widely used to conduct a multitude of transplant studies (Saracino, 2017). In 
addition to the UNOS data, other secondary sources including the Social Security Death 
Master File, Centers for Medicare and Medicaid Services, National Death Index, 
Surveillance Epidemiology and End Results, and National Center for Health Statistics 
contribute to the SRTR database (Massie et al., 2014). 
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Data collection. Data were collected at different points in time: before the 
transplant, at the time of the transplant, and posttransplant. Recipients were followed 
longitudinally, and a large amount of information was collected at each follow-up 
transplant milestone until death (UNOS Transplant Pro, 2018). Donor information; 
candidate organ matching data; and recipient, transplant, and follow-up data were 
collected using standardized organ-specific data collection forms. Wait-list data were 
collected using the Transplant Candidate Registration. When a candidate is transplanted, 
the OPO recovering the organ and the transplant center complete the Transplant 
Recipient Registration (TRR) form, which includes information about the recipient and 
donor characteristics as well as information on matching donor to transplant candidates 
(UNOS Transplant Pro, 2018). Transplant centers complete Transplant Recipient Follow-
up (TRF) forms at 6 and 12 months posttransplant and yearly after that until the recipient 
expires. TRR and TRF forms are submitted to the OPTN database using the UNet system 
(UNOS Transplant Pro, 2018). UNet is a longitudinal database in which pretransplant 
data are used to match waiting candidates with donated organs, and posttransplant data 
are used to analyze transplant outcomes (Leppke et al., 2013). 
SRTR data quality. Data submission to UNOS is federally mandated. Transplant 
centers are required to maintain, and update transplant wait list by reporting candidate 
outcomes such as changes in disease severity and other events, including death and 
transplant (Leppke, 2013). Data used for organ allocation are generally reliable and 
complete. However, missing data are a limitation of SRTR data and will require careful 
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exploration and a strategy to address this limitation (Massie, Kucirka, & Segev, 2014; 
Saracino, 2018).  
In the United States, federal law requires transplant center outcomes to be 
published. UNOS is required to publish center-specific risk-adjusted statistics to measure 
the performance of transplant centers. Centers are flagged for poor performance when the 
adjusted survival is below a threshold (SRTR, 2018). For this reason, transplant centers 
are required to submit timely and accurate data to UNOS so that their survival statistics 
can be adjusted appropriately. Therefore, transplant centers need to have processes in 
place to prospectively collect and submit data to UNOS, contributing to a robust national 
database (Leppke et al., 2013). The UNOS UNet electronic system has built-in data 
validation processes to increase data accuracy. UNOS conducts site visits every three 
years to ensure that transplant programs are following OPTN policies (UNOS, 2018). 
During the UNOS site visit, data submitted to UNet are audited for completeness and 
accuracy. 
Usage of SRTR data. Data are routinely analyzed to answer research questions 
about the events that follow transplant candidacy, organ donation, and organ transplant, 
and used to publish annual trends in transplantation, outcomes, and statistics pertinent to 
transplant center performance. Researchers can request data from the SRTR by 
completing a data use agreement (DUA). Several investigators have used SRTR to 
answer transplant-related questions (Israni et al., 2018). Researchers have analyzed 
SRTR data and developed organ-specific donor risk models (Dutkowski et al., 2011; 
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Feng et al., 2006; Halldorson et al., 2009; Rana et al., 2008,). However, to date, this study 
is the only one that has used SRTR data to derive donor quality score tailored to 
NAFLD/CC transplant candidates.  
County Health Rankings & Roadmaps 
 The Robert Wood Johnson Foundation and the University of Wisconsin 
Population Health Institute produce the County Health Rankings every year. The 
rankings are derived with more than 30 measures of health indicators for nearly every 
county in the United States, providing a snapshot of how healthy a community is. Data 
are collated from different sources, including the Behavioral Risk Factor Surveillance 
System; the National Center for Chronic Disease Prevention and Health Promotion; the 
Dartmouth Institute; and the U.S. Census (County Health Rankings & Roadmaps, 2018). 
The rankings are based on a population health model developed by the American’s 
Health Ranking and used by the University of Wisconsin Population Health Institute to 
rank counties. Remington, Catlin, and Gennuso (2015) describe the methodology used to 
calculate the rankings. This study will utilize selected County Health Rankings.  
Usage of county health rankings & roadmaps. Relationships between 
community health indicators and transplant outcomes were explored for the first time by 
Schold et al. (2012) in a kidney transplant study where the authors developed a composite 
index called County Health Status (CHS), which is a proxy indicator of community 
health disparities. They found that high-risk communities were associated with an 
increased risk of kidney graft failure. Ross, Patzer, Goldberg, and Lynch (2017) found 
76 
 
 
 
that the CHS score was a determinant of liver transplant wait-list survival. They found 
that LT candidates in high health risk counties were associated with increased wait-list 
mortality. Pointer et al. (2018) found that patients in high-risk communities had less  
favorable post-pancreatic surgery outcomes.  
Data Access and Data Linkage 
The SRTR DUA requires that data will be used solely for bona fide analysis, and 
not for any other purposes not indicated in the statistical analysis plan. I made no 
attempts to identify patients or to use data unlawfully and unethically in violation of the 
Health Insurance Portability and Accountability Act (HIPAA) or any federal or state laws 
on confidentiality of patient medical records (SRTR, 2018; OPTN, 2018). SRTR released 
data as SAS datasets that were linked as needed, as shown in Figure 5. 
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Figure 5. SRTR data linkage.  
Note: Adapted from https://www.srtr.org/assets/media/docs/SAFsLinkingDiagram.pdf 
 
I used the following SAS datasets to identify the study population and to select original 
or derived study variables.  
1. DONOR_DECEASED: contains information on all deceased donor; 
2. CAND_LIIN: includes all candidates for liver or intestine transplant and 
contains candidate registration and wait list information; 
3. TX_LI: contains recipient and liver transplant information collected through 
the TRR forms; and 
4. TXF_LI: post-transplant follow-up data table contains follow-up information 
collected at six months, one year and then annually, until the patient receives a 
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subsequent transplant, dies or is lost to follow-up. Follow-up information in 
this table is collected using the TRF forms.  
I use the statistical software SAS version 9.4 (SAS Institute, Cary NC) to access 
the SRTR database and to prepare and combine the data in one analytical SAS dataset. 
The linkage diagram in Figure 5 indicates the foreign key variables needed to link the 
SAS datasets (SRTR, 2018). I linked the candidate SAS dataset CAND_LIIN to the 
donor table DONOR_DECEASED through donor_id and to the transplant table TX_LI 
though px_id. I linked TX_LI to the follow-up table TXF_LI through tx_id.  
I downloaded county health indicators from a publicly available website, County 
Health Rankings & Roadmaps (2018). I used the County Federal Information Processing 
Standard (FIPS) code, which is the geographic identifier used in the County Health 
Rankings, for data linkage. I converted the county FIPS codes into zip codes and then 
used them to link County Health Rankings to the recipient zip code in the SRTR 
database. 
Study Variables and Operational Definitions 
I selected the research study variables based on expert opinion, literature review, 
and the availability in the SRTR database. Below is a list of the variables that I 
considered in model building; only some of these candidate predictors were included in 
the final parsimonious model.  
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Dependent Variables 
I defined the outcome variable as liver allograft survival at 1-year posttransplant. 
Graft survival was defined considering graft status: graft failure (date of graft failure), or 
death (date of death), or if alive with graft functioning (date of the last follow-up). I 
coded a censoring variable indicating graft survival at 1-year posttransplant as “one” if 
liver allograft failed or if recipient expired within 1-year posttransplant, and “zero” if the 
patient was alive with graft functioning at the date of the last contact. The outcome 
variable was a time-to-event variable defined as the months from the date of LT to the 
date of the last contact and paired with the appropriate censoring variable (Saracino, 
2017). I provide in Table 4 the name and coding of the original variables available in the 
SRTR database, and in Table 5, I describe the coding of the outcome variables that were 
used in the survival analysis. 
Table 4 
SRTR Variables Used to Define Outcomes and Coding 
SRTR variable name Label Coding 
TFL_PX_STAT Patient status A: Living;  
D: Death;  
L: Lost to follow-up;  
N: Not seen; 
R: Retransplanted 
 
TFL_PX_STAT_DT Patient status/date Date 
 
REC_TX_DT Transplant date Date 
 
TFL_FAIL_PRIME_GRAFT_FAIL  Date of graft failure Date 
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Table 5 
Derived Outcomes and Coding: Graft Survival post-Transplant 
Outcome variables Coding 
Graft survival time Months from transplant to last contact (death, 
graft failure, last follow-up or date of 
subsequent liver transplant). 
 
Censoring 1 = liver graft failure or recipient expired;  
0 = alive or lost to follow-up at last contact or 
at subsequent liver transplant. 
 
 
 
Independent Donor Variables  
In the first step of the donor risk model development, I considered donor-only 
variables as potential independent predictors of graft survival. These factors are known at 
the time an offer for a liver organ is made. Some of the donor variables are related to 
donor demographics, some to donor behaviors that can lead to disease transmission, and 
some to the donor health and cause of death. Tables 6 and 7 describe donor variables as 
they are stored in the SRTR database, and Table 8 their operationalization that I used to 
develop the donor risk model. 
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Table 6 
SRTR Donor Variables and Original Coding 
SRTR variable name Label Coding 
DON_AGE_IN_MONTHS Donor age (months) Numeric 
DON_GENDER Donor gender M = Male; F = Female 
   
DON_HGT_CM Donor height (cm) Numeric 
DON_WGT_KG Donor weight (kg) Numeric 
DON_CAD_DON_COD Donor cause of death 1: Anoxia;  
2: Cerebrovascular/Stroke; 
3: Head Trauma;  
4: CNS Tumor; 998: 
Unknown; 999: Other 
 
DON_HIST_DIAB History of diabetes 1: No; 2: Yes, 0-5 Years; 3: 
Yes, 6-10 Years;  
4: Yes, > 10 Years; 
5: Yes, Duration Unknown; 
998: Unknown 
 
DON_HIST_INSULIN_DEPND Insulin dependent 
1=Yes,0=No 
DON_INSULIN Donor insulin N=No; Y=Yes; 
U=Unknown 
 
DON_HTN History of 
hypertension 
1: No; 2: Yes, 0-5 Years; 3: 
Yes, 6-10 Years;  
4: Yes, > 10 Years; 
5: Yes, Duration Unknown; 
998: Unknown 
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Table 7 
SRTR Donor Labs and Infection Profile Variables and Coding 
SRTR Variable Name Label Coding 
DON_SODIUM Last serum sodium 
Prior to procurement 
Numeric 
   
   
DON_SERUM_CREAT Final serum creatinine Numeric 
   
   
DON_HCV_STAT HCV antibody status 1: Positive; 2: Negative;  
3: Unknown; 4: Cannot 
disclose; 5: Not done;  
6: Indeterminate;  
7: Pending. 
 
DON_HBV_SURF 
_ANTIBODY 
HBsAb (Hepatitis B 
surface antibody) 
C: Cannot disclose;  
I: Indeterminate;  
N: Negative; ND: Not 
Done; P: Positive; PD: 
Pending;  
U: Unknown. 
 
DON_HBV_SURF 
_ANTIGEN 
HBsAg (Hepatitis B 
surface antigen) 
C: Cannot disclose;  
I: Indeterminate; N: 
Negative; ND: Not 
done;  
P: Positive; PD: 
Pending;  
U: Unknown 
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Table 8 
Derived Independent Donor Variables and Coding 
Donor factors Label Coding 
DONOR_AGE Donor age (yrs.) 
Continuous variable 
DON_HGT_CM Donor height in (cm) 
Continuous variable 
DON_WGT_CM Donor weight (kg) 
Continuous variable 
DONOR_BMI Body mass index 
(kg/m²) 
 
Underweight = BMI<18.5;  
Normal weight = 18.5≤ BMI≤ 24.9  
Overweigh = 25≤ BMI≤ 29.9;  
Obese = BMI ≥ 30 
 
DONOR_COD Donor cause of death 1: Anoxia;  
2: Cerebrovascular/stroke;  
3: Head trauma;  
4: Other 
 
DONOR_HTN Donor hypertension 1=yes; 0=no 
DONOR_DIAB Donor diabetes 1=yes; 0=no 
DON_DCD Donor after circulatory 
death 
1=Yes; 0=No 
HCV_POS Donor hcv positive 1=positive; 0=negative 
HBSAB_POS Donor HBsAb  1=positive; 0=negative 
HBSAG_POS Donor HBsAg 1=positive; 0=negative 
DON_HYPERN Donor hypernatremia 1=Yes (if DON_SODIUM ≥160 µmol/L); 
0=No (if DON_SODIUM <160 µmol/L 
 
DON_MDRD Donor MDRD 
 (ml/min/1.73 m2) 
1 = <15; 2 = 15-29; 3 = 30-44;  
4 = 45-59; 5 = 60-89; 6 = >90  
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Below are descriptions of the donor variables that will be explored.  
Donor age. The use of older donors has increased remarkably in the last two 
decades. Although old donors have been associated with worse graft outcomes, especially 
in patients with hepatitis C virus infections, there is evidence that some old donors can 
still lead to excellent results. The independent variable donor age is available in months 
and will be converted in years. 
Donor height and body weight. Body height and body weights considered 
associated with organ volume will be considered alone or in combined measurements, 
such as body mass index and body surface area among the donor factor candidates for the 
risk model.  
Body surface area (BSA). BSA will be calculated using the Mosteller’s formula 
using Equation 6:  
√𝐻𝑒𝑖𝑔ℎ𝑡(𝑐𝑚)𝑥 
𝑊𝑒𝑖𝑔ℎ𝑡(𝑘𝑔)
3,600
                                     (6) 
Donor BSA together with recipient BSA will be used in donor recipient matching to 
estimate liver size.  
Donor body mass index. The variable body mass index (BMI) of weight-for-
height is an indicator of obesity. It is calculated using a person’s height and weight as in 
Equation 7: 
𝐵𝑀𝐼 =
𝑊𝑒𝑖𝑔ℎ(𝑘𝑔)
𝐻𝑒𝑖𝑔ℎ𝑡 (𝑚)2
                                        (7) 
Chang et al. (2017) showed that the relationship between BMI and posttransplant 
overall survival is quadratic and U shaped. Therefore, I categorized BMI as suggested by 
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the CDC. A BMI of less than 18.5 kg/m² indicates underweight; a BMI of 18.5-24.9 
kg/m² normal weight; a BMI of 25-29.9 kg/m² the overweight category; and a BMI of 
more than 30 is an indication of obesity (CDC, 2018).  
Donation after cardiac death (DCD). Livers procured from DCD donors can 
bridge the gap between the demand for liver organs and donor supply. If properly 
managed, DCD donors can offer a valuable alternative to the donation after brain death 
(DBD), considered the standard of care which supplies the majority of LTs. DCD donors 
are associated with higher risk of graft failure, compared to DBD donations (Firl et al., 
2015). 
Donor diabetes. Donor macrovesicular steatosis is a known predictor of graft 
failure (Hamar & Selzner, 2017). However, macro-steatosis is only available in the SRTR 
database on biopsied donors. I considered donor diabetes as a surrogate of donor steatosis 
(Zheng et al., 2014). I combined three SRTR variables indicating the history of donor 
diabetes or insulin dependence to indicate the presence or absence of donor diabetes. 
Donor hypertension. Donor hypertension has been identified as a strong 
predictor of low graft survival in kidney transplant, and I evaluated in this study as a 
potential independent predictor of liver graft failure (Rao et al., 2009). 
Donor cause of death. Donor cause of death has been found to be an independent 
predictor of transplant outcomes. Stroke has been found to be associated with worse graft 
survival in LT and used in donor risk-adjusted models (Feng et al., 2006).  
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Donor hypernatremia. Donor hypernatremia before procurement, which could 
be a surrogate of prolonged donor intensive care, is defined as donor plasma sodium level 
≥160 µmol/L. Donor hypernatremia has been reported to reduce graft survival (Khosravi, 
Firoozifar, Ghaffaripour, Sahmeddini, & Eghbal, 2013).  
Disease transmission variables. Before being transplanted, donors are screened 
for infectious disease and tested for positive hepatitis B surface antibody (HBsAb), 
hepatitis B surface antigens (HBsAg) and HCV antibody status.  
Modification of diet in renal disease (MDRD). Donor Glomerular Filtration 
Rate estimated by the 4-variable equation from the MDRD was used to estimate the renal 
function of potential donors using Equation 8:  
MDRD = 175 x SerumCr-1.154 x age-0.203 x 1.212 (if black) x 0.742 (if female) (8) 
Independent Transplant Variables  
I considered a more extensive version of the donor risk model that included 
transplant variables, such as cold ischemia time, donor ABO matching, and donor size 
matching, to explore the impact of transplant factors and to assist in decision making 
about donor/recipient matching. Tables 9 and 10 describe transplant variables and their 
operationalization that I used in model building. I describe below the transplant variables 
that were considered.  
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Table 9 
SRTR Transplant Matching Variables and Original Coding 
SRTR Variable name Label 
 
Coding 
REC_COLD_ISCH_TM Total cold ischemic time Numeric 
 
REC_HGT_CM Recipient height (cm) Numeric 
 
REC_WGT_KG Recipient weight (kg) 
 
Numeric 
DON_HGT_CM Donor height (cm) 
 
Numeric 
DON_WGT_KG Donor weight (kg) 
 
Numeric 
DON_ABO Donor’s blood type A; A1; A1B; A2B;  
AB; B, 0 
 
REC_ABO Recipient’s blood type A; A1; A1B; A2B;  
AB; B, 0 
 
 
Table 10 
Derived Transplant Matching Variables and Coding 
Transplant Factors Label 
 
Coding 
CIT Cold ischemia time (hrs.) Continuous variable 
 
BSA_Ratio Donor/recipient BSA ratio Continuous variable 
 
ABO_Match ABO match 1: Incompatible;  
2: Compatible; 
3: Identical 
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Cold ischemia time. Geographic disparities in access to liver transplantation can 
lead to usage of liver organs with prolonged cold ischemia, a known risk factor for early 
allograft dysfunction (Sibulesky et al., 2016). Cold ischemia time is defined as the 
interval from the clamping of donors’ vessels, loss of blood supply and infusion of cold 
organ preservation to the moment of removal from storage and insertion into the 
recipient’s abdominal cavity. The in-vivo cold preservation solution maintains 
hypothermic conditions and minimizes ischemic injuries. Cold ischemia time is 
influenced by the distance between the donor and the recipient centers and increases 
when long distances have to be traveled (Sibulesky et al., 2016).  
BSA donor recipient ratio. Many factors affect liver size, such as weight, height, 
BMI and BSA. Fukazawa et al., (2013) proposed using the ratio of donor to recipient 
BSA index to predict size match. They found that both small-for-size and large-for-size 
liver grafts had an adverse effect on liver graft survival.  
Donor-to-recipient ABO match. Livers are usually matched by ABO. 
Mismatched donors may either be ABO compatible or ABO incompatible. The usage of 
ABO-mismatched organs has been controversial in liver transplantation in the past 
because of the high risk of antibody-mediated rejection. However, due to improvements 
in immune-suppressant regimen and improved graft survival, ABO incompatible organs 
can be considered a viable option to increase donor availability and reach the goal of full 
potential in organ utilization (Goss & Rana, 2017). Often, an ABO incompatible graft can 
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represent the only option in case of urgency when an ABO compatible organ is not 
readily available.  
Recipient Covariates 
Graft survival is affected not only by donor factors and transplant factors but also 
by recipient factors. Moreover, the transplant center has an impact on graft outcomes. 
Recipient factors will be used as covariates for risk adjustment. Table 11 presents known 
recipient characteristics associated with graft survival after LT, and Table 12 indicates 
grouped or calculated variables.  
Table 11 
SRTR Recipient Covariates and Original Coding. 
SRTR variable name Label Coding 
REC_AGE_IN_MONTHS_AT_TX Calculated recipient 
age in months at TX  
 
Numeric 
CAN_GENDER Candidate gender 
 
M = male; F = female 
REC_HGT_CM Recipient height (cm) 
 
Number 
REC_WGT_KG Recipient weight (kg) 
 
Number 
CAN_LAST_SERUM_SODIUM Last SRTR MELD 
 
Numeric 
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Table 12 
Derived Recipient Covariates and Coding. 
SRTR variable name Label Coding 
REC_AGE_AT_TX Age at transplant Continuous Variable 
CAN_GENDER Candidate gender 1 = Male; 2 = Female 
REC_BMI Body mass index (kg/m²) underweight = BMI<18.5;  
normal weight = 18.5≤ BMI≤ 24.9 
overweigh = 25≤ BMI≤ 29.9;  
obese = BMI ≥ 30 
 
MELD  MELD score 1=<15; 2=15-20; 3=26-30; 4=>30  
 
REC_DIAB Recipient diabetes 1=Yes; 0=No 
 
Recipient age and gender. I used recipient age and gender for demographic 
adjustments. 
Recipient BMI. BMI, an indicator of obesity in recipients of LT, was categorized 
as suggested by CDC. Recipient BMI has been associated with graft and patient survival.  
Model for end-stage liver disease score (MELD). The MELD score, a reliable 
measure of disease severity, and known mortality risk after LT ranges from 6 to 40, with 
low scores indicating healthier recipients. It is calculated using pre-transplant labs serum 
creatinine, serum bilirubin, International Normalized Ratio for prothrombin time, as well 
as ascites and hepatic encephalopathy, available in SRTR database (Kamath et al., 2001). 
The MELD score is used to prioritize patients on the liver wait list. It represents the 
recipient risk of wait-list mortality. 
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Recipient diabetes. Recipientdiabetes, is a known risk factors of patient post-
transplant survival (Northup et al., 2010). I recoded the SRTR variable that indicates the 
type of diabetes to reflect the presence of non-insulin dependent, insulin dependent, or 
absence of recipient diabetes.  
Modifying External Variables  
Modifying variables are associated with the outcome but not with the independent 
predictors. The effect of the donor risk score can change among different subgroups. I 
explored two external variables: distance from the transplant center and community 
health status, as described in Table 13.  
Table 13 
Mediating External and Coding 
Mediating variable Label Coding/measurement 
DIST_FROM_CTR Distance from center (miles) Numeric  
CHS_GRP Community health status group 0–10; 11–20; 
 21–30; 31-40  
 
Community health status (CHS). The CHS is a composite index that combines 
ranks of 10 selected county health indicators likely to be related to transplant outcomes. I 
provided detailed information on county health indicators in Appendix A. CHS ranges 
from 0 (indicating that a county is in the first quintile or the lowest risk for each of the 10 
health indicators) to 40 (indicating that a county is in fifth quintile or higher risk for each 
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of the 10 health indicators). Table 14 illustrates the data sources and contributing 
community health indicators that make up the CHS. 
Other Variables 
 Expanded criteria donor. The SRTR database has a variable that indicates 
whether or not a donor meets the expanded criteria. I did not include this variable in the 
model because I explored the variables included in the ECD definition (donor age, 
hypertension, and serum creatinine), individually in model building.  
PHS increased-risk donors. Information about PHS increased-risk donors 
(previously known as CDC high-risk donors) was available in SRTR. Increased-risk 
donors are often discarded and not considered by LT candidates because at high risk of 
blood-borne disease transmission. I explored the impact of increased-risk donors on liver 
graft survival in the study population to determine if these donors increased the risk of 
graft failure in NAFLD/CC recipients. The concept of increased risk donors was created 
to identify a donor population potentially at risk of a recent acquisition of HIV or viral 
hepatitis. These recently infected donors could inadvertently transmit the virus to 
recipients yet would appear negative on serologic testing. Importantly, most increased 
risk donors will be truly negative for each of these infections, and the chance that they 
will transmit the infection is very low. So increased risk is not necessarily related to the 
donor quality. Therefore, I did not consider the denomination PHS increased risk in the 
model. Appendix B provides more details about CDC high-risk and PHS increased-risk 
criteria.   
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Table 14 
Community Health Score and Contributing Health Indicators 
Community Health 
Indicator 
Source Value 
Premature death (years) National Center for 
Health Statistics - 
Mortality files 
 
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
 
Low birth weight (%) National Center for 
Health Statistics - 
Natality files 
 
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
Poor physical health 
(days) 
Behavioral Risk Factor 
Surveillance System 
 
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
 
Poor mental health 
(days) 
Behavioral Risk Factor 
Surveillance System 
 
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
 
Fair or poor health (%) Behavioral Risk Factor 
Surveillance System 
 
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
 
Income inequality American Community 
Survey  
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
 
Preventable hospital 
stays (%) 
Dartmouth Atlas of 
Health Care 
 
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
 
Adult smoking (%) Behavioral Risk Factor 
Surveillance System 
 
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
 
Adult obesity (%) CDC Diabetes 
Interactive Atlas 
 
Quintiles: 
1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 4 
 
Physical inactivity (%) CDC Quintiles: 
 Interactive Atlas 1st = 0; 2nd = 1; 3rd = 2; 4th = 3; 5th = 5 
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Study Validity 
Observational studies are not experimental as they involve the direct observation 
of study subjects in their natural setting. Therefore, they are assessed for potential 
selection or information biases that may influence the validity and reliability of study 
findings. There are a few critical issues to consider in evaluating observational transplant 
studies where the outcome is a time-to-event, such as patient and graft survival, including 
a potential differential loss to follow-up and misclassification bias. 
Information Biases 
Transplant registry data are collected longitudinally. Therefore, it is possible to 
analyze long-term outcomes, but at the same time, differential loss to follow-up can lead 
to bias. In SRTR data, transplant recipients are followed until death occurs. However, 
incomplete follow-up is often present for many reasons. Statistical methods used to 
analyze cohort studies assume that censoring is non-informative, i.e., not related to the 
study outcome, graft survival. Informative censoring occurs when subjects are lost to 
follow-up for reasons related to this study, that may only lead to biased estimates in the 
regression models and also reverse the effect of a risk factor that can appear as a 
protective factor. Sensitivity analyses can be used to analyze data under the informative 
censoring assumption using considering the best and worst-case scenarios and use of the 
drop-out event as a study endpoint (Steyerberg, 2008, Saracino, 2017). Moreover, it is 
likely that various recipient and donor factors were measured with error. Centers may use 
different data collection approach or systematic errors in data collection.  
95 
 
 
 
Selection Biases 
Marginal or non-optimal donors are considered non-ideal for multiple reasons. 
However, improvements in surgery strategies and medical management of these organs 
have led to improved post-transplant graft and patient survival in the last decade. 
Marginal donors are considered a plausible option to offset donor shortage, and, their 
utilization has increased. Studies still provide conflicting results impeding the creation of 
accepted guidelines, and transplant programs have center-specific decision-making rules 
to determine which patients should receive marginal donors (Pezzati, Ghinolfi, De 
Simone, Balzano, & Filipponi, 2015). Unobserved heterogeneity in center practice 
variation can lead to selection bias. Heterogeneity between centers can be addressed by 
incorporating the transplant center as a random effect. Survival models with random 
effect, called frailty models, can be used to account for the center effect on graft survival. 
I did not address center variation in this study. 
Threats to Internal and External Validity 
I did not include all possible donor factors associated with liver graft survival in 
thefinal donor risk model. When relevant variables are omitted, the model functional 
form is misspecified, or data are missing not at random. Therefore, in these cases, the 
statistical model does not capture adequately the variation in the dependent variables for 
the population being studied and can be a threat to internal validity. I used bootstrapping 
to assess internal model validation (Harrell, 2015). I considered several steps to address 
the threat of internal validity including the use of restricted cubic splines to fit nonlinear 
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patterns and, appropriate coding of predictors, including combining variables (Harrell, 
2015). Internal validation addressed the stability of the selection of predictors, and the 
quality of predictions, and helped in selection among candidate models.  
Inferences from SRTR studies are likely to generalize across the United States, but 
unlikely to be extrapolated to other countries. External validation outside the United 
States can be questionable due to differences in policies and procedures or because not all 
variables available in SRTR are collected in foreign transplant registries (Massie, 
Kucirka, & Segev, 2014). The donor risk models only apply to adult NAFLD/CC LT 
recipients are invalid in a pediatric setting. 
Data Analysis Plan 
I described the data cleaning procedures in this section, and also the power analysis 
and the statistical analysis approach used to answer the research questions.  
Sample Size and Power Analysis 
The study was not underpowered because SRTR data included all NAFLD/CC LT 
performed in the United States that met the inclusion criteria. Therefore, the sample size 
was sufficient for bootstrapping validation (Harrell, 2015). I used the Cox PH regression 
to analyze the primary research question. The model tested whether or not the 
independent variables predicted graft failure at 1-year post-transplant. Because I included 
the total population of NASH/CC LT in the study, a priori power analysis was not 
required but was useful to indicate the minimum sample size that was necessary to get the 
desired power and effect size.  
97 
 
 
 
I conducted Cox PH model-based power calculations using the R statistical 
package powerSurvEpi (Qiu et al., 2015). Assumptions for sample size calculation 
included: a power of .80, a type I error rate α=.005, and a postulated hazard ratio of 1.6 
(i.e., the DCD donors having 1.6 times an expected risk of graft failure, compared to non-
DCD donors). Previous studies assumed 15 percent of recipient transplanted with DCD 
donors, and 16 percent of NAFD/CC recipients experiencing liver graft failure within 3-
year post-transplant. The required sample size was 1,742 (Qiu et al., 2015). Observational 
studies need covariate adjustment, and the sample size calculation requires an additional 
assumption regarding the correlation between the covariate of interest and the other 
covariates. The sample size required increased to 2,178 under the assumption of covariate 
correlation, ρ²= 0.20 and to 2,489 for ρ²= 0.30 (Qiu et al., 2015).  
Data Cleaning and Screening Procedures  
The SRTR database package provided Standard Analysis Files (SAF), datasets 
and SAS formats along with information about data linkage and the data dictionary, 
primary and foreign key variables that allowed linkage between candidate information; 
donor information; transplant information; and post-transplant follow-up information 
(SRTR, 2012). The first data management step I undertook was to identify the study 
variables to include in the analysis either directly or as derived variables. In this 
preliminary data preparation phase, I merged different datasets and processed to obtain a 
final dataset that contains both original variables and composite variables, restricted to 
NASH/CC recipients of LT that meet the inclusion criteria. I prepared the variables to 
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perform survival analyses. I merged the SRTR data with the Community Health 
Indicators.  
I used summary statistics to describe the study population. I summarized 
quantitative variables using mean, standard deviations, minimum, maximum, median and 
other quantiles. I summarized categorical variables using frequencies. I used descriptive 
statistics to describe the distribution, central tendency, and dispersion to screen for 
outliers, inconsistencies, and missing values. I set outliers to missing if there were 
obvious mistakes. When necessary, I combined discrete variables in collapsed categories. 
Different transplant centers collect SRTR data, and some variables are collected for 
purposes other than research. Therefore, missing data and measurement errors were 
possible. Exploratory data analysis of key variables helped identify quality issues 
(Massie, Kucirka, & Segev, 2014). 
Statistical Analysis 
I summarized the characteristics of the study population through descriptive 
statistics. I assessed group comparisons for continuous variables using independent t-tests 
or when the assumption of normality is not met by Wilcoxon rank sum rank tests. I used 
Fisher exact tests or the likelihood ratio chi-square tests to compare categorical variables. 
I used the Cox PH regression model to assess the effect of independent donor, transplant, 
recipient and external variables on the risk of the occurrence of graft failure for all 
causes. I performed Wald tests to determine whether or not individual coefficients of the 
Cox PH models were equal to zero.  
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I selected the initial set of potential predictors and covariates to consider in the 
model based on previous studies and expert knowledge. After restricting the list, I 
reviewed variable distribution and missing data. I discarded variables with a large 
number of missing data that were known to be powerful predictors of graft failure. I 
removed variables with narrow distribution not expected to be important predictors of 
graft failure. I used Kaplan-Meier curves to depict the univariate relationships of 
categorical predictors at the initial stage of the analysis, as well as at the end of the study 
to present the prediction characteristics of the model. I used the log-rank tests to compare 
survival curves. 
I performed preliminary univariate Cox PH regressions as a screening tool to 
evaluate the association of each candidate predictor with graft survival, to assess the 
functional form and to explore the non-linear effect of continuous predictors. I 
categorized continuous variables when possible, based on clinically accepted thresholds. 
When not possible, and when non-linear relationships exist, I transformed continuous 
predictors using restricted cubic splines functions and modeled them as non-linear 
predictors. 
Restricted cubic splines are piecewise polynomial joined together at knots which 
are constrained to be liner at the tails. Harrell (2015) suggests modeling continuous 
predictors using restricted cubic splines with no more than five knots as they shape well 
the non-linear predictors and provides a useful tool to investigate the relationships 
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between dependent and independent variables. Restricted cubic splines are very flexible 
and with a robust behavior at the tails of the predictor distributions (see Harrell, 2015).  
I used augmented backward variable elimination using 1000 bootstrap samples for 
model building and to select the final variables. I examined the proportional hazard 
assumption, verifying the pattern of the scaled Schoenfeld residuals against time. To 
evaluate the Cox PH model’s discriminative ability, I used Harrell’s C-statistics. Model 
performance on the data used to fit it is optimistic, better than the performance with new 
data from the same population. Overfitting causes optimism, a threat to model validity. I 
used bootstrap resampling to correct overfitting or optimism in model performance (see 
Harrell, 2015).  
Most studies on identifying risk factors for graft failure risk have employed the 
Cox PH model. Traditional models are unable to address the complexities of the donor, 
transplant, recipient, and external factors. In this study, I explored the potential of random 
survival forest (RSF), a statistical learning method adapted to right-censored survival 
data. RSFs grow many trees using bootstrap samples from the original data and use 
aggregate results of many trees for prediction and to rank variables by their predictive 
importance. RSFs are non-parametric alternatives to the Cox PH model that can capture 
complex and non-linear relationships and, high order interactions, and do not rely on 
distributional assumptions. However, they are “black boxes,” and their inferential 
procedures are not understood. In this study, I used machine learning approaches to 
complement traditional models, not to replace them.  
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I performed all statistical analyses using SAS version 9.4 (SAS Institute) and R 
version R3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).  
Research Questions and Hypotheses 
The purpose of this retrospective cohort study was to investigate donor, 
transplant, recipient and community factor that impact graft survival in the study 
population. I answered the following research questions and hypotheses:  
Research Question 1 
What are the relationships between post-transplant graft survival among 
NAFLD/CC recipients and a number of donor characteristics (age, gender, height, 
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death, 
HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia)? 
𝐻01: There is no association between post-transplant graft survival among 
NAFLD/CC recipients and a number of donor characteristics (age, gender, height, 
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death, 
HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia). 
𝐻𝑎1: There is an association between post-transplant graft survival among 
NAFLD/CC recipients and a number of donor characteristics (age, gender, height, 
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death, 
HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia). 
The analytic objective of this research question was to develop a donor risk model 
that evaluated the intrinsic qualities of the liver allograft and predicted graft failure risk 
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capturing donor only characteristics, and that summarizes into a single continuous graft 
failure risk score the quality of the deceased liver donor, the DQ-NAFLD score. 
Therefore, I included only variables known at the time of the donor offer and evaluation 
in the development of a donor-only score. I fit a Cox PH model to estimate the relative 
risk of graft failure independently associated with each donor variable. I generated 
graphical displays of how each donor predictor is related to the log hazard of graft failure. 
The Cox PH model expressed a relationship between the hazard rate and a set of 
predictors or covariates. I derived the DQ-NASH score from the coefficient of the Cox 
proportional hazard model.   
Research Question 2  
What are the relationships between post-transplant graft survival among 
NAFLD/CC recipients and transplant factors (cold ischemia time, ABO matching, and 
size matching)?  
𝐻02: There is no association between post-transplant graft survival among 
NAFLD/CC recipients and a number of transplant factors (cold ischemia time, ABO 
matching, and size matching). 
𝐻𝑎2: There is an association between post-transplant graft survival rate among 
NAFLD/CC recipients and transplant factors (cold ischemia time, ABO matching, and 
size matching). 
This research question explored the impact of transplant factors on graft survival. 
I fit a Cox PH model to estimate the relative risk of graft failure independently associated 
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with transplant factor. I generated graphical displays of how each transplant predictor is 
related to the log hazard of graft failure.  
Research Question 3 
What are the relationships between post-transplant graft survival among 
NAFLD/CC recipients and a number of donor characteristics (age, gender, height, 
weight, BMI, the cause of death, hypertension, diabetes, donor after circulatory death, 
HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors 
(cold ischemia time, ABO matching, size matching,) after adjusting for characteristics of 
recipients of liver transplant (age, gender, BMI, biological MELD). 
𝐻03: There is no association between post-transplant graft survival among 
NASH/CC recipients and a number of donor characteristics (age, gender, height, weight, 
BMI, cause of death, hypertension, diabetes, donor after circulatory death, HCV status, 
HBsAb status, HBsAg status, MDRD, donor hypernatremia) and transplant factors (cold 
ischemia time, ABO matching, size matching) after adjusting for characteristics of 
recipients of liver transplant (age, gender, BMI, biological MELD). 
𝐻𝑎3: There is an association between post-transplant graft survival rate among 
NASH/CC recipients and a and a number of donor characteristics (age, gender, height, 
weight, BMI, cause of death, hypertension, diabetes, donor after circulatory death, HCV 
status, HBsAb status, HBsAg status, MDRD, hypernatremia) and transplant factors (cold 
ischemia time, ABO matching, size matching) after adjusting for characteristics of 
recipients of liver transplant (age, gender, BMI, biological MELD).  
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Adding additional factors to the DQ-NAFLD donor-only model to account for 
these other sources of variation resulted in a higher predictive ability of the model, or a 
slightly higher C-statistic. However, the initial goal of the donor-only DQ-NAFLD was to 
summarize the risk of graft failure based on deceased donor factors only, and not to 
explain all sources of variation that contribute to liver graft outcomes. To address this 
question, I adjusted the Cox PH model for recipient characteristics to evaluate how the 
strength of the association between the donor risk score and graft failure changes after the 
adjustment. I developed a  more extended version of the DQ-NASH risk score that 
included donor, transplant, and recipient factors useful in decision making for matching 
individual candidates to donors.   
Transplant clinicians are interested in exploring how donor age, brain versus 
cardiac death, and cold ischemia time changed in subgroups of biochemical MELD 
scores (S. Asrani, personal communication, September 3, 2018). To assess these factors, I 
tested pre-specified interactions within strata of biochemical MELD score. I considered a 
model containing a second-order interaction for the triplet of factors, as well as all first-
order interactions. All interaction effects were not significant.  
Research Question 4 
What are the relationships between post-transplant graft survival among 
NAFLD/CC recipients and the health risk status of the county were recipients reside 
measured by the community health score (CHS)? 
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𝐻04: There is no association between post-transplant graft survival among 
NAFLD/CC recipients and the health risk status of the county were recipient resides, 
measured by the CHS. 
𝐻𝑎4: There is an association between post-transplant graft survival among 
NAFLD/CC recipients and the health risk status of the county were recipient resides, 
measured by the CHS. 
I used univariate Cox PH model to explore the effect of graft failure across 
counties grouped by risk category to assess if high-risk counties were associated with 
increased patient and graft survival.  
Research Question 5 
What are the relationships between post-transplant graft survival among 
NAFLD/CC recipients and the distance from the transplant center? 
𝐻05: There is no association between post-transplant graft failure among 
NAFLD/CC recipients and distance from the transplant center. 
𝐻𝑎5: There is an association between post-transplant graft failure among 
NAFLD/CC recipients and distance from the transplant center. 
This question explored the associations of distance from center and liver graft 
failure, to study if living in a high community health risk is associated with worse post-
transplant outcomes. To address this question, I developed a univariate Cox PH model to 
explore the effect of increased distance from the transplant center on the risk of patient 
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and graft survival. I used choropleths maps to visualize patterns in patient and graft 
survival outcomes in relation to their geographic distance from the transplant center. 
Research Question 6  
What are the relationships between post-transplant graft survival among 
NAFLD/CC recipients, DQ-NAFLD risk score and external community factors (CHS and 
distance from the transplant center)? 
𝐻06: There is no association between post-transplant graft survival among 
NASH/CC recipients, DQ-NAFLD risk score and external community factors (CHS and 
distance from the transplant center). 
𝐻𝑎6: There is an association between post-transplant graft survival among 
NAFLD/CC recipients, DQ-NAFLD risk score and external community factors (CHS and 
distance from the transplant center). 
I used Kaplan Meier curves to explore the graft survival curves by quintiles of 
DQ- NAFLD risk score, by quintiles of community health risk score, and by quintiles of 
distance from the transplant center. I tested differences in survival curves using the log-
rank test.  
Moreover, I tested the interaction effect between DQ- NAFLD score and 
Community Health Risk score as well as the interaction between DQ- NAFLD score and 
distance from the transplant center. More specifically, I tested the hypothesis that 
recipients who reside in high-risk communities, or who are very distant from the 
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transplant center, are more likely to fail their high-risk graft compared to recipients in 
low-risk communities. 
Ethical Considerations 
In general, the usage of existing secondary data does not require IRB approval if 
it does not involve human subjects. The Walden Institutional Review Board reviewed the 
study to determine if the study met the ethics. Data requests to SRTR required 
completing a DUA which included a research plan and a security plan, describing how 
data would be stored and who would have access to data (Leppke et al., 2013). Data were 
password protected, available only to authorized researchers. 
Researchers required using the data solely for bona fide analysis, and not for any 
other purposes. Researchers did not attempt to identify patients and use the information 
unlawfully and unethically in violation of the Health Insurance Portability and 
Accountability Act (HIPAA) or any federal or state laws regarding confidentiality of 
patient medical records (Gliklich, Dreyer, & Leavy, 2014; OPTN, 2018). The final 
analysis was reviewed by SRTR to ensure compliance with the terms of the DUA 
regarding confidentiality (OPTN, 2018). 
Summary 
I proposed a population-based longitudinal cohort study that used SRTR data 
between 2013 and 2016 and Community Health data to develop the DQ-NAFLD/CC a 
donor quality index score. I achieved this by assessing multiple donor characteristics 
estimates for the quality of a liver allograft. This study provides a useful metric for risk 
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evaluation and stratification. Through additional analyses, I explored how donor quality 
can predict liver graft survival independently or additively with recipient characteristics, 
transplant, and external community factors. The analysis of how external factors impact 
the transplant risk models shed important light on the understudied effect of 
environmental factors on post-liver transplant outcomes. Chapter 4 presents the results of 
the statistical analyses performed to answer the study hypotheses according to the 
statistical analysis plan. Chapter 5 provides an interpretation of the results and the 
potential implications and contributions of study findings, as well as suggestions for 
future research.    
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Chapter 4: Results 
The purpose of this retrospective observational quantitative study was to analyze 
data from the SRTR registry to develop a donor quality score tailored to NAFLD/CC 
candidates on the wait list for a liver transplant (the DQ-NAFLD risk score) and to 
explore the impact of external factors including community health indicators and 
geographic factors related to the counties where recipients of LT reside. Both a donor 
intrinsic factor DQ-NAFLD risk score, as well as an extended DQ-NAFLD risk score, 
were developed. The study population included consecutive adult recipients of LT 
between July 1, 2013, and December 31, 2016, whose indication for LT was NAFLD/CC. 
During the study period, 24,497 patients received an LT, but only 3,165 met the inclusion 
criteria. Moreover, the purpose of the study was to analyze the external impact on graft 
survival within 1 year post LT, and of community health factors and distance from 
recipient residence to transplant center on liver graft survival within 1 year post LT. 
SRTR data were merged with data from the County Health Rankings & Roadmaps 
database to link patients to their community health risk based on their county of 
residence.  
Cox PH models were used to predict liver graft failure at 1-year post LT. The 
fourth chapter outlines the selection of the study cohort and contains the results of the 
statistical analysis conducted to answer six research questions. This chapter contains a 
summary of the baseline and demographic characteristics of the study cohort of 
NAFLD/CC recipients of LT and a comparison of these characteristics to a control cohort 
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of recipients transplanted for etiologies other than NAFLD/CC and HIV. The statistical 
analysis methods used were checked to ensure the assumptions were met, and study 
findings were summarized for each research question.  
Data Collection 
This study included retrospective secondary observational data from the SRTR 
registry, a transplant population-based database that contains nationwide information on 
recipients of solid organs transplant. SRTR combines data from different sources 
including transplant centers. All recipients in the SRTR database remained anonymized, 
and no attempt was made to identify patients. For this study, SRTR database tables were 
merged with county health indicators downloaded from a publicly available website, the 
County Health Rankings and Roadmaps (2018). The FIPS code was converted into zip 
code and used to link county health indicators and rankings to the recipient zip code in 
the SRTR database. 
Data Access and Acquisition  
Data were requested from SRTR. Walden University’s IRB approval number for 
the study is 12-10-18-0296616. The SRTR database was queried to identify subjects that 
met the inclusion criteria. Furthermore, all of the prespecified variables listed in Chapter 
3 were reviewed. Donor steatosis, an important predictor of graft failure, was available 
only when donor biopsy was performed. Not all donors were biopsied. Because a large 
number of missing biopsies was expected, donor steatosis was not included on the 
original list of the study variables. However, donor biopsy data were reviewed to assess 
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the sample size availability and to evaluate the feasibility of a subset analysis that 
included donor steatosis. The response variable, graft survival post LT, was censored at 1 
year while graft failure or death for any causes were considered events as described in the 
study protocol outlined in Chapter 3. Some variables were not used because insufficient 
information was available or because they had poor distributions.  
Inclusion Criteria and Cohort Selection 
There were 24,997 liver-only transplants performed between July 1, 2013, and 
December 31, 2016. Figure 6 depicts the selection process steps along with the patients 
excluded at each step. By applying the exclusion criteria in sequence, I excluded 
recipients younger than 18-year old  (1,953), recipients with a previous transplant 
(1,161), multiorgan transplant recipients (2,079), live donor transplant recipients (884), 
Status 1 recipients (540), and recipients transplanted for indication other than NAFLD 
and CC (15,220). As showed in Figure 6, the final study population consisted of 3,165 
adult NASH/CC recipients of a primary, deceased donor, liver-only transplant during the 
study period. Patient follow-up for graft failure started on the day of the transplant. The 
outcome of interest in the current analysis was graft failure or death for any causes. 
Patients were followed from the time of transplant until the earliest of graft failure, death, 
loss to follow-up, or the conclusion of the observation period. In total, there were 419 
graft failure events of which 294 died within 1-year post LT, whereas 2,746 patients had 
a functioning graft at the end of follow-up. All consecutive patients who met the 
inclusion criteria were considered.  
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Figure 6. Flow chart of study population including exclusion criteria. 
Recipients of 
LT 
07/01/2013 -
12/31/2016
Initial 
Poulation 
N=24,997
Age at 
Transplant ≥ 
18 Years
Age<18 
Years 
Excluded
N=23,044
Previous 
Transplants 
Excluded
N=21,883
Liver 
Transplant 
Alone
Multiple 
Transplant
s Excluded
N=19,809
Deceased 
Donor Only
Living 
Donors 
Excluded
N=18,925
Non Status 1 
Recipients
Status 1 
Recipients 
Excluded
N=18,385
NAFLD and CC
Non-
NAFLD/CC 
Excluded
N=3,165
113 
 
 
 
Exploratory Data Analysis 
Data were initially explored to get a good first glimpse before formal modeling 
using summary statistics and graphical representations to spot potential outliers, to 
investigate patterns of missing variables, to assess correlations among variables, and to 
explore the distributional shape of continuous variables and the frequency distribution of 
categorical variables. Graphical analysis of study variables is provided in Appendix C. 
Before modeling, I analyzed the mechanism of missingness to quantify the extent 
of missing data and to examine combinations of predictors with missing data on the same 
subjects. Most of the donor variables, including donor demographics, height and weight, 
donor sodium, donor diabetes, and donor cause of death, had no or very few missing 
values. Only 0.06% of patients in the study cohort had missing HIV data, while 0.09% 
had missing cold ischemia time. Donor diabetes was missing in 1.14% of subjects, while 
donor hypertension was missing in 0.76% of subjects, and they tended to be missing in 
the same patients. Donor steatosis was missing in 38% of cases and was not included in 
multivariate analyses. Data on HBsAb was missing in 79.3% of subjects; therefore, these 
data were excluded from subsequent analyses.  
Outliers are values outside a typical range. Boxplots were used to detect outliers, 
or values at least 3 times the interquartile range, and those were checked for biological 
plausibility. Exploratory data analysis did not indicate implausible values for most of the 
study variables. Four extreme outliers for MDRD were found and removed. 
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Descriptive Statistics 
I compared the baseline characteristics of the study cohort to a control group of 
recipients transplanted for other etiologies to identify differences. Since the advent of 
DAAs, the number of LTs due to HCV has dramatically decreased. Therefore, patients 
transplanted with HCV were excluded from the comparison because no longer relevant in 
transplant practice. I compared and summarized baseline characteristics of LT recipients 
for both NAFLD/CC and other indications for LT in Table 15, confirming literature 
finding that NAFLD/CC patients are older and have more comorbidities (O’Leary et al., 
2011), and supporting the decision to develop risk models tailored to NAFLD/CC. I 
assessed group differences using the non-parametric Wilcoxon rank sum test for 
continuous variables and the chi-squared test or Fisher’s exact test to compare 
proportions of categorical variables. I presented continuous data as median and 
interquartile range (IQR), and categorical data as percentages as reported in Table 15. 
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Table 15 
Characteristics of Study and Control Cohorts 
 
Non-NAFLD/CC 
N=10534 
NAFLD/CC 
N=3165 p-value 
Recipient characteristics    
Recipient age 58.0 (50.0, 64.0) 60.0 (54.0, 66.0) <.001 
Recipient sex:   <.001 
  Female 31.8% 43.2%  
  Male 68.2% 56.8%  
Recipient BMI (kg/m2) 28.0 (24.0, 32.0) 31.0 (27.0, 35.0) <.001 
Recipient BSA (m2) 1.99 (1.81, 2.17) 2.08 (1.88, 2.27) <.001 
Biological MELD score 19.0 (12.0, 30.0) 23.0 (17.0, 32.0) <.001 
                                                                                                        (table continues) 
. 
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Non-NAFLD/CC 
N=10534 
NAFLD/CC 
N=3165 
p-
value 
Donor characteristics    
Donor age 43.0 (28.0, 56.0) 45.0 (29.0;57.0) .003 
Donor sex:   .850 
  Female 41.1% 41.3%  
  Male 58.9% 58.7%  
Donor height (cm) 170 (165, 178) 172 (163, 180) .264 
Donor weight (kg) 80.0 (68.0, 94.0) 81.0 (68.9, 97.5) <.001 
Donor BMI (kg/M2) 27.0 (23.0, 31.0) 28.0 (24.0, 32.0) <.001 
Donor BSA (M2) 1.95 (1.77, 2.14) 1.97 (1.79, 2.18) <.001 
Donor diabetes   .224 
  No diabetes 87.5% 86.3%  
  No insulin dependent 6.52% 7.03%  
  Insulin dependent 6.00% 6.65%  
Donor HTN 38.3% 40.1% .083 
Donor hypernatremia 7.15% 7.74% .278 
Donor cause of death:   .243 
  Trauma 29.6% 28.8%  
  Anoxia 34.0% 32.8%  
  Cva 33.9% 35.8%  
  Other 2.54% 2.65%  
Donor DCD 6.89% 6.96% .942 
Donor MDRD: 70.0 (40.0, 103) 69.0 (39.0, 102) .405 
Whole/split:   .073 
  Whole 98.6% 99.0%  
  Reduced/split 1.41% 0.98%  
Increased risk 21.5% 19.2% .006 
                                                                                                        (table continues) 
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Non-NAFLD/CC 
N=10534 
NAFLD/CC 
N=3165 
p-
value 
Transplant/matching     
Cold ischemia time (hrs.) 5.96 (4.65;7.42) 5.90 (4.60;7.33) .360 
ABO compatibility:   1.000 
  ABO identical/compatible 98.9% 98.2%  
  ABO incompatible 1.11% 1.80%  
Donor/recipient size match:   <.001 
  Small for size 7.82% 10.2%  
  Normal for size 83.1% 81.7%  
  Large for size 9.12% 8.06%  
Geography and community     
Distance to transplant center 36.0 (14.0, 104) 51.0 (18.0, 117) <.001 
Distance to transplant center:   <.001 
  0-8 15.2% 10.2%  
  9-51 43.1% 40.5%  
  52-218 31.1% 39.3%  
  219+ 10.5% 10.0%  
Community health score 15.0 (10.0, 21.0) 17.0 (12.0, 25.0) <.001 
Community health score:   <.001 
  <=10 28.6% 21.6%  
  11-20 45.2% 41.4%  
  21-30 20.8% 26.2%  
  >30 5.32% 10.8%  
1-year graft survival (%) 86.1 (84.3, 
87.9) 
87.4 (85.8, 89.1) .310 
Note. In the non-NAFLD/CC group, HCV patients (N=7,850) were excluded because 
they were no longer relevant in transplant practice. 
 
NAFLD/CC recipients were statistically significantly older (Mdn=60; IQR=54-66) than 
the control group (Mdn=58, IQR=50-64) with a higher BMI (Mdn=31; IQR=27-35), as 
compared the other etiologies (Mdn=28; IQR=24-32). There were statistically 
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significantly more females (43%) than males (32%), with p<.001. NAFLD/CC recipients 
were transplanted at significantly higher median MELD score at 23 (IQR=17-32), as 
compared to the control group (Mdn=19; IQR=12-33) and received statistically 
significantly more donor livers small for size, 10.2% versus 7.8%, p<.001). The overall 
liver graft survival curves for the two groups were compared through the Kaplan-Meier 
curves, as depicted in Figure 7. NAFLD/CC recipients were significantly less likely to 
survive without losing the liver allograft within 1-year post LT, with an overall liver graft 
survival at 1-year of 86.7% versus 89.0% (p<.001). The median CHS for the study cohort 
was 15. Subjects were grouped by CHS, as shown in Table 16.  
 
Figure 7. Kaplan-Meier survival curves by liver etiology. 
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Table 16 
Characteristics of Study Cohort by Community Health Score 
 
Low CHS risk 
N=1,463 
High CHS risk 
N=1,554 p-value 
Recipient characteristics    
Recipient age 61.0 (54.0, 66.0) 60.0 (54.0, 65.0) .056 
Recipient sex:   .496 
  Female 42.7% 44.0%  
  Male 57.3% 56.0%  
Recipient BMI (kg/M2) 31.0 (26.0, 35.0) 32.0 (27.0, 36.0) .001 
Recipient BSA (M2) 2.05 (1.85, 2.26) 2.10 (1.91, 2.29) <.001 
Meld 24.0 (18.0, 34.0) 22.0 (17.0, 29.0) <.001 
Donor characteristics    
Donor age 44.0 (29.0;57.0) 45.0 (30.0, 57.0) .791 
Donor sex:   .303 
  Female 39.9% 41.8%  
  Male 60.1% 58.2%  
Donor height (cm) 173 (164,180) 172 (165,180) .876 
Donor weight (kg) 81.0 (69.1;96.4) 81.6 (69.4,98.9) .131 
Donor BMI (kg/M2) 27.0 (24.0;32.0) 28.0 (24.0, 2.0) .155 
Donor BSA (M2) 1.97 (1.79;2.17) 1.98 (1.80, 2.19) .156 
Donor diabetes:   .565 
  No diabetes 86.7% 86.1%  
  No insulin dependent 7.16% 6.87%  
  Insulin dependent 6.12% 7.06%  
Donor HTN 39.5% 40.1% .778 
Donor hypernatremia 6.70% 8.88% .031 
(table continues) 
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Low CHS risk 
N=1,463 
High CHS risk 
N=1,554 p-value 
Donor cause of death:   .337 
  Trauma 29.8% 27.9%  
  Anoxia 33.6% 32.3%  
  Cva 34.2% 37.1%  
  Other 2.46% 2.77%  
Donor DCD:   .084 
  DBD 91.9% 93.6%  
  DCD 8.07% 6.37%  
Donor MDRD 70.0 (41.0, 101) 68.0 (37.2, 103) .389 
Transplant/matching    
CIT (hr) 6.06 (4.95, 7.76) 5.70 (4.43, 7.10) <.001 
Abo compatibility:   .221 
  Identical/compatible 98.6% 99.2%  
  Incompatible 1.37% 0.84%  
Donor/recipient size 
match: 
  .001 
  Normal for size 80.0% 83.5%  
  Small for size 10.0% 10.2%  
  Large for size 9.98% 6.25%  
Distance to Tx Ctr 31.0 (14.0, 97.0) 70.0 (29.2;132.0) <.001 
1-year graft survival (%) 86.1 (84.3, 87.9) 87.4 (85.8, 89.1) .310 
 
Demographic characteristics of recipients in low and high-health risk 
communities were comparable. Recipients resident in low health risk communities had a 
statistically significantly lower BMI (Mdn=31.0; IQR=26.0-35.0) compared to residents 
in high-risk communities (Mdn=32.0; IQR=27.0-36.0). NAFLD/CC recipients in low 
health risk communities were transplanted at a statistically significantly higher median 
MELD score at the time of transplant at 24 (IQR=18.0-34.0) compared to the high health 
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risk counterpart at 22 (IQR=17.0-29.0). Recipients from low health risk counties were 
more likely to receive donors who were large for size (9.98% versus 6.25%, p<.001). 
Recipients resident in low health risk counties had a much longer median distance from 
the transplant center (31 miles, IQR=14.0-97.0) than those who resided in high health risk 
counties (70 miles, IQR=29.2-132.0). The Kaplan-Meier survival analysis in Figure 8 
showed that 1-year graft survival did not differ significantly between recipients in low 
and high health-risk communities. 
 
 
Figure 8. Kaplan-Meier survival curves by community health score. 
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Univariate Preliminary Analysis 
I conducted univariate analyses to learn about candidate predictors and their 
relation to 1-year graft survival post LT as a prelude to subsequent multivariate analyses. 
The variables included in the univariate screening were donor’s gender, age, height, BMI, 
BSA, donor cause of death, hypertension, diabetes, hypernatremia, microsteatosis, 
macrosteatosis, MDRD, DCD, recipient’s age, gender, BMI, BSA, cold ischemia time, 
ABO compatibility, donor and recipient size match.  
Univariate Analysis of Continuous Predictors` 
I conducted univariate analyses to explore the association between categorical and 
continuous variables with 1-year graft survival post LT. Continuous predictors included 
in a Cox PH model must meet the underlying assumption of linear relationship with the 
log hazard of the time to event outcome. I transformed continuous variables using RCS 
transformations, which are flexible functions with robust behavior at the tails of predictor 
distributions. I used the linearity Wald tests via RCS transformations to test the 
assumptions of linear relationships between continuous predictors and the risk of graft 
failure for NAFLD/CC recipients of LT. I also used splines to model the effects of 
nonlinear predictors in subsequent analyses, and I placed the knots on the spline curve 
defining the end of one segment and the start of the next so that the overall curve was 
smooth and continuous. 
The fit depends more on the number of knots, and the exact location of knots is 
not critical (see Harrell, 2015). So, I placed the knots at fixed percentiles of predictor’s 
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marginal distribution as recommended by Harrell (2015), who also suggested that five 
knots are sufficient to provide a good fit of nonlinear patterns that are likely to occur in 
practice. Therefore, I selected the number of knots for each continuous predictor between 
three and five to balance the best fit and overfitting, resulting in a parsimony model with 
the lowest Akaike Information Criteria and maximum likelihood. In a univariate Cox PH 
model, the relative hazard, which is the ratio of the hazard at time t to the hazard at 
baseline is a function of the exponentiated continuous predictor x, as shown in Equation 
9: 
                                              
ℎ(𝑡)
ℎ(0)
= 𝑒𝑥                                                           (9) 
If the natural logarithm is taken in both size of the Cox PH model, the log relative hazed 
is a linear function of the predictors: 
𝑙𝑛(
ℎ(𝑡)
ℎ(0)
) = 𝑥 
Figures 9-11 depict univariate display plots of the estimated relationship between 
continuous independent predictors modeled as RCSs and log hazard ratio for graft failure 
from a sample of 3,165 NAFLD/CC recipients and 419 graft failures, including deaths. 
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Figure 9. Functional relationships between donor height, donor weight, donor BMI and 
donor BSA, and log relative hazard of graft failure at one-year post LT. 
Note. Number of knots and location, respectively: donor height (3 knots at 157, 172 and 
185 cm), donor weight (3 knots at 59, 81 and 113 kg), donor BMI (3 knots at 21, 28, and 
23kg/m2), donor BSA (knots at 1.6, 2.0, and 2.4m2). 
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Figure 10. Functional relationships between donor MDRD, donor age, recipient age and 
recipient BMI, and log relative hazard of graft failure at 1-year post LT. 
Note. Number of knots and location, respectively: donor MDRD (3 knots at 17, 69, and 
137), donor age (4 knots at 18, 35, 52, and 71 years), recipient age (4 knots at 42, 57, 64, 
and 70 years), and recipient BMI (3 knots at 24, 31 and 39 kg/m2). 
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Figure 11. Functional relationships between recipient BSA, donor/recipient BSA, CIT, 
and MELD score, and log relative hazard of graft failure at 1-year post LT. 
Note. Number of knots and location, respectively: recipient BSA (3 knots at 1.7, 2.1 and 
2.4m2 ), donor/recipient BSA (3 knots at 0.8, 1.0 and 1.2), CIT (4 knots at 3.1, 5.1, 6.6 
and 10.0 hours) MELD score (3 knots at 13, 23 and 39). 
 
Table 17 summarizes the results of the univariate association of each continuous 
predictor modeled through RCS with the time-to-event outcome and formal tests of the 
linearity using, respectively the Wald 𝜒2 test for association and the Wald 𝜒2 test for 
linearity (Harrell, 2015). Donor height was significantly associated with the log hazard 
for graft failure post LT (𝜒2(3) = 8.23, p = .035), and the association was not 
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significantly different from linear 𝜒2(2) = 2.97, p=.226). The donor’s factors, weight, 
BMI, BSA, MDRD, and age were not significantly associated with liver graft survival.  
Recipient’s age (𝜒2(3) = 10.12, p=.016), BMI (𝜒2(2) = 6.12, p=.047), BSA 
(𝜒2(2) = 7.32, p = .025) and MELD score (𝜒2(2) = 6.02, p=.044), were significantly 
associated with graft failure, with significant nonlinearity, respectively, (𝜒2(1) = 6.10, 
p=.013) for BMI, (𝜒2(1) = 5.13, p=.024) for BSA, and (𝜒2(1) = 4.37, p=.037) for 
MELD score. Donor/Recipient BSA was significantly associated with the outcome 
(𝜒2(2) = 8.27, p = .016), and with significant nonlinearity (𝜒2(1) = 5.12, p=.024), 
while CIT was not significantly associated with the outcome.  
Table 17 
Univariate Association and Linearity Tests for Continuous Variables Predicting Liver 
Graft Failure 
Variable  
Association 
Wald 𝜒2(𝑑. 𝑓. ) 
 
Linearity 
Wald. 𝜒2(𝑑. 𝑓. ) 
 
Donor height (cm) 8.23 (3)* 2.97 (2) 
Donor weight (kg) 1.02 (2) 0.14 (1) 
Donor BMI (kg/M2) 4.18 (2) 0.37 (1) 
Donor BSA (M2) 0.81 (2) 0.74 (1) 
Donor MDRD 4.18 (2) 1.42 (1) 
Donor age (yrs.) 0.52 (3) 0.39 (2) 
Recipient age (yrs.) 10.12 (3)* 1.73 (2) 
Recipient BMI (kg/M2) 6.12 (2)* 6.10 (1)* 
Recipient BSA (M2) 7.34 (2)* 5.13 (1)* 
Donor/recipient BSA 8.27 (2)* 5.12 (1)* 
CIT (hrs.) 1.62 (2) 0.07 (1) 
MELD score 6.02(2)* 4.37 (1)* 
Note. NAFLD/CC Recipients (n=3165).* p<.05. Each predictor modeled as RCS. 
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Univariate Analysis of Categorical Predictors 
I conducted univariate Kaplan-Meier survival analyses to examine independent 
predictors and their effect on graft survival by comparing the survival experiences across 
each predictor categories. I performed log-rank tests to determine if there were 
differences in the survival distribution for the different categories of each independent 
variable. Pairwise log-rank comparisons were conducted to determine which categories 
had different survival distributions. Compared to recipients of DBD donors, DCD donor 
recipients experienced a significantly worse graft survival at 1-year post LT, 𝜒2 (1) = 
18, p = <.0001 (Figure 12).  
 
Figure 12. Kaplan-Meier survival curves by donor type. 
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The survival distributions for the three categories of donor diabetes were 
statistically significantly different, 𝜒2 (2) = 17.6, p < .0001 (Figure 13). The Bonferroni 
corrected pairwise comparisons found that recipients who received a diabetes insulin 
dependent donor had a statistically significant worse graft survival at one year, as 
compared to recipients who received donors without diabetes (p=.004) or donors with 
non-insulin dependent diabetes (p=.001) (Figure 13).  
 
Figure 13. Kaplan-Meier survival curves by donor diabetes. 
 
Donor/recipient liver size was associated with graft survival at 1-year post LT, 
𝜒2(2) = 10.7, p = .005 (Figure 14). Bonferroni corrected post-hoc comparisons revealed 
that compared to normal for size donors, large for size donors was associated with an 
unfavorable graft survival experience (p = .003). 
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Figure 14. Kaplan-Meier survival curves by donor/recipient size match. 
 
Donor gender (𝜒2(1) = .4, p = .51), hypertension (𝜒2(1) = .3, p = .58), donor 
cause of death (𝜒2(3) = 3.8, p = .28), micro steatosis (𝜒2(2) = 4.2, p = .12), macro 
steatosis (𝜒2(3) = 5.1, p = .079), ABO compatibility (𝜒2(1) = 0.1, p = .74), and 
hypernatremia (𝜒2(1) = 0.1, p = .72), were not associated with 1-year post LT graft 
survival in Kaplan-Meier analyses (Figures 15, 16, 17, 18, 19, 20, 21).  
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Figure 15. Kaplan-Meier survival curves by donor gender. 
 
Figure 16. Kaplan-Meier survival curves by hypertension. 
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Figure 17. Kaplan Meier survival curves by cause of death. 
  
Figure 18. Kaplan-Meier survival curves by microsteatosis stage. 
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Figure 19. Kaplan-Meier survival curves by macrosteatosis stage. 
 
Figure 20. Kaplan-Meier survival curves by ABO compatibility. 
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Figure 21. Kaplan-Meier survival curves by hypernatremia. 
 
Figure 22 depicts Kaplan-Meier graft survival curves of NAFLD/CC recipients 
who received Public Health Service increased risk and non-increased risk donors. The 
log-rank test compared survival experience between the two donor risk categories and 
found no statistically significant difference (p=.96). Table 18 contains information about 
graft survival probability at 1-year post LT and the 95% CIs.  
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Figure 22. Kaplan-Meier survival curves by public health increased donor risk. 
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Table 18 
One-year post LT Graft Survival Probability and 95% Confidence Intervals 
Variable  Level  1-year survival  95% CI 
Total  Overall   
Gender Male .87 (.84, .88) 
 Female .86 (.84, .88) 
Donor diabetes No diabetes .87 (.86, .88) 
 No insulin dependent .90 (.87, .94) 
 Insulin dependent  .78* (.72, .84) 
Donor hypertension No hypertension .87 (.85, .89) 
 Hypertension .86 (.84, .88) 
Donor hypernatremia Hypernatremia .88 (.84, .92) 
 No hypernatremia .87 (.85, .88) 
Micro steatosis Mo .83 (.80, .87) 
 M1 .87 (.84, .90) 
 M2 .89 (.84, .94) 
Macro steatosis Mo .86 (.83, .90) 
 M1 .87 (.84, .89) 
 M2 .80 (.73, .87) 
Donor DCD DBD .87 (.86, .89) 
 DCD  .77*** (.72, .83) 
Donor cause of death Trauma .88 (.86, .90) 
 Anoxia .87 (.85, .89) 
 CVA .86 (.84, .88) 
 Other .83 (.75, .92) 
Size match Normal for size .87 (.86, .89) 
 Small for size .87 (.83, .90) 
 Large for size  .81* (.77, .85) 
ABO compatibility Identical/compatible .87 (.85, .88) 
 Incompatible .88     (.79, .99) 
Note. * p<.05, **p<.01, ***p<.001. 
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Research Question 1 
The first research question was based on whether there is a relationship between 
post-transplant graft survival among NAFLD/CC recipients and a number of donor 
characteristics (age, gender, height, weight, BMI, the cause of death, hypertension, 
diabetes, donor after circulatory death, HCV status, HBsAb status, HBsAg status, 
MDRD, hypernatremia). To answer this question, I considered a semiparametric 
approach or a multivariable Cox PH regression model using graft survival outcomes, 
which included intrinsic donor factors and a nonparametric machine learning approach or 
random survival forests (RSF).   
The initial list of candidate predictors, based on literature review and combined 
with knowledge matter, included 13 donor’s variables: age, sex, height, weight, BMI, 
BSA, hypertension, the cause of death, hypernatremia, DCD, MDRD, HCV, and HBsAb. 
I analyzed variable distributions and patterns of missing data in the preliminary phase. 
The distributions of HCV and HBsAb status were too narrow to allow the inclusion in the 
model. I excluded HBsAg because it was missing in a large number of subjects. I 
removed four extremely high values for MDRD because they were considered as 
potential errors.   
Cox PH Approach 
I analyzed donor height, donor BMI, and donor BSA separately in alternative 
models because of collinearity, and I compared the models using the Akaike Information 
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Criteria (AIC). At least one of the donor factors considered was missing in 47 cases (or 
1.5% of cases). Because the sample size was large enough for adequate power, and the 
sample was representative of the target population, I conducted complete cases analysis.  
The effective sample size available was sufficiently large to allow fitting a 
saturated pre-specified model with all predictors, including the non-significant in the 
univariate analysis. I used smoothing transformations of continuous predictors to relax 
the linearity assumption and prevent residual confounding. I tested model distributional 
assumptions using smoothed scaled Schoenfeld residuals for each predictor and the 
graphical visualization. I did not observe any trend against time and no major violations. I 
tested the validity of the proportional hazard assumption for each covariate and globally. 
The global test of proportional hazard was not statistically significant (p= .245) indicating 
that the proportionality of hazards was met at significance level α=.05. 
Dunkler, Plischke, Leffondré, & Heinze (2014) recently proposed a variable 
selection strategy which combines significance and change in estimation criterion, the 
augmented backward elimination, which enables assigning a specific role to independent 
variables. This strategy allows the inclusion in the model of “passive variables,” 
regardless of their significance, just based on subject-matter knowledge. I applied an 
augmented backward elimination to reduce the number of predictors in the final model, in 
1000 bootstrap samples drawn from the original data, with a level of significance set to 
α=.2 and the threshold of the relative change-in-estimate criterion ‘τ’ set to .1. This 
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strategy allowed to include into the model donor age and DCD regardless of their 
statistical significance, as known predictors of graft failure. 
The independent donor variables selected in the final model included: age, height, 
diabetes, DCD, and MDRD. Harrell (2015) suggested that at least 10–20 events are 
needed per degree of freedom, as a rule of thumb. The study sample included 412 events 
and approximately 20 degrees of freedom to spend to fit the model, which used 12 
degrees of freedom. I tested the overall significance of the Cox PH model or the model 
goodness of fit using the likelihood ratio test (𝜒2(11) = 48.68, p <.0001) indicating that 
the model was statistically significant and adequate in predicting the graft survival 
experience of NAFLD/CC recipients of LT. 
The results of the selected Cox regression model are presented in Table 19, which 
shows the estimated coefficients, the adjusted hazard ratios (AHR) along with the 95% 
confidence intervals (CI), of each categorical predictor, for each parameter used in the 
splines. Recipients of DCD grafts were more than twice likely to lose their grafts within 
1-year post LT (AHR=2.17, 95% CI=1.60, 2.95). Receiving donors with insulin-
dependent diabetes was associated with an increased risk of graft failure within 1-year 
post LT (AHR=1.71, 95% CI= 1.24, 2.38). The final RCS regression model results in 
Table 19 include estimated coefficients for each parameter used in the splines, which do 
not have an immediate interpretation but can be better described graphically. Tables 20-
22 provide useful interpretations of the RCSs variables.  
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Table 19  
Multivariate Cox PH Model for Donor Variables Predicting Liver Graft Function 
Variable Estimated β 
SE(β) 
Wald ᵪ2 AHR (95% CI) 
Donor type    
  DBD  Reference   
  DCD .776 (.156) 4.96 2.17 (1.60, 2.95)** 
Donor diabetes    
  No Diabetes  Reference   
  Non-insulin dependent -.344 (.230) -1.49 0.71 (1.24, 2.38) 
  Insulin dependent .539 (.167) 3.23 1.71 (1.24, 2.38)* 
MDRD linear -.004 (.003) -1.34 1.00 (0.99, 1.01) 
MDRD’ .001 (.003) 0.43 1.00 (0.99, 1.01) 
Donor height linear -.031 (.011) -2.90 0.97 (0.95, 0.99)* 
Donor height’ -.064 (.034) 1.87 1.07 (1.00,1.14)  
Donor height’’ -.261 (.163) -1.60 0.77 (0.56, 1.06) 
Donor age linear .009 (.014) 0.60 1.01 (0.98, 1.04) 
Donor age’ -.038 (.045) -0.83 0.96 (0.88, 1.05) 
Donor age’’ .012 (.125) 0.95 1.13 (0.88, 1.44) 
Note. NAFLD/CC recipients (n=3,165). β =estimated coefficient of Cox PH model, 
SE=standard error, AHR=adjusted hazard ratio. CI=confidence intervals. 
*p<.01, **p<.001 
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Table 20  
Selected Estimates for Donor Age from the Multivariate Cox PH Regression  
Donor Age (yrs) AHR 95% CI 
20 1.01 (0.76, 1.33) 
 
40 1.04 (0.95, 1.14) 
 
45 Reference  
50 0.97 (0.89, 1.05) 
60 1.00 (0.85, 1.17) 
Note: Donor age (yrs.) adjusted to donor height of 172 cm, no diabetes, DBD donor,  
MDRD of 69. AHR=adjusted hazard ratio, CI=confidence intervals. 
 
Table 21  
Selected Estimates for Donor MDRD from the Multivariate Cox PH Regression  
MDRD ARH 95% CI 
30 1.14 
 
(0.97, 1.33) 
50 1.06 
 
(0.99, 1.14) 
60 1.03 
 
(1.00, 1.06) 
69 Reference   
80 0.96 
 
(0.95, 0.99) 
 
100 0.92 
 
(0.87, 0.98) 
 
120 0.88 (0.79, 0.98) 
Note: MDRD adjusted to no diabetes, DBD, donor height of 172 cm, donor age of 45 yrs. 
AHR=adjusted hazard ratio, CI=confidence intervals. 
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Table 22 
Selected Estimates for Donor Height from the Multivariate Cox PH Regression  
Donor height (cm) AHR 95% CI 
130 2.67 
 
(1.41, 5.07) 
 
140 1.97 
 
(1.26, 3.07) 
 
160 1.08 
 
(0.90, 1.29) 
 
172 Reference  
180 1.01 (0.89, 1.45) 
 
180 0.84 (0.57, 1.23) 
Note: Donor height (cm) adjusted to donor age of 45 yrs., no diabetes, DBD donor, 
MDRD of 69. AHR=adjusted hazard ratio, CI=confidence intervals. 
 
Table 21 summarizes the AHR and 95% CI for selected MDRD values. 
Compared to a median reference donor with MDRD of 69, liver allografts from donors 
with an MDRD of 100 provided a reduction of 8% in the risk of graft failure within 1-
year post LT (AHR=0.92, 95% CI=0.79, 0.98). Compared to a median donor of 172 cm 
height, livers from donors of 140 cm height were associated with 97% higher risk of graft 
failure (AHR=1.97, 95% CI 1.26, 3.07). This finding indicated that holding all other 
variables constant to their reference values, liver allografts from donors with a height of 
140 cm were almost twice more likely to fail within 1-year post LT, compared to grafts 
from donors with a height of 172 cm (Table 22).  
Figure 23 illustrates the adjusted hazard of graft failure as a function of donor age 
(yrs.), as follows: (A) Donor MDRD (B) and donor height (cm) (C), holding all other 
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variables constant at representative levels set at their reference category or mean values 
(DBD donors, without diabetes, with MDRD of 69, of 45 years, with a height of 172 cm).  
 
 
Figure 23. Restricted cubic splines of the association between donor age (A), donor 
MDRD (B) and donor height (cm) (C) and adjusted relative hazard of graft failure at 1-
year post LT. 
Note. The model is adjusted for the following variables set at reference category: donor 
type (DBD), diabetes (No), or median category: MDRD (69), donor age (45 yrs.), donor 
height (172 cm). 
 
144 
 
 
 
When compared to an average reference donor, donor age was not associated with 
the risk of graft failure, as shown in Figure 23 (A). The risk of graft failure decreased, as 
MDRD increases as displayed in Figure 23 (B). Decreasing donor height was associated 
with an increased risk of graft failure, as shown in Figure 23 (C).  
After fitting a Cox PH model that included splines, I computed hazard ratios by 
comparing specific values of a variable, with a single reference value. From Figure 23 
(A), the 95% CI of the AHR includes one for each value of donor age, compared to an 
average donor. From Table 20, the AHR for a 50-year donor compared to a 45-year 
donor was 0.97 (95% CI=0.89, 1.05). From Figure 23 (B), donors with MDRD 80 or 
greater were associated with improved survival.  
The Donor Intrinsic DQ-NAFLD Score 
The DQ-NAFLD risk score is an estimate of the relative risk of posttransplant 
graft failure for an adult recipient from a cadaveric donor, compared to a reference donor: 
a 45-year DBD donor of 172 cm height, with no diabetes and MDRD of 69. From the 
Cox PH model, the risk for subject j is expressed as: 
                           𝜆(𝑡|𝑥𝑗) = 𝜆0(𝑡)𝑟𝑗(𝑡)                                
I used the coefficients of the Cox PH model in conjunction with individual covariates to 
estimate DQ-NAFLD risk score for an individual. The risk score for a subject ‘j’ is the 
hazard ratio for that person relative to the baseline, as shown in Equation 10: 
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𝐷𝑄 − 𝑁𝐴𝐹𝐿𝐷(𝑗)                                                                     (10)
= exp(𝛽1 x I(𝐷𝐶𝐷(𝑗)) + 𝛽2𝑥 𝑀𝐷𝑅𝐷(𝑗) + 𝛽3 𝑥 𝑀𝐷𝑅𝐷(𝑗)
′ + 𝛽4𝑥 ℎ𝑒𝑖𝑔ℎ𝑡(𝐽)
+ 𝛽5 𝑥 ℎ𝑒𝑖𝑔ℎ𝑡(𝑗)
′ + 𝛽6 𝑥 ℎ𝑒𝑖𝑔ℎ𝑡(𝑗)
′′ + 𝛽7 𝑥 𝑎𝑔𝑒(𝑗) + 𝛽8 𝑥 𝑎𝑔𝑒(𝑗)
′
+ 𝛽9 𝑥 𝑎𝑔𝑒(𝑗)
′′ + 𝛽10 x I(𝑁𝑜𝑛 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗))
+  𝛽11x I(𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗) ))  
𝑓𝑜𝑟 j=1….N 
Where I(e)=1 if the event is true, I(e)=0 otherwise, 
The predictors, donor’s age, height, and MDRD, are expressed as restricted cubic splines. 
I modeled the predictor MDRD as RCR with 3 knots, 𝑡1 = 17, 𝑡2 = 69, 𝑡3 = 137. The 
nonlinear term is: 
𝑀𝐷𝑅𝐷(𝑗)
𝑖 = (𝑀𝐷𝑅𝐷(𝑗) − 𝑡1)+
3 −
(𝑡3 − 𝑡1)
(𝑡3 − 𝑡2)
 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡2)+
3
+  
(𝑡2 − 𝑡1)
(𝑡3 − 𝑡2)
 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡3)+
3
 
I modeled the predictor donor height as RCS with 4 knots, 𝑡1 = 154, 𝑡2 = 167, 𝑡3 =
176, 𝑡4 = 188. The nonlinear terms are: 
ℎ𝑒𝑖𝑔ℎ𝑡(𝑗)
′ = (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡1)+
3 −
(𝑡4 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡2)+
3
+  
(𝑡3 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡4)+
3
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ℎ𝑒𝑖𝑔ℎ𝑡(𝑗)
′′ = (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡2)+
3 −
(𝑡4 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡3)+
3
+  
(𝑡3 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 𝑡4)+
3
 
I modeled the predictor donor age as RCS with 4 knots, 𝑡1 = 18, 𝑡2 = 35, 𝑡3 = 52, 𝑡4 =
71. The nonlinear terms are: 
𝑎𝑔𝑒(𝑗)
′ = (𝑎𝑔𝑒(𝑗) − 𝑡1)+
3 −
(𝑡4 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (𝑎𝑔𝑒(𝑗) − 𝑡2)+
3
+  
(𝑡3 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (𝑎𝑔𝑒(𝑗) − 𝑡4)+
3
 
𝑎𝑔𝑒(𝑗)
′′ = (𝑎𝑔𝑒(𝑗) − 𝑡2)+
3 −
(𝑡4 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝑎𝑔𝑒(𝑗) − 𝑡3)+
3
+  
(𝑡3 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝑎𝑔𝑒 − 𝑡4)+
3  
Where (𝑧)+ is equal to z if z > 0, and 0 otherwise. 
Replacing the estimated model coefficients, the Equation 10 became:  
𝐷𝑄 − 𝑁𝐴𝐹𝐿𝐷(𝑗) = exp [0.77 x I ( 𝐷𝐶𝐷(𝑗)) − 
0.04 𝑥 𝑀𝐷𝑅𝐷(𝑗) + 0.001 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 17)+ 
3
−
(137−17)
(137−69)
 𝑥(𝑀𝐷𝑅𝐷(𝑗) − 69)+
3
+
(69−17)
(137−69)
 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 137)+
3
− 0.031 𝑥 ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 0.064 𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 154)+ 
3
−
(188−154)
(188−176)
 𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) −  167)+
3
+
(176−154)
(188−176)
 𝑥(ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 188)+
3
−
0.261 𝑥(ℎ𝑒𝑖𝑔ℎ𝑡(𝐽) − 67)+
3
−  
(188−167)
(188−176)
 𝑥(ℎ𝑒𝑖𝑔ℎ𝑡(𝐽)  − 176)+
3
+
(176−167)
(188−176)
 𝑥 (ℎ𝑒𝑖𝑔ℎ𝑡(𝐽)  − 188)+
3
 + 0.009 𝑥 𝑎𝑔𝑒(𝑗) − 0.038 𝑥 (𝑎𝑔𝑒 − 18)+ 
3 −
(71−18)
(71−52)
 𝑥 (𝑎𝑔𝑒(𝑗) −  35)+
3
+
(52−18)
(71−52)
 𝑥(𝑎𝑔𝑒(𝑗) − 71)+
3
+ 0.012 𝑥 (𝑎𝑔𝑒(𝑗) − 35)+
3
−
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(71−35)
(71−52)
 𝑥 (𝑎𝑔𝑒(𝑗)  − 52)+
3
+
(52−35)
(71−52)
 𝑥 (𝑎𝑔𝑒(𝑗)  − 71)+
3
 + 
0.344 𝑥 I(𝑁𝑜𝑛 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗)) + 0.539 𝑥 𝐼(𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗))] 
Validation of the Donor Intrinsic DQ-NAFLD Model 
I conducted an internal validation to assess the performance of the final chosen 
model. The apparent performance of the model on the data used to fit the model will be 
better than the performance of the model in another set of data. The bootstrap approach 
described by Harrell et al. (1996) allows quantifying the overfitting or “optimism” 
inherent in predictive accuracy. I estimated the optimism by taking 1000 bootstrap 
samples with replacement from the full data and evaluating the difference between model 
performance in each bootstrap sample and model performance on the whole sample. I 
estimated the “optimism” as the average of these differences across 1000 bootstrap 
samples. I then subtracted the estimate of optimism from the naïve estimate of predictive 
ability to obtain the bias-corrected predictive ability. 
Validation of model discrimination. Discrimination of the final model indicated 
by the Harrell’s C-statistic represents the proportion of pairs of subjects that can be 
ordered such that the subject with higher predicted survival is the one who survived 
longer (not always possible, based on censoring). The C-statistic summarizes the 
predictive power of the DQ-NAFLD. The C-statistic ranges from 0.5 to 1.0, with higher 
values indicating greater discriminatory power, or the ability to separate more successful 
from less unsuccessful graft outcomes along the DQ-NAFLD scale. The apparent or 
naïve C-statistics was equal to 0.598, while the bootstrap optimism corrected C-statistics 
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was 0.587. A C-statistic nearly 0.60 is only moderately predictive. This result is 
consistent with other donor risk models since multiple factors are affecting graft survival 
not included in the DQ-NAFLD model. A model that accounts for more sources of 
variation would have a higher C-statistics. However, the goal of this intrinsic donor risk 
model was to summarize graft failure risk based on donor characteristics alone and not to 
describe all sources of variation (Rao et al., 2009). 
Figure 24 displays the estimated relationship between DQ-NAFLD risk score 
calculated from the intrinsic model and log hazard ratio for graft failure at 1-year post 
LT.  
 
Figure 24. Restricted cubic spline estimates of the relationship between  
DQ-NAFLD risk score and log relative hazard of graft failure at 1-year post LT.  
Note. Knots at 0.74, 0.93 and 1.67. 
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I estimated the relationship using a RCS with 3 knots at 0.71; 0.95; and 1.66. I 
further illustrated the discrimination of the final model by grouping patients in categories 
of the DQ-NAFLD risk score. I used the cutoffs of 0.71 (first knot) and 1.65 (third knot) 
obtained from the estimated spline transformation of the risk score to identify, low, 
medium, and high-risk donors. The Kaplan-Meier curves in Figure 25 show that the 1-
year graft survival post LT was statistically significantly different across risk categories 
of the DQ-NAFLD score (𝜒2(2) = 28.07, p < .0001). After adjusting for multiple testing, 
recipients of high-risk donors based on the DQ-NAFLD score were more likely to 
experience liver graft failure within 1-year post LT, compared to medium risk (p <.0001) 
and low risk (p <.0001). 
 
Figure 25. Kaplan-Meier graft survival by risk score.  
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Validation of model calibration. I validated the model for calibration accuracy 
in predicting the probability of graft surviving 1-year post LT. The model calibration plot 
in Figure 26 illustrates the agreement between observed and predicted estimated graft 
survival probability within 1-year post LT in the NAFLD/CC population. The blue curve 
in Figure 26 represents the estimated overfitting-corrected calibration curve. Well-
calibrated models have a slope of 1, while models providing too extreme predictions have 
a slope less than one. The calibration curve slope indicates some overfitting. The 
bootstrap estimated calibration of slope shrinkage was 0.83, suggesting that about 17% of 
the fitted model is noise. 
 
Figure 26. Bootstrap estimate of calibration accuracy for 1-year from the final Cox PH 
model.  
Note. The blue curve corresponds to 1000 bootstrap corrected estimates.  
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Nomogram of the Intrinsic DQ-NAFLD Cox Model 
I used the multivariable Cox PH model to build a nomogram depicted in Figure 
27 for predicting 1-year graft survival probability. The nomogram shows the impact of 
each predictor on the outcome graphically. Points are assigned to each independent 
variable, donor age, donor MDRD, donor diabetes, DCD status, and donor height, 
according to the degree of their impact on graft survival. The nomogram allows 
estimating the probability of 1-year graft survival for a NAFLD/C recipient of LT when 
donor predictor variables are provided. The nomogram assigns to each independent donor 
variable in the model a point, and the total points are projected to a probability of graft 
survival scale that ranges for 0 to 1. 
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Figure 27. Nomogram from the fitted Cox PH model of intrinsic donor factors for 
predicting graft failure in NAFLD/CC. 
The nomogram can be used to obtain manually predicted points for each subject 
from a regression model. Once the reader manually totals the points, the predicted values 
can be read at the bottom. For example, a recipient of LT from a donor who was 60-year-
old (point 2), insulin dependent (points 62), DBD (points 0) with MDRD of 70 (points 
15) and with a high of 170 (points 10), for a total of 86 points, had an estimated 
probability of liver graft survival at 1 year equal to 0.82. 
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Random Survival Forest (RSF) 
RSF algorithm developed by Ishwaran et al. (2008) is a non-parametric tree-based 
learning machine method that, unlike the Cox PH model, requires no distributional 
assumption of the candidate predictors. RSF utilizes randomly selected bootstrap samples 
from the data to grow survival trees and can be used to identify and rank important risk 
factors for graft failure within 1-year posttransplant. I conducted an RSF based on trees 
grown from a sample of 3,165 NAFLD/CC recipients of LT and nine independent donor 
factors for the prediction of graft survival post LT. I created a  random forest of 1000 
survival trees with a pre-specified number of predictors randomly selected before each 
node split set to three, with node size set to 10, or terminating nodes with no fewer than 
ten observations. Table 23 summarizes details of the RSF parameters I used to grow the 
forest and the generalization error estimate from the forest. The overall estimated 
prediction error rate for the random survival forest was 35.26%.  
 
Table 23 
RFS Algorithm Result Using Random Log-Rank Splitting Criteria 
Parameter 
 
Value 
Sample size 3115 
Number of events 412 
Number of trees 1000 
Forest terminal node size 10 
Average number of terminal nodes 219 
Number of variables tried at each split 3 
Total number of variables 9 
Number of random split 10 
Error rate 35.26% 
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Out-of-bag prediction error. Each bootstrap sample selects approximately 
63.2% of the data to train each tree. As the RSF is built, the remaining 36.8% of 
observations (the Out-of-Bag (OOB) sample), can be used to test each tree and estimate 
the OOB error, which is an unbiased estimate of the true error, a measure of the 
predictive ability of the forest (Breiman, 1996). Hastie, Tibshirani, and Friedman (2009) 
showed that the OOB prediction error estimates are almost identical to n–fold cross 
validation estimates. This feature of the RSF allows obtaining internal model fit and 
validation in the same algorithm. Figure 28 depicts the RSF generalization error as a 
function of the number of trees and shows that the forest tends to stabilize after a few 
hundred trees. The OOB error estimate was 35.26%, indicating that the forest was 
reasonably good in predicting 1-year graft survival post LT. The OOB Harrell’s C-
statistics was .64, indicating a better predictive ability of the RSF, compared to the Cox 
PH model. 
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Figure 28. The OOB error for RSF for 1000 trees. 
 
Variable importance in random survival forests. I used the RSF to assess the 
relative importance of variables. I considered two different criteria of ranking variables:  
variable importance (VIMP), and minimal depth. VIMP ranks the most important 
variables according to their impact on the predictive ability of the forest, and minimal 
depth assumes that variables with high predictive impact are those that most frequently 
split at the root node. Figure 29 illustrates the VIMP and the minimum depth plots 
showing the top variables contributing to the predictive accuracy of the forest, with 
higher values indicating more importance for the VIMP measures and lower values more 
importance for the minimal depth measure. Table 24 summarizes the ranking of 
variables. Donor sex, hypertension, and hyponatremia were the least important factors 
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based on both criteria. The top donor’s variables averaging the two measurements were 
height, age, MDRD, diabetes, and DCD. 
Table 24 
Results for the Variable Importance Measures for Donor’s Characteristics 
Variable 
 
Depth Depth rank VIMP VIMP rank 
Height (cm) 1.75 1 0.038 3 
Diabetes 1.75 2 0.020 5 
DCD 1.87 3 0.017 6 
Age (yrs.) 1.92 4 0.039 2 
MDRD 1.96 5 0.042 1 
Cause of death 2.43 6 0.026 4 
Sex 3.92 7 0.017 7 
Hypernatremia 4.09 8 0.005 9 
Hypertension 4.26 9 0.014 8 
 
Note. Variables considered in the RSF for NAFLD/CC recipients of LT. 
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Figure 29. Variable importance, minimal variable depth of donor characteristics using 
RSF to model liver graft failure for NAFLD/CC.  
 
Variable dependence. Although the RSF is considered a “black box” approach, 
graphical methods can help examine the dependency of the forest prediction on the 
independent variables. Variable dependence plots show the predicted response relative to 
a covariate of interest. The top donor’s variables identified using minimal depth, and 
VIMP that contributed most to the predictive accuracy of the forest were further analyzed 
to explore how the forest predicted graft failure or death depends on these variables. 
Figures 30 illustrates the relationship among height, cadaveric donor type, age, and 
MDRD on 1-year graft survival post LT for NAFLD/CC patients. Blue circles events and 
red dots indicate censored cases, i.e., graft failure or death within 1-year. Boxplots 
indicate the distribution of predicted survival for all cases within each cadaveric donor 
158 
 
 
 
group (Figure 30) or diabetes group (Figure 31) and show that recipients of DCD donors 
or recipients of insulin-dependent diabetes have lower predicted graft survival. Variable 
dependence of predicted 1-year graft survival on continuous variables, donor’s height, 
age, and MDRD are depicted in Figure 30. Censored cases are marked in red and events 
in blue. Loess smooth curve indicates the survival trend with increasing values. 
Recipients of donors taller than 160 cm, with high MDRD and younger than 60 years 
have higher predicted graft survival within 1-year post LT. Variable dependence can be 
interpreted only in general terms as a graft survival prediction for a patient, as a function 
of the values of all covariates in that particular patient. 
 
Figure 30. Variable dependence of 1-year graft survival post LT on height, cadaveric 
donor type, age and MDRD. 
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Figure 31. Variable dependence of 1-year graft survival post LT on diabetes. 
 
Research Question 2 
The second research question was based on whether there are relationships 
between post-transplant graft survival among NAFLD/CC recipients and transplant 
factors (cold ischemia time, ABO matching, and size matching). Univariate analyses 
showed that ABO compatibility and CIT modeled as RCS with four knots were both not 
statistically significantly associated with graft survival at 1-year post LT. The CIT, a 
significant predictor of graft survival in other studies (Feng et al., 2006), although not 
significant, was included in the model because of clinical relevance. The overall 
significance of the Cox PH model or the model goodness of fit was tested using the 
likelihood ratio test (𝜒2 (6) = 49.21, p <.0001), indicating that the model was statistically 
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significant and adequate in predicting the graft survival experience of a NAFLD/CC 
recipients of LT.  
ABO continued to be not statistically significant when adjusted for CIT and size 
match. Compared to normal for size grafts, livers large for size (AHR=1.52, 95% 
CI=1.15, 2.02) was associated with an increased risk of graft failure of 52% within 1-year 
post LT (Table 25). Table 25 shows the estimated coefficients of transplant-related 
predictors of graft survival at 1-year post LT, including each parameter used in the 
splines, and the AHRs along with the 95% CIs. Figure 32 provides a useful interpretation 
of association between CIT and the adjusted relative hazard and show that, after adjusting 
for ABO and size match at their reference category, for each value of the CIT, the 95% 
CI of the estimated AHR includes one, indicating that CIT is not statistically significantly 
associated with the hazard of graft failure at 1-year post LT. 
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Table 25 
Multivariate Cox PH Model for Transplant Variables Predicting Liver Graft Failure.  
Variable Estimated β 
SE (β) 
Wald ᵪ2 AHR (95% CI) 
ABO compatibility    
   ABO compatible Reference   
  ABO incompatibility -.121 (.501) -0.24 1.28 (0.78, 2.01) 
Donor/recipient size match    
  Normal for size Reference   
  Small for size  .069 (.164) 0.42 1.07 (0.78, 1.48) 
  Large for size  .423 (.144) 2.92 1.52 (1.15, 2.02)*** 
CIT linear .042 (.011) 0.39 0.97 (0.86, 1.01) 
CIT’ -.114 (.421) -0.27 1.45 (0.94, 2.23) 
CIT’’ .389 (1.266) 0.31 0.31 (0.09, 1.05) 
Note. NAFLD/CC recipients (n=3165). β =estimated coefficient of Cox PH model, 
SE=standard error, AHR=adjusted hazard ratio, CI=confidence interval.  
***p<.001 
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Figure 32. Restricted cubic splines of the association between CIT and relative hazard of 
graft failure at 1-year post LT. 
Note. The model is adjusted for the following variables set at reference category: ABO 
compatibility (compatible), donor/recipient size match (normal for size). 
 
Research Question 3 
Research question three explores the relationships between post-transplant graft 
survival among NAFLD/CC recipients and a number of donor characteristics (age, 
gender, height, weight, BMI, the cause of death, hypertension, diabetes, donor after 
circulatory death, HCV status, HBsAb status, HBsAg status, MDRD, hypernatremia) and 
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transplant factors (CIT, ABO matching, size matching) after adjusting for characteristics 
of recipients of liver transplant (age, gender, biological MELD).To answer the third 
research question, I developed an extended version of the intrinsic donor model that 
included in addition to donor factors, recipient and transplant factors. At the first step, I 
used a priori information based on subject-specific knowledge and literature review to 
derive a working set of candidate independent variables known as relevant predictors or 
covariates for the study question to consider during statistical modeling. Next, I excluded 
variables whose distributions were too narrow or with a substantial amount of missing 
data, and this led to a final list of candidate predictors. I used Cox PH regression to 
examine the association between selected donor, recipient and transplant variables, and 
with the outcomes.  
Model Building  
The pre-specified list of candidate predictors included donors’ age, gender, 
diabetes, MDRD, hypertension, hypernatremia, the cause of death, and donor DCD, 
recipient’s age, gender, and biological MELD, organ size match, ABO compatibility, and 
cold ischemia time. To reduce the number of predictors in the final model, I applied an 
augmented backward elimination in 1000 bootstrap samples drawn from the original data, 
with the level of significance ‘α’ set to 0.2 and the threshold of the relative change-in-
estimate criterion ‘τ’ set to 0.1 (Dunkler, Plischke, Leffondré, & Heinze, 2014). This 
strategy allowed to include into the model regardless of their statistical significance donor 
age, DCD and CIT, as known predictors of graft failure. 
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The total number of complete cases included 3,118 recipients of LT, while 47 or 
1.5% of cases were missing. I conducted a complete case analysis, and there were no 
significant interactions. The final selected parsimonious model included eight predictors 
from the initial set: recipient’s age and MELD score, donor’s age, DCD, MDRD, 
diabetes, donor/recipient size match, and CIT. The overall likelihood ratio test was 
𝜒2(19) =70.91 (p< .0001). This test evaluates the omnibus null hypothesis that all model 
coefficients were 0, which was rejected against the alternative hypothesis that the 
selected Cox PH regression model was statistically significant, and adequate in 
explaining the graft survival experience of NAFLD/CC recipients of LT patients. 
I used smoothing transformations of continuous predictors to relax the linearity 
assumption and prevent residual confounding. I tested the model distributional 
assumption using smoothed scaled Schoenfeld residuals for each predictor and graphical 
visualization. I did not observe any trends against the log of time. The global test of 
proportional hazard (p=.08) supported the validity of the proportional hazard assumption 
at the α=.05 level of significance. 
Model Selected  
The independent variables selected in the final model included: recipient’s age 
and MELD score, donor’s age, DCD, MDRD, diabetes, donor/recipient size match, and 
CIT. Harrell (2015) suggested as a rule of thumb that at least 10–20 events are needed per 
degree of freedom. The study sample included 412 events and approximately 20 degrees 
of freedom to spend-to-fit the model, which used 19 degrees of freedom. The available 
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effective sample size was sufficiently large to allow the fit of an initial saturated pre-
specified model, where I considered all predictors, including the non-significant in the 
univariate analysis. I tested the overall significance of the Cox PH model or the model 
goodness of fit using the likelihood ratio test with 𝜒2(19) = 70.91, p <.0001), indicating 
that the model was statistically significant and adequate in predicting the graft survival 
experience of a NAFLD/CC recipients of LT. 
The results of the Cox regression model selected presented in Table 26 include 
the estimated coefficients, the standard errors as well as the AHRs along with the 95% 
CIs of each categorical predictor, for each parameter used in the splines. Recipients of 
livers from donors with insulin-dependent diabetes were almost twice more likely to lose 
their liver allograft within 1-year post LT (AHR=1.77, 95% CI=1.27, 2.46), compared to 
recipients of donors with no diabetes. Receiving a DCD liver allograft was associated 
with a 2.5-fold increased risk of graft failure (AHR=2.51, 95% CI=1.83, 3.46). 
NAFLD/CC recipients of large for size livers were 1.4 times more likely to lose their 
liver allograft or die within 1-year post LT than recipients of normal for size donors 
(AHR=1.45, 95% CI=1.08, 1.92). The final RCS Cox regression model results presented 
in Table 26, include estimated coefficients for each parameter used in the splines that do 
not have an immediate interpretation.  
 
 
 
 
 
166 
 
 
 
Table 26 
Multivariate Cox PH Model for Donor, Recipient and Transplant Variables Predicting 
Liver Graft Failure 
Exposure Estimated β 
SE(β) 
Wald ᵪ2 AHR (95% CI) 
Donor age linear -0.004 (0.014) -0.29 1.00 (0.91, 1.02) 
Donor age’ 0.007 (0.044) 0.16 1.01 (0.92, 1.02) 
Donor age’’ 0.002 (0.123) 0.01 1.00 (0.79, 1.27) 
MDRD linear -0.004 (0.003) -1.74 1.00 (0.99, 1.00) 
Mdrd’  0.002 (0.003) 0.99 1.00 (1.00, 1.00) 
Donor diabetes    
 Non-diabetic  Reference   
 Non-insulin dependent -0.313 (0.231) -1.36 0.73 (0.46, 1.15) 
 Insulin dependent 0.572 (0.168) 3.41 1.77 (1.27, 2.46)*** 
Cadaveric donor type    
  DBD Reference   
  DCD 0.922 (0.162) 5.69 2.51 (1.83, 3.46)** 
CIT -0.007 (0.109) -0.07 0.99 (0.80, 1.23) 
CIT’ 0.083 (0.423) 0.20  1.09 (0.47, 2.49) 
CIT ‘‘ -0.118 (0.285) -0.09  0.89 (0.07, 11.03) 
          (table continue) 
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Exposure Estimated β 
SE(β) 
Wald ᵪ2 AHR (95% CI) 
Donor/recipient size     
  Normal for size  Reference   
  Small for size 0.149 (0.168) 0.89 1.16 (0.84, 1.61) 
  Large for size 0.369 (0.147) 2.52 1.45 (1.08, 1.92) 
MELD    
  MELD <15 Reference   
  MELD score 15-24 -0.169 (0.151) -1.12 0.84 (0.63, 1.13) 
  MELD score 25-34 0.199 (0.160) 1.24 1.22 (0.89, 1.67) 
  MELD score ≥35 0.285 (0.171) 1.66 1.33 (0.95, 1.86) 
Recipient age linear -0.002 (0.015) -0.12 0.99 (.97, 1.10) 
Recipient age’ 0.037 (0.029) 1.25 1.04 (.98, 1.01) 
Recipient age ‘‘ -0.248 (0.226) -1.10 0.78 (.50, 1.21) 
Note. NAFLD/CC recipients (n=3,115), β =estimated coefficient of Cox PH model, 
SE=standard error, AHR=adjusted hazard ratio, CI=confidence interval.  
* p<.05, **p<.01, ***p<.001 
 
 
Tables 27-29 provide a useful interpretation of RCS. After fitting a Cox PH model 
that includes splines, I computed hazard ratios by comparing specific values of a 
continuous variable, with a single reference value. I calculated AHRs, and 95% CIs 
constructed from splines for donor age (Table 27), for CIT (Table 2), and donor MDRD 
(Table 28), at selected predictor values. From Table 28, compared to a reference donor 
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with MDRD of 69, liver allografts from donors with an MDRD of 30 provided an 
increase in the risk of graft failure within 1-year post LT of 17% (ARH=1.17, 95% CI= 
1.01, 1.37).  
 
Table 27 
Estimated AHRs and 95% CI for Selected Values of Donor Age from the Multivariate 
Cox PH Regression  
Selected donor age (yrs.) ARH 95% CI 
20 1.05  (0.80, 1.39) 
 
30 1.01  (0.85, 1.21) 
 
45 Reference  
60 1.09 (0.92, 1.28) 
Note. AHR=adjusted hazard ratio, CI=confidence interval. 
Table 28 
Estimated AHRs and 95% CI for Selected Values CIT from the Multivariate Cox PH 
Regression 
Selected CIT (hrs.) AHR 95% CI 
3 0.98 (0.72, 1.35) 
5 0.98 (0.89, 1.08) 
5.9 Reference  
10 1.24 (0.98, 1.58) 
Note. AHR=adjusted hazard ratio, CI=confidence interval. 
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Table 29 
Estimated AHRs and 95% CI for Selected Values of MDRD from the Multivariate Cox 
PH Regression 
Selected MDRD ARH 95% CI 
30 1.17 (1.00, 1.37) 
 
45 1.08 (0.84, 1.39) 
 
60 1.03 (1.00, 1.06) 
69 Reference  
80 0.96 (0.94, 0.99) 
90 0.94 (0.91, 0.98) 
Note. AHR=adjusted hazard ratio, CI=confidence interval. 
 
Figures 33-35 show the predicted relative risk of graft failure as a function of 
donor age, CIT, and donor MDRD, holding all other variables constant at representative 
levels (DBD, no diabetes, 45-year old, donor MDRD of 69, CIT of 5.9) by MELD score. 
The solid blue line represents the estimated adjusted hazard ratio or relative risk for the 
Cox regression model with restricted cubic splines and dashed lines represent the 95% 
confidence interval of the estimate. If the 95% confidence interval includes 1, the hazard 
ratio is not significant. I did not observe any association between donor age and 1-year 
graft survival in each MELD score category (Figure 33). Decreased CIT is associated 
with improved 1-year graft survival for recipients for MELD score 15-24 (Figure 34). 
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Figure 35 (A and B) shows that the relative risk of graft failure increases as MDRD 
decreases, respectively, for MELD score <15 and MELD score 15-24. No association 
between MDRD and the risk of 1-year graft failure for other MELD score categories.  
 
 
 
 
Figure 33. RCS relationships between donor age (yrs.) adjusted to reference values by 
MELD score: <15 (A), 15-24 (B), 25-34 (C), > 35 (D). 
Note. The model is adjusted for the following variables set at reference category: donor 
type (DBD), diabetes (No), or median category: MDRD (69), normal for size donors, and 
CIT of 5.9 hours.  
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Figure 34. RCS relationships between CIT (hrs.) adjusted to reference values by MELD 
score: <15 (A), 15-24 (B), 25-34 (C), > 35 (D). 
Note. The model is adjusted for the following variables set at reference category: donor 
type (DBD), diabetes (No), or median category: MDRD (69), donor age (45 yrs.), and 
normal for size donors.  
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Figure 35. RCS relationships between donor MDRD adjusted to reference values by 
MELD score: <15 (A), 15-24 (B), 25-34 (C), > 35 (D). 
Note. The model is adjusted for the following variables set at reference category: donor 
type (DBD), diabetes (No), or median category: donor age (45 yrs.), normal for size 
donors, and CIT of 5.9 hours.  
 
The extended DQ-NAFLD risk score is an estimate of the relative risk of 
posttransplant graft failure for an adult recipient from a particular cadaveric donor, 
compared to a reference 45-year old donor, DBD, with a height of 172 cm, with no 
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diabetes and MDRD of 69, with an estimated graft normal for size, a 60-year old 
recipient with MELD score between 15 and 24, and with CIT of 5.9 hours. The Cox PH 
model assumes that the risk for subject j is: 
                           𝜆(𝑡|𝑥𝑗) = 𝜆0(𝑡)𝑟𝑗(𝑡)                       
I used the coefficients of the Cox PH model in conjunction with individual covariates to 
estimate extended DQ-NAFLD risk score for an individual. The risk score for a subject 
‘j’ is the hazard ratio for that person relative to the baseline, as shown in Equation 11: 
𝐸𝑥𝑡𝑒𝑛𝑑𝑒𝑑 𝐷𝑄 − 𝑁𝐴𝐹𝐿𝐷(𝑗)                                                          (11)
= exp(𝛽1 𝑥 𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) + 𝛽2 𝑥 𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
′ + 𝛽3 𝑥 𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
′′
+ 𝛽4 𝑥 𝑀𝐷𝑅𝐷(𝑗) + 𝛽5 𝑥 𝑀𝐷𝑅𝐷(𝑗)
𝑖 + 𝛽6𝑥 𝐼(𝑁𝑜𝑛 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗))
+  𝛽7𝑥 𝐼(𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗)) +  𝛽8 𝑥 𝐼(𝐷𝐶𝐷(𝐽)) + 𝛽9 𝑥 𝐶𝐼𝑇(𝐽)
+ 𝛽10 𝑥 𝐶𝐼𝑇(𝑗)
′ + 𝛽11 𝑥 𝐶𝐼𝑇(𝑗) 
′′
+ 𝛽12  𝑥 𝐼(𝑆𝑚𝑎𝑙𝑙 𝑓𝑜𝑟 𝑆𝑖𝑧𝑒(𝑗)) +  𝛽13𝑥 𝐼(𝐿𝑎𝑟𝑔𝑒 𝑓𝑜𝑟 𝑆𝑖𝑧𝑒)
+ 𝛽14 𝑥 𝐼(𝑀𝐸𝐿𝐷 (15 − 24)(𝑗)) + 𝛽15 𝑥 𝐼(𝑀𝐸𝐿𝐷 (25 − 34)(𝑗))
+  𝛽16 𝑥 𝐼(𝑀𝐸𝐿𝐷 (≥ 35)(𝑗)) + 𝛽17 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
+ 𝛽18 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
′ + 𝛽19 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
′′  )  
Where I(e)=1 if the event is true, I(e)=0 otherwise 
𝑓𝑜𝑟 j=1….n 
I expressed the predictors: donor age, MDRD, CIT and recipient age as RCSs.  
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I modeled the predictor donor age as RCS with four knots, 𝑡1 = 18, 𝑡2 = 35, 𝑡3 = 52, 
𝑡4 = 71. The nonlinear terms are: 
𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
′ = (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡1)+
3 −
(𝑡4 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡2)+
3
+  
(𝑡3 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡4)+
3
 
𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
′′ = (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡2)+
3 −
(𝑡4 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡3)+
3
+  
(𝑡3 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡4)+
3
 
 
I modeled the predictor MDRD as RCS with three knots, 𝑡1 = 17, 𝑡2 = 69, 𝑡3 = 137. 
The nonlinear term is: 
𝑀𝐷𝑅𝐷(𝑗)
𝑖 = (𝑀𝐷𝑅𝐷(𝑗) − 𝑡1)+
3 −
(𝑡3 − 𝑡1)
(𝑡3 − 𝑡2)
 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡2)+
3
+  
(𝑡2 − 𝑡1)
(𝑡3 − 𝑡2)
 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡3)+
3
 
I modeled the predictor CIT as RCS with four knots, 𝑡1 = 3.1, 𝑡2 = 5.1, 𝑡3 = 6.6, 𝑡4 =
10. The nonlinear terms are: 
𝐶𝐼𝑇(𝑗)
′ = (𝐶𝐼𝑇(𝐽) − 𝑡1)+
3 −
(𝑡4 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡2)+
3
+ 
(𝑡3 − 𝑡1)
(𝑡4 − 𝑡3)
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡4)+
3
 
𝐶𝐼𝑇(𝑗)
′′ = (𝐶𝐼𝑇(𝐽) − 𝑡2)+
3 −
(𝑡4 − 𝑡2)
(𝑡4 − 𝑡3)
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡3)+
3
+  
(𝑡3 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡4)+
3
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I modeled the predictor recipient age as RCS with four knots, 𝑡1 = 42, 𝑡2 = 57, 𝑡3 = 64, 
𝑡4 = 70. The nonlinear terms are: 
𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
′
= (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡1)+
3 −
(𝑡4 − 𝑡1)
(𝑡4 − 𝑡3)
𝑥 (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡2)+
3
+  
(𝑡3 − 𝑡1)
(𝑡4 − 𝑡3)
𝑥 (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡4)+
3
 
𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
′′
= (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡2)+
3 −
(𝑡4 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡3)+
3
+  
(𝑡3 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗) − 𝑡4)+
3
 
Where (𝑧)+ is equal to z if z > 0, and 0 otherwise. 
Replacing the estimated model coefficients, Equation 11 is obtained:  
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𝐸𝑥𝑡𝑒𝑛𝑑𝑒𝑑 𝐷𝑄 − 𝑁𝐴𝐹𝐿𝐷(𝑗)
= exp (−0.004 𝑥 𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗)
+ 0.007 𝑥 ((𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡1)+
3
−
(𝑡4 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡2)+
3
+ 
(𝑡3 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡4)+
3
)
+ 0.002 𝑥 ((𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡2)+
3
−
(𝑡4 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡3)+
3
+ 
(𝑡3 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝐷𝑜𝑛𝑜𝑟 𝐴𝑔𝑒(𝑗) − 𝑡4)+
3
) − 0.004 𝑥 𝑀𝐷𝑅𝐷(𝑗)
+ 0.002 𝑥 ((𝑀𝐷𝑅𝐷(𝑗) − 𝑡1)+
3
−
(𝑡3 − 𝑡1)
(𝑡3 − 𝑡2)
 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡2)+
3
+ 
(𝑡2 − 𝑡1)
(𝑡3 − 𝑡2)
 𝑥 (𝑀𝐷𝑅𝐷(𝑗) − 𝑡3)+
3
)
− 0.313 𝑥 𝐼(𝑁𝑜𝑛 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗))
+  0.572 𝑥 𝐼(𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝐷𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡(𝑗)) +  0.922  𝑥 𝐼(𝐷𝐶𝐷(𝐽))
− 0.07  𝑥 𝐶𝐼𝑇(𝐽) + 0.083 𝑥 ((𝐶𝐼𝑇(𝐽) − 𝑡1)+
3
−
(𝑡4 − 𝑡1)
(𝑡4 − 𝑡3)
 𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡2)+
3
+ 
(𝑡3 − 𝑡1)
(𝑡4 − 𝑡3)
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡4)+
3
) − 0.118 𝑥((𝐶𝐼𝑇(𝐽) − 𝑡2)+
3
−
(𝑡4 − 𝑡2)
(𝑡4 − 𝑡3)
𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡3)+
3
+  
(𝑡3 − 𝑡2)
(𝑡4 − 𝑡3)
 𝑥 (𝐶𝐼𝑇(𝐽) − 𝑡4)+
3
)
+ 0.149 𝑥 𝐼(𝑆𝑚𝑎𝑙𝑙 𝑓𝑜𝑟 𝑆𝑖𝑧𝑒(𝑗)) +  0.369𝑥 𝐼(𝐿𝑎𝑟𝑔𝑒 𝑓𝑜𝑟 𝑆𝑖𝑧𝑒)
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− 0.169 𝑥 𝐼(𝑀𝐸𝐿𝐷 (15 − 24)(𝑗)) +  0.199 𝑥 𝐼(𝑀𝐸𝐿𝐷 (25 − 34)(𝑗))
+  0.285 𝑥 𝐼(𝑀𝐸𝐿𝐷 (≥ 35)(𝑗)) − 0.002 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
+ 0.037 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
′ − 0.248 𝑥 𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡 𝐴𝑔𝑒(𝑗)
′′  ) 
Model Validation 
I performed the internal validation to assess the performance of the final chosen 
model. The bootstrap approach described by Harrell et al. (1996) allows quantifying the 
overfitting or “optimism” inherent in predictive accuracy. I estimated the optimism by 
taking 1000 bootstrap samples with replacement from the full data and evaluating the 
difference between model performance in each bootstrap sample and on the whole 
sample. I estimated the optimism as the average of these differences across 1000 
bootstrap samples. I then subtracted this estimate of optimism from the naïve estimate of 
predictive ability to obtain the bias-corrected predictive ability. 
Validation of model discrimination. Discrimination of the final model indicated 
by the Harrell’s C-statistic represents the proportion of pairs of ordered subjects such that 
the subject with higher predicted survival is the one who survived longer. The C-statistic 
summarizes the predictive power of the DQ-NAFLD and ranges from 0.5 to 1.0. High 
values indicate greater discriminatory power, or the ability to separate “more successful” 
from “less unsuccessful” graft outcomes along the DQ-NAFLD scale. According to 1000 
bootstrap samples, the apparent or naïve C- statistics was equal to .613, and the bootstrap 
optimism corrected C-statistics was .601. The extender DQ-NAFLD model provides only 
a slight improvement in accuracy, compared to the donor intrinsic DQ-NAFLD model. A 
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C-statistic nearly 0.60 is only moderately predictive. This ted result is consistent with 
other donor risk models since multiple factors not included in the DQ-NAFLD model 
affects graft survival.  
 Figure 36 displays the estimated relationship between DQ-NAFLD risk scores 
calculated from the extended model and log-hazard ratio for graft failure at 1-year post 
LT. The relationship was estimated using an RCS with three knots at 0.62, 0.69 and 1.73. 
I used the cutoffs of 0.62 (first knot), and 1.73 (third knot) obtained from the estimated 
spline transformation of the risk score to identify low, medium, and high-risk donors.  
 
Figure 36. Restricted cubic spline estimates of the relationship between the extended 
DQ-NAFLD risk score and log relative hazard of graft failure at 1-year post LT.  
Note. Knots at 0.62, 0.96 and 1.73.  
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The Kaplan-Meier curves and log-rank test in Figure 37 show that the 1-year graft 
survival post LT was statistically significantly different across risk categories of the DQ-
NAFLD score (𝜒2(2) = 45.4, p <.0001). After adjusting for multiple testing, recipients of 
high-risk donors based on the DQ-NAFLD score were more likely to experience liver 
graft failure within 1-year post LT, compared to medium risk (p<.0001) and low risk (p 
<.0001). 
 
Figure 37. Kaplan-Meier graft survival by risk score. 
 
Validation of model calibration. I validated the model for calibration accuracy 
in predicting the probability of graft survival 1-year post LT. The model calibration plot 
in Figure 38 determines the agreement between observed and predicted estimated graft 
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survival probability within a 1-year post LT in the NAFLD/CC population. The blue 
curve in Figure 38 represents the estimated overfitting-corrected calibration curve. The 
calibration curve slope indicates some overfitting. The bootstrap estimated calibration of 
slope shrinkage was 0.80, suggesting that about 20% of the fitted model is noise. 
 
Figure 38. Bootstrap estimate of calibration accuracy for 1-year from the final Cox PH 
model.  
Note. The blue curve corresponds to 1000 bootstrap corrected estimates.  
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Nomogram of the Extended DQ-NAFLD Cox Model 
I used the multivariable Cox PH model to build a nomogram, as depicted in 
Figure 39, for predicting 1-year graft survival probability. The nomogram shows the 
impact of each predictor on the outcome graphically. Points are assigned to each 
independent donor, recipient, and transplant variables in the model according to the 
degree of their impact on graft survival. The nomogram allows estimating the probability 
of 1-year graft survival for a NAFLD/CC recipient of LT when the selected donor, 
recipient, and transplant predictor variables are provided. The nomogram assigns a point 
to each independent donor variable in the model, and the total points are projected to a 
probability of graft survival scale that ranges from 0 to 1. The nomogram can be used to 
obtain manually predicted points for each subject from a regression model. Once the user 
manually totals the points, the predicted values can be read at the bottom.  
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Figure 39. Nomogram from the fitted Cox PH model of extended donor factors for 
predicting graft failure in NAFLD/CC. 
 
For example, a NAFLD/CC recipient of LT of 60 years (26 points) and MELD Score 18 
(0 points) is considered herein matched with a DCD donor (100 points), 35-year-old (2 
points), without diabetes (0 points), with MDRD of 80 (4 points), with an estimated CIT 
of 5 hours (0 points) and with an estimated graft large for size (40 points). The resulting 
total points are 172, which has an estimated probability of .78 for liver graft survival at 
one year. 
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Predicted DQ-NAFLD Scores  
Figure 40 provides an insight into the distributions of the calculated DQ-NAFLD 
scores using the two models. In this figure, the variation of the donor predicted hazard 
ratios of graft failure within 1-year posttransplant using the two DQ-NAFLD models is 
presented. The observed DQ-NAFLD scores in the donor-only model ranged from 0.1 to 
6.6 with a median value of 0.93 (IQR, 0.83, 1.11) while the observed scores in the 
extended DQ-NAFLD ranged from 0.26 to 4.2, with a median value of 0.96 (IQR, 0.76, 
1.25). The DQ-NAFLD score can be interpreted as a measure of relative graft failure 
hazard rate compared with the median donor, which has a relative hazard failure rate of 1. 
Figure 41 displays the side by side of the DQ-NAFLD scores classified by risk group 
category using the two DQ-NAFLD models. 
 
Figure 40. Kernel density distributions of DQ-NAFLD scores.  
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Figure 41. Side by side boxplots by DQ-NAFLD model and risk group. 
 
Research Question 4 
The fourth research question explores the relationships between post-transplant 
graft survival among NAFLD/CC recipients and the health risk status of the county were 
recipients reside, measured by the community health score (CHS). A total of 3017 
NAFLD/CC recipients of LT had CHS data, and there were 397 events, i.e., graft failures 
or deaths within 1-year post LT. CHS data were not available for 148 study subjects. To 
answer the research question, I modeled CHS as RCS with four knots at 6, 12, 18, and 30 
in a Cox PH model of graft survival. The corresponding global likelihood ratio test 
(𝜒2(3) = 4.70, p=.185) indicated that CHS was not statistically significantly associated 
with graft survival at 1-year post LT. Therefore, the null hypothesis of no association 
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between CHS and post-transplant graft failure is not rejected. Alternatively, I ued the 
knot positions as cutoffs to categorize CHS in five groups: CHS ≤ 6, 7 ≤ CHS ≤ 12, 13 ≤ 
CHS ≤ 18, 19 ≤ CHS ≤ 30, and HCS>30. I estimated survival curves using the Kaplan-
Meier method for each of the five categories of CHS, as portrayed in Figure 42. 
 
Figure 42. Kaplan-Meier graft survival by CHS with cut-off points obtained from the 
estimated spline transformation of the risk score. 
 
I compared the survival curves using the log-rank test. The overall log-rank test 
(𝜒2(4) = 10.6, p=.0.032) indicated a statistically significant difference in graft survival 
experience among the CHS groups. I performed post hoc Benjamín and Hochberg 
adjusted multiple comparisons that control the false discovery rate to identify where the 
differences across groups lied. The pairwise corrections revealed that, compared to 
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recipients of LT who resided in low health risk counties (CHS<6), recipients who resided 
in counties with high community health risk (CHS >30) had a worse graft survival 
experience post LT (p = .041). All other pairwise comparisons were not statistically 
significant. 
Similarly, when, I modeled CHS as a categorical predictor in a Cox PH model, 
the global likelihood ratio test (𝜒2(4) = 10.34, p =.04) revealed that CHS was 
statistically significantly associated with graft survival at 1-year post LT indicating that 
the null hypothesis of no association between CHS and graft survival is rejected. The 
association between CHS and 1-year graft survival tends to be conflicting depending on 
how CHS is modeled: significant when CHS is categorized, not significant when CHS is 
modeled as RCS.  
Table 30 summarizes the results of the Cox PH model. Compared to the reference 
category of CHS <6, recipients of LT who reside in counties with CHS>30 were more 
likely to lose their liver allograft within 1-year post LT (HR=1.81, 95% CI 1.08, 3.05).  
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Table 30 
Univariate Cox Regression Model for CHS Predicting Liver Graft Failure 
Variable (CHS) Estimated β 
SE(β) 
Wald ᵪ2 AHR (95% CI) 
  < 6 Reference   
  7-12 0.216 (0.265) 1.12 1.35 (0.78, 2.26) 
  13-18 0.255 (0.271) 0.94 1.29 (0.76, 2.20) 
  19-30 0.328 (0.297) 1.10 1.40 (0.78, 2.48) 
  >30 0.594 (0.265) 2.24 1.81 (1.08-3.05)* 
 
Note. NAFLD/CC recipients (n=3017). β =estimated coefficient of Cox PH model, 
SE=standard error, AHR=adjusted hazard ratio. CI=confidence interval.* p<.05. 
 
Choropleth graph (Figure 43) shows the donor graft survival aggregated by 
county by three groups of graft failures. The graph illustrates the county estimated graft 
survival at 1-years colored according to group value from light to dark blue, with darker 
colors indicating more favorable graft survival. Counties with unavailable information 
are indicated in black. The choropleth graph provides a visual illustration of the variation 
in graft survival across countries. There were 1145 counties represented in the analysis, 
and there were counties with few patients.  
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Figure 43. Choropleth graph of 1-year graft survival by county. 
Research Question 5 
The fifth research question was based on whether or not there was a relationship 
between post-transplant graft survival among NAFLD/CC recipients and the distance 
from recipient residence to the transplant center. I analyzed a total of 3,137 NAFLD/CC 
recipients of LT.  There were 414 events; r graft failures or deaths within 1-year post LT. 
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I excluded from the analysis twenty-eight subjects with missing zip code data as I could 
not calculate the distance from their residence to the transplant center.  
To answer the research question, I modeled distance from recipient residence to 
transplant center as RCS with four knots at 5, 27, 85, and 422 miles. The corresponding 
global likelihood ratio test (𝜒2(2) = 4.10, p=.25) indicated that distance from recipient 
residence to the transplant was not significantly associated with graft survival at 1-year 
post LT. Therefore, the null hypothesis of no association is not rejected. Alternatively, I 
used the knot positions as cutoffs to categorize distance to the transplant center in 5 
groups: ≤5 (miles), 6-27 (miles), 28-85 (miles), 46-422 (miles), and >422 (miles). Figure 
44 illustrates the Kaplan-Meier survival curve for the five distance groups. The log-rank 
test (𝜒2(4) = 4.0, p =.40) showed no differences in survival experience across the five 
distance from transplant center groups. 
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Figure 44. Kaplan-Meier graft survival by distance from transplant center with cut points 
obtained from the estimated spline transformation of the risk score. 
 
Similarly, when I modeled the distance from transplant center as a categorical 
predictor in a Cox PH model, the global likelihood ratio test ( 𝜒2(4) = 4.02, p = .40) 
indicated that geographic distance was not associated with graft survival at 1-year post-
transplant. Compared to the reference category of LT recipients’ distance from the 
transplant center of ≤ 5 miles, all other recipients in other distance categories were as 
likely to lose their liver graft within 1-year post LT, as summarized in Table 31. These 
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results confirm that the null hypothesis of no association between distance and graft 
survival is not rejected. 
Table 31 
Univariate Cox Regression Model for Distance from Transplant Center Predicting Liver 
Graft Failure 
Variable (Distance, miles) Estimated β 
SE (β) 
Wald ᵪ2 AHR (95% CI) 
≤5 Reference   
6-27 -0.105 (0.222) -0.474 .90 (0.58, 1.39) 
28-85 -0.052 (0.221) -0.234 .94 (0.62, 1.47) 
86-422 -0.283 (0.226) -1.256 .75 (0.48, 1.17) 
> 422 -0.203 (0.307) -0.660 .82 (0.45, 1.40) 
Note. NAFLD/CC recipients (n=3017). β =estimated coefficient of Cox PH model, 
SE=standard error, AHR=adjusted hazard ratio, CI=confidence interval.  
  
Research Question 6 
Research question six was based on exploring relationships between DQ-NAFLD 
risk score and external community factors (CHS and distance from recipient residence to 
transplant center) among NAFLD/CC recipients of LT.  
To answer the question, I developed a Cox PH model to measure the combined 
effect of DQ-NAFLD risk score category, distance from recipient residence to transplant 
center, and CHS on the risk of graft failure within 1-year post LT. There were 2971 
observations, and 390 events, and no significant interactions. The model goodness-of-fit 
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tested using the likelihood ratio test (𝜒2(10) = 39.05, p <.0001) indicated model adequacy 
in explaining the graft survival experience of NAFLD/CC recipients of LT patients. The 
results of the Cox PH model are summarized in Table 32. Compared to recipients with 
low-risk donors based on the DQ-NAFLD score, recipients of medium risk livers 
(HR=1.57, 95% CI 1.12, 2.19) and high-risk livers (HR=2.57, 95% CI 1.84, 4.13) based 
on the DQ-NAFLD score were more likely to lose their grafts within the first-year post 
LT. Compared to the reference category of CHS <6, recipients of LT who resided in 
counties with CHS>30 were more likely to lose their liver allografts within 1-year post 
LT (HR=1.85, 95% CI 1.08, 3.17). The scatterplots in Figure 45 depict the direction and 
strength of the relationship between the donor risk score and community health score, 
respectively, Figure 45(A) and distance from transplant center Figure 45 (B). 
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Table 32 
Multivariate Cox Regression Model for NAFLD/CC Risk Score and External Factors 
Predicting Liver Graft Failure. 
Variables Estimated β  
SE (β) 
Wald ᵪ2 AHR (95% CI) 
Risk Score     
  Low Reference   
  Medium 0.452 (0.171) 2.95 1.57 (1.12, 2.20)* 
  High 1.014 (0.206) 4.91 2.76 (1.84, 4.13)*** 
CHS     
  <6 Reference   
  7-12 0.331 (0.276) 1.20 1.39 (0.81, 2.39) 
  13-18 0.280 (0.280) 1.00 1.32 (0.76, 2.29) 
  19-30 0.387 (0.312) 1.25 1.47 (0.80, 2.71) 
  >30 0.616 (0.274) 2.25 1.85 (1.08, 3.17)* 
Distance     
  < 6 Reference   
  7-27 -0.181 (0.225) -.81 0.83 (0.54, 1.30) 
  28-85 -0.086 (0.224) -.38 0.92 (0.59, 1.4) 
  86-422 -0.299 (0.229) -1.29 0.74 (0.47, 1.17)] 
  ≥ 422 -0.245 (0.324) -.75 0.78 (0.41, 1.48) 
Note. NAFLD/CC recipients (n=2971), β =estimated coefficient of Cox PH model, 
SE=standard error, AHR=adjusted hazard ratio, CI=confidence intervals.  
* p<.05, **p<.001, ***p<.0001. 
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Figure 45. Scatterplot of NAFLD/CC donor risk score; (A) CHS, (B) distance from 
recipient residence to transplant center. 
 
Summary of Results 
In summary, the current study revealed that NAFLD/CC recipients of a liver 
transplant had different characteristics from recipients transplanted for other etiologies: 
they were sicker, as transplanted at a higher MELD score, older, and more obese, as 
having a higher BMI. The novel donor risk model tailored to this patient population is 
driven by four donor factors: insulin-dependent diabetes, DCD, height, and MDRD. 
Donor age did not have a strong impact on liver graft survival in the Cox PH model. 
However, in addition to the variables identified as strong predictors in the semiparametric 
model, the RSF selected donor age as a predictor of graft failure. An extended version of 
the intrinsic donor model, which included selected transplant and recipient factors, found 
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no association between donor age and 1-year graft survival in each MELD score 
category. Decreased CIT was associated with improved 1-year graft survival recipients 
with MELD score 15-24 but not for low MELD score (<15) or high MELD score (≥25). 
In addition to donor insulin-dependent diabetes, DCD, donor MDRD, donor/recipient 
size match, and recipient age had an impact on graft survival within 1-year post LT. 
NAFLD/CC recipients of LT had a higher probability of losing their graft within the first-
year post LT. The study also revealed that receiving a Public Health extended high-risk 
donor did not increase the risk of graft survival.  
 In the context of community health scores, a difference in graft failure was 
observed at the extremes; between recipients of LT who resided in low health risk 
counties (CHS<6) versus recipients who resided in high health risk communities 
(CHS>30). The impact of community health scores on graft failure within 1-year post LT 
was observed in both univariate and multivariable Cox PH models. Findings suggested 
that in addition to donor quality, the environment in which the patient resides had an 
impact on the risk of graft failure. Residing far from the transplant centers was not 
associated with an increased risk of graft failure. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
The epidemic increase in the incidence of NAFLD has led to an increase in the 
prevalence of liver disease from NAFLD progression compared to other liver etiologies 
(O’Leary et al., 2011; Pais et al., 2016). Consequently, NAFLD has become one of the 
leading indications for liver transplant. The incidence of NAFLD has been intimately tied 
to the components of metabolic syndrome. NAFLD patients who progress to cirrhosis or 
HCC, leading to the need of a liver transplant, have to face two major obstacles: (a) the 
presence of comorbidities and (b) a low MELD score due to better liver functioning, 
placing them on the bottom of the wait list. Therefore, many of them may die while being 
on the liver transplant wait list due to organ shortage and low priority (O’Leary et al., 
2011). Transplant centers are trying to increase the utilization of marginal donors to 
increase the donor pool. Donor risk models provide useful tools to help match marginal 
donors to the appropriate recipients.  
Interpretation of the Findings 
This study confirmed that NAFLD/CC patients have baseline characteristics 
different from other etiologies, which justifies the decision to develop donor risk models 
tailored for NAFLD/CC. Moreover, NAFLD/NASH recipients of LT had lower 1-year 
graft survival compared to other etiologies, reflecting their longer permanence on the 
wait list and comorbidities. The purpose of this retrospective study was to develop an 
intrinsic donor and an extended DQ-NAFLD score aimed at identifying the donor 
characteristics that can lead to poor posttransplant outcomes in this patient population. 
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The theoretical framework that guided this study was grounded in the socio-ecological 
model, which allowed me to explore the complex interplay among external 
environmental factors, expressed in terms of the county CHS and distance from the 
transplant center. Two sources of data, the SRTR database and the community health 
indicators, were adapted from the Robert Wood Johnson Foundation’s community health 
rankings, making it possible to explore different levels of the socio-ecological model in 
the development of donor risk models.  
The developed extended donor model improved only slightly the predictive 
accuracy but allowed the assessment of the additional impact of MELD score and CIT on 
posttransplant graft failure. Findings indicated that although the distance from the 
transplant center does not have an impact on post LT graft survival, the county where a 
patient resides has an impact. However, it is not clear whether the CHS is the appropriate 
metric to explain county discrepancies in health and socioeconomic risk.  
Public Health Service Increased Risk 
Increasing the donor pool by increasing the utilization of marginal donors can 
improve access to a scarce resource for NAFLD/CC candidate for LT. Potential organ 
donations at an increased risk for transmitting hepatitis B, hepatitis C, and human 
immunodeficiency virus are often discarded because the label associated to PHS 
increased risk organ carries a stigma that dramatically reduces the utilization of this organ 
source (Fleetwood, Lusciks, Poirier, Hertl, & Chan, 2016). However, the risk of 
transmitting disease in the era of nucleic acid testing is very low; still, patients are 
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reluctant to accepting PHS increased risk donors (Volk et al., 2017). This study 
demonstrated that the use of PHS increased risk donor livers did not alter significantly the 
risk of liver graft failure within 1-year post LT.  
Kaplan-Meier graft survival curves between recipients of non-PHS increased risk 
versus PHS increased risk overlapped, suggesting that some of the underutilized PHS 
increased risk donors could be used for NAFLD/CC patients and not discarded due to 
stigmatization. This result is aligned with the findings from a study conducted by Pruett, 
Clark, and Taranto (2017) that showed that posttransplant outcomes, including 1-year 
patient and graft survival as well as the risk of unexpected transmission of HIV, HBV, or 
HCV after deceased donor kidney transplantation, did not change with the status of PHS 
extended risk donors. The finding that donor livers with PHS extended risk denomination 
did not alter the probability of graft survival in NAFLD/CC patients may be used to 
support patients’ and physicians’ decision-making regarding the use of PHS increased 
risk livers. This finding can also be used to help patients gauge the potential risk of 
undetected HIV, HBV, or HCV infection transmission versus refusing an organ for 
transplant and prolonging the stay on the wait list.  
Intrinsic Donor DQ-NAFLD Model 
Donor risk models have been previously proposed to evaluate donor quality of 
deceased donor livers to assist in decision-making. Feng et al. (2006) developed the first 
donor risk index using data in the pre-MELD era. This was followed by other developed 
risk models to predict posttransplant graft survival using donor, recipient, and transplant 
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factors (Blok et al., 2015; Braat et al, 2012; Dutkowski et al., 2011; Halldorson et al., 
2009; Winter et al., 2018). These models have been used for risk stratification and 
validated in subsequent studies. However, none of these models is tailored for 
NAFLD/CC recipients of LT.  
The intrinsic DQ-NAFLD donor model was developed using post-MELD and 
post-Share 35 data, and only included donor factors available at the time of donor offer 
that summarized the likelihood of graft failure after LT. The model reflects current 
practice and is tailored for NAFLD/CC recipients of LT. The model is driven by DCD, 
donor diabetes, MDRD, and donor height. Donor age, not a significant predictor in the 
Cox PH model, was included in the model to adjust the results because of clinical 
relevance, and also because it was used in other donor risk models. Donor diabetes, as a 
surrogate of liver steatosis, was not taken into account in previous donor risk models, 
while kidney function (expressed by the MDRD) was recently included to develop a 
donor quality index using the French liver transplant registry (Winter et al., 2018).  
Macrosteatosis on donor biopsy, a known predictor of graft failure (de Graaf et 
al., 2012), was only available for 38% of donors who had biopsy data in SRTR. For this 
reason, macrosteatosis was not included in the multivariable donor risk models. The 
Kaplan-Meier curve shows a tendency of macrosteatosis donors with Stage M2 to have a 
worse but not statistically significant 1-year graft survival experience, compared to M0 
and M1 stages of macrosteatosis when transplanted to NAFLD/CC recipients.  
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The DQ-NAFLD score represents the relative risk of posttransplant liver graft 
failure from the use of a particular deceased donor, compared to the average donor set at 
reference values for categorical predictors and average values of continuous covariates. 
For example, a donor with an estimated DQ-NAFLD of 1.45 will have an estimated risk 
of liver graft failure of 45% higher than the average reference donor. Lower DQ-NAFLD 
values are associated with increased donor quality and longer graft survival. Intrinsic 
donor DQ-NAFLD classifies liver organs as high, medium, or low risk. The observation 
of transplant practices and outcomes with these organs in NAFLD/CC recipients based on 
these estimated risk classifications can help identify subsets of NAFLD/CC recipients 
across these risk categories who can still achieve excellent outcomes. This is a definite 
step forward for an optimal allocation of donor livers to NAFLD recipients.  
Impact of Transplant Factors  
Fukazawa et al. (2013) proposed using the ratio of donor to recipient BSA index 
to estimate size match, and found that both small-for-size and large-for-size liver graft 
extremes can increase the risk of graft failure post LT. In a single-center study on adult 
and pediatric patients, Akdur et al. (2015) found that large-for-size liver grafts can cause 
abdominal compartment syndrome leading to graft failure. The current study revealed 
that, in the context of NAFLD/CC recipients of LT, receiving a large-for-size donor had a 
higher likelihood of graft failure compared to a normal-for-size done in both univariate 
and multivariate analyses.  
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Extended DQ-NAFLD Model 
Among the candidate donor predictors considered, insulin-dependent diabetes, 
DCD, height, and MDRD were selected as stronger predictors of graft failure in the Cox 
PH model for the NAFLD/CC population. Additionally, donor age resulted as an 
important predictor of graft failure in the RSF model. With the addition of recipient and 
transplant factors, the extended version of the DQ-NAFLD improved only slightly the 
predictive ability of the model but allowed the prediction of the relative risk of a 
specified donor liver across different MELD score or different values of CIT.  
The extended donor model revealed that donor/recipient size match affected graft 
survival. In particular, recipient age and reception of a large-for-size donor led to 
worsening graft survival. In both donor risk models, NAFLD/CC recipients using elderly 
donors did not experience a worse 1-year graft survival, suggesting that matching elderly 
donors to recipients with NAFLD/CC may be safe. Long term effects of old donors 
transplanted in NAFLD/CC recipients on graft and patient survival and other 
posttransplant outcomes should be further investigated.  
Impact of Community Health Scores 
Factors such as socioeconomic status, individual behavior, education, 
environmental risks, social support, access to healthy food, and health care vary widely 
by region and counties. Under the lens of the socio-ecological system, there are complex 
social and environmental determinants that increase or decrease the risk of poor 
posttransplant outcomes. Ross et al. (2017) included the CHS adapted from the Robert 
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Wood Johnson Foundation’s community health rankings and found that disparities in 
health and economic conditions, and travel distance, had an impact on wait-list mortality.  
To address the impact of external factors in the social-ecological model, I used in 
this analysis the CHS, a county-level measure of community health resources and risk. 
CHS is a score derived from multiple aspects of community health factors, such as access 
to care, and social and environmental risk factors, such as: (a) years of potential life lost, 
(b) proportion of children with low birth weight, (c) proportion of adults with poor or fair 
reported health, (d) adults’ poor reported physical health days, (e) poor reported mental 
health days, (f) proportion of individuals reporting tobacco use, (g) adult obesity 
prevalence, (h) physical inactivity prevalence, (i) rate of preventable hospital stays, and 
(j) median annual household income. A cumulative score with a range from 0-40 was 
computed for each county (the county CHS), obtained by adding up scores from each of 
the 10 community health indices. Each county received a score of 0-4 based on quintile 
ranking (zero points if the county belonged to the 1st quintile for a particular index and 
one point for each subsequent quintile). NAFLD/CC recipients of LT who resided in high 
health risk counties with a CHS > 60 were more likely to lose their grafts within 1-year 
post LT compared to low health risk counties (p = .041) suggesting that the environment 
can play a role in post-transplant outcomes.  
Impact of Geographic Distance from Transplant Center 
Studies revealed that among patients eligible for a liver transplant, greater 
geographic distance from the transplant center was associated with a lower likelihood of 
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being listed or receiving a liver transplant (Goldberg et al., 2017). Although geographic 
distance has proven important on wait-list outcomes, this study has shown that greater 
geographic distance from the transplant centers was not associated with worsening 1-year 
graft survival post-transplant, suggesting that long-distance management of NAFLD/CC 
liver transplant recipients is not associated with worsening outcomes. However, the 
analysis was biased towards recipients that got transplanted. 
Limitations of the Study 
This study has several limitations that merit discussion. Retrospective nature of 
this quantitative study can only prove associations but not causation and can lead to 
confounding attributable to unobserved variables. The SRTR database I used in this study 
had a significant amount of missing data that were not analyzed. Donor biopsy was only 
present in 38% of cases; therefore, I did not include macrosteatosis in the multivariable 
models. This study revealed that donor insulin-dependent diabetes increased the 
likelihood of graft failure within 1-year post LT. Information about donor diabetes 
obtained from the donor next of kin might be inaccurate if the person interviewed had 
limited or erroneous information. The study was powered to develop multivariate donor 
risk models. 
Consecutive sampling selection of all patients that met the inclusion criteria 
reduced selection bias. Therefore, inferences from SRTR studies are likely to generalize 
across United States. However, the model is expected to present some threats to external 
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validity and unlikely to generalize with data from non-US transplant centers with 
different policies and procedures (Massie, Kucirka, & Segev, 2014).  
I calculated the distance from recipient residence to transplant center through zip 
code distances using the Haversine formula, which is the shortest distance between two 
points on the surface of a sphere, an approximation of the actual distance.  
 The aggregate nature of the community health factors can lead to model estimates 
that may be subject to ecologic bias. Moreover, at the county-level, the choropleth graph 
showed a county-based variation in liver graft survival. However, some counties had only 
a few study subjects, which can decrease the accuracy of the estimated graft survival by 
county. The small number of LT performed for NAFLD/CC recipients complicate the 
task of demonstrating that patients from disadvantaged counties all share the same 
elevated risk of poor outcomes making county rankings of transplant outcomes highly 
unstable. 
Many factors can impact post-transplant outcomes, and both DQ-NAFLD models 
developed herein do not capture all aspects. Therefore, even if the models have shown 
that some donor factors have a large or small impact, they can only be used to support 
decision making at the time of donor acceptance, as several many other factors will play a 
role as well. For example, even though the analyses showed that, in both Cox PH models 
used to develop the DQ-NAFLD scores, donor age did not impact graft survival, it does 
not imply that it is safe to transplant each elderly donor to NAFLD/CC recipients. The 
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analysis was biased towards elderly donors that got transplanted, as transplant centers can 
reject older donors for several reasons. 
Recommendations 
This current study found that donor age is not a strong predictor of 1-year graft 
survival and may be extended in the future to explore whether older donors can be safely 
used to transplant NAFLD/CC recipients. The rate of steatosis among the general 
population is increasing, leading to an increasing number of cadaveric donors with 
hepatic steatosis. The progression from steatosis to fibrosis, and ultimately, cirrhosis is 
quite slow. However, in the current donor pool with an increasing prevalence of 
metabolic syndrome, the impact of donor steatosis on NAFLD/CC recipients and the 
likelihood to result in long term recurrence of NAFLD or NASH, compared to other 
etiologies, should be explored further. 
The DQ-NAFLD, as well as other donor risk metrics, have been developed 
considering 1-year organ survival post-transplant. However, liver transplant recipients 
tend to gain weight within the first-year post LT. Therefore, some NAFLD/CC recipients 
of LT can develop recurrent NAFLD and NASH, and a smaller percentage can incur 
cirrhosis and require a re-transplant. Defining donor quality for NAFD/CC recipients of 
LT beyond 1-year graft survival but based on the recurrence of NAFLD in its progressive 
forms of NASH cirrhosis, can enhance the definition of donor quality and measure 
peculiar aspects of NAFLD/CC recipients. The SRTR database does not include post-LT 
complications needed to explore this aspect. However, data collected at the transplant 
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centers could be used to explore disease recurrence and the need for re-transplant in the 
short and long term 
County differences in post-transplant graft survival do exist as the choropleth map 
revealed. These disparities are driven only in part by county socioeconomic status or 
CHS. The county aspect could be analized as a shared frailty term in a Cox PH model 
with a random effect to represent any unexplained variation in graft survival across 
counties, excluding low volume counties from the analysis. Moreover, CHS resulted as 
an independent predictor of graft failure when categorized, but not when modeled as 
RCS. This instability and conflicting result show the need for further validation of CHS 
in other populations. Further exploration of alternative county metrics and patient-level 
socioeconomic factors could contribute to explain county variation if used in risk 
adjustment donor models. 
This study revealed that the use of PHS increased risk donors did not alter the 
probability of graft survival in NAFLD/CC patients. Different reasons can lead to the 
denomination of PHS extended risk donor, not all of them equally likely to increase the 
probability of undetected HIV, HBV, or HCV infection transmission. Therefore, further 
studies are needed to identify a subset of PHS increased risk donors that increase the risk 
of unintended transmission and graft failure. 
Implications 
 The changing patterns in indication for LT herein pointed to the development of a 
post-MELD era post Share 35 donor quality score tailored to NAFLD/CC recipients. DQ-
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NAFLD quantifies the quality of the liver graft by scoring the characteristics of the graft 
before LT. Therefore, it is a crucial factor for a better match between a liver graft and its 
recipient and can lead to a positive social change if used as a tool to assist both 
physicians and patients in the decision of graft usage.  
 The nomogram developed in this study using the DQ-NAFLD donor models, or a 
calculator created using the model estimates, can provide some information to patients 
and physicians of an expected outcome, which can be expressed in terms of expected 1-
year survival or as expected AHR for a specific donor matched to a particular recipient. 
Understanding and quantifying the impact of donor factors that do affect 
posttransplant graft survival, and donor factors that have minimal or no impact for this 
patient population, can contribute to freeing more donors to allocate to NAFLD/CC, who 
are at high risk of death while waiting for a liver. Moreover, understanding the impact of 
recipient factors, such as MELD, and transplant factors, such as CIT and donor/recipient 
size match, can help in achieving the ultimate goal of optimal donor/recipient matching. 
Conclusion 
Organ shortage leads to the utilization of non-optimal donors, and donor risk 
models provide a metric to quantify donor quality and help allocate non-optimal donors 
to appropriate recipients. However, many organs are discarded, some of which could be 
utilized with excellent results if adequately selected and matched to the appropriate LT 
candidates. Donor risk models provide the first step to match marginal donors to the 
appropriate recipients optimally. The creation and validation herein of DQ- NAFLD 
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donor risk models, tailored to NAFLD/CC recipients of LT, is a major step forward in the 
optimal utilization of a scarce resource for this patient population. NAFLD/CC is 
becoming one of the top indications for LT, but often NAFLD/CC candidates have low 
priority and high mortality on the wait list. The DQ-NAFLD score can contribute to 
NAFLD/CC LT candidates matched appropriately, who may die while on the wait list or 
may be removed because they are too sick to be transplanted. Moreover, understanding 
the impact of external geographic and community factors can help develop more accurate 
donor risk models adjusted for sociodemographic risk factors. Concerns remain that after 
adjusting for donor characteristics, posttransplant graft failure in NAFLD/CC recipients 
continues to be subjected to community disparities. 
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Appendix A: County Health Indicators 
County Health Indicators (CHI) are compiled annually using county-level 
measures from a variety of national and state data sources by the University of Wisconsin 
Population Health Institute and the Robert Wood Johnson Foundation. Since 2010, CHIs 
are available for almost all counties (over 30000 counties) and are used to compare 
county health status. The estimated CHI and their 95% CI are available for each county. 
Tables A1-A5 describe the CHSs by category: health outcomes, health behaviors, clinical 
care, social and economic factors, and physical environments. They indicate how each 
CHI is measured and the source of data and identify the selected group of indicators that 
will be used to develop the transplant community health score. 
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Table A1 
Community Health Indicators: Health Outcomes 
Focus 
Area 
CHI  
Measure 
Description Source Used in 
Transplant 
CHS 
Length of 
life  
Premature death Years of potential life lost before 
age 75 per 100,000 population (age-
adjusted) 
National Center for 
Health Statistics - 
Mortality files 
 
 
Yes 
Quality 
of life  
Poor or fair 
health 
Percentage of adults reporting fair 
or poor health (age-adjusted) 
Behavioral Risk Factor 
Surveillance System 
 
 
Yes 
Poor physical 
health days 
Average number of physically 
unhealthy days reported in past 30 
days (age-adjusted) 
Behavioral Risk Factor 
Surveillance System 
 
 
Yes 
Poor mental 
health days 
Average number of mentally 
unhealthy days reported in past 30 
days (age-adjusted) 
Behavioral Risk Factor 
Surveillance System 
 
 
Yes 
Low birthweight Percentage of live births with low 
birthweight (< 2500 grams) 
National Center for 
Health Statistics - 
Natality files 
 
 
Yes 
Notes: CHI: County health index; CHS: community health score.  
Source: http://www.countyhealthrankings.org/  
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Table A2 
Community Health Indicators: Health Behaviors 
Focus Area CHI  
Measure 
Description Source Used in 
Transplant 
CHS 
Tobacco 
use  
Adult smoking Percentage of adults who are 
current smokers 
Behavioral Risk Factor 
Surveillance System 
 
 
Yes 
Diet and 
exercise  
Adult obesity Percentage of adults that report a 
BMI of 30 or more 
 
 
CDC Diabetes Interactive 
Atlas 
 
Yes 
Food environment 
index 
Index of factors that contribute to 
a healthy food environment, 0 
(worst) to 10 (best) 
 
 
USDA Food  
Environment Atlas, Map 
the Meal Gap  
 
No 
Physical inactivity Percentage of adults aged 20 and 
over reporting no leisure-time 
physical activity 
CDC Diabetes Interactive 
Atlas 
Yes 
Access to exercise 
opportunities 
Percentage of population with 
adequate access to locations for 
physical activity 
Business Analyst, Delorme 
map data, ESRI, & US 
Census Tigerline Files 
 
 
No 
Alcohol 
and drug 
use  
Excessive 
drinking 
Percentage of adults reporting 
binge or heavy drinking 
Behavioral Risk Factor 
Surveillance System 
 
 
No 
Alcohol-impaired 
driving deaths 
Percentage of driving deaths with 
alcohol involvement 
Fatality Analysis 
Reporting System 
 
 
No 
Sexual 
activity  
Sexually 
transmitted 
infections 
Number of newly diagnosed 
chlamydia cases per 100,000 
population 
National Center for 
HIV/AIDS, Viral 
Hepatitis, STD, and TB 
Prevention 
 
 
No 
Teen births Teen birth rate per 1,000 female 
population, ages 15-19 
National Center for Health 
Statistics - Natality files 
 
No 
Notes: CHI: County health index; CHS: community health score.  
Source: http://www.countyhealthrankings.org/ 
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Table A3 
Community Health Indicators: Clinical Care 
Focus 
area 
CHI  
measure 
Description Source Used in 
transplant 
CHS 
Access to 
care  
Uninsured Percentage of population under age 65 
without health insurance 
Small area health 
insurance estimates 
 
 
No 
Primary care 
physicians 
Ratio of population to primary care 
physicians 
Area health resource 
file/American Medical 
Association 
 
 
No 
Dentists Ratio of population to dentists Area Health Resource 
file/national provider 
identification file 
 
 
No 
Mental health 
providers 
Ratio of population to mental health 
providers 
CMS, national provider 
Identification file 
 
 
No 
Quality of 
care  
Preventable 
hospital stays 
Number of hospital stays for 
ambulatory-care sensitive conditions 
per 1,000 Medicare enrollees 
 
 
Dartmouth Atlas of 
Health Care 
Yes 
Diabetes 
monitoring 
Percentage of diabetic Medicare 
enrollees ages 65-75 that receive 
HbA1c monitoring 
 
 
Dartmouth Atlas of 
Health Care 
No 
Mammography 
screening 
Percentage of female Medicare 
enrollees ages 67-69 that receive 
mammography screening 
Dartmouth Atlas of 
Health Care 
No 
Notes: CHI: County health index; CHS: community health score.  
Source: http://www.countyhealthrankings.org/  
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Table A4 
Community Health Indicators: Social and Economic Factors 
Focus Area CHI  
Measure 
Description Source Used in 
transplant 
CHS 
Education  High school 
graduation 
Percentage of ninth-grade cohort 
that graduates in four years 
 
 
EDFacts No 
Some college Percentage of adults ages 25-44 
years with some post-secondary 
education 
 
American 
Community Survey 
No 
Employment  Unemployment Percentage of population ages 16 
and older unemployed but seeking 
work 
Bureau of Labor 
Statistics 
 
 
No 
Income  Children in 
poverty 
Percentage of children under age 18 
in poverty 
Small Area Income 
and Poverty 
Estimates 
 
 
No 
  Income 
inequality 
Ratio of household income at the 
80th percentile to income at the 20th 
percentile 
 
 
American 
Community Survey 
Yes 
Family and 
social 
support  
Children in 
single-parent 
households 
 
Percentage of children that live in a 
household headed by single parent 
American 
Community Survey 
No 
 
Social 
associations 
 
Number of membership associations 
per 10,000 population 
 
County Business 
Patterns 
 
No 
 
Community 
safety  
 
Violent crime 
 
Number of reported violent crime 
offenses per 100,000 population 
 
 
Uniform Crime 
Reporting - FBI 
 
No 
Injury deaths Number of deaths due to injury per 
100,000 population 
CDC WONDER 
mortality data 
No 
Notes: CHI: County health index; CHS: community health score.  
Source: http://www.countyhealthrankings.org/ 
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Appendix B: Donor Screening for Disease Transmission 
Donor Screening 
OPTN policy requires donor screening to determine if the potential donor has an 
infection that could be transmitted to recipients through the transplanted organ. All 
donors are screened for human immunodeficiency (HIV), hepatitis B (HBV), hepatitis C 
(HCV), syphilis, cytomegalovirus (CMV) and Epstein Barr viruses (EBV). Serological 
tests can screen donors who developed HIV, HBV, or HCV several months before organ 
donation. Federal law only prohibits the transplantation of HIV infected donors. Donor 
shortage and medical advances in treating viral infections lead to the utilization of organ 
with HCV and HBV infections. HBV and HCV-infected donors are typically offered to 
patients known to have the same infections, or to uninfected patients in urgent need for a 
transplant. 
CDC High Risk and PHS Increased Risk Donors 
OPTN policy also requires a medical and social history interview conducted with 
the deceased donor’s close family members to assess potential donor social behaviors and 
past medical history. This information is used to identify at-risk of transmitting HIV, 
HBV, or HCV to transplant recipients. High or increased risk refers to a set of donor 
behaviors that can increase the risk of transmission, as described in Table B1. 
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Table B1 
CDC High-Risk and PHS Increased-Risk Donors 
CDC High Risk (1994) PHS Increased Risk (2013) 
MSM in the preceding 5 years  
 
MSM in the preceding 12 months  
Non-medical injection drug use in preceding 5 
years  
 
Non-medical injection drug use in preceding 12 months  
Sex in exchange for money/drugs in preceding 5 
years  
 
People who have had sex in exchange for money or drugs 
in the preceding 12 months  
Known or suspected to have HIV infection in the 
preceding 12 months  
People who have had sex with a person known or 
suspected to have HIV, HBV, or HCV infection in the 
preceding 12 months  
Women who have had sex with a man with a 
history of MSM behavior in the preceding 12 
months  
 
Women who have had sex with a man with a history of 
MSM behavior in the preceding 12 months  
People who have had sex with a person who had 
sex in exchange for money or drugs in the 
preceding 12 months  
 
People who have had sex with a person who had sex in 
exchange for money or drugs in the preceding 12 months  
People who have had sex with a person who 
injected drugs by intravenous, intramuscular, or 
subcutaneous route for nonmedical reasons in the 
preceding 12 months  
 
People who have had sex with a person who injected drugs 
by intravenous, intramuscular, or subcutaneous route for 
nonmedical reasons in the preceding 12 months  
A child who is ≤18 months of age and born to a 
mother known to be infected with, or at increased 
risk for HIV infection (should not be used)  
 
A child who is ≤18 months of age and born to a mother 
known to be infected with, or at increased risk for HIV, 
HBV, or HCV infection  
A child who has been breastfed in the past 12 
months by a mother known to have or at risk for 
HIV infection  
A child who has been breastfed within the preceding 12 
months and the mother is known to be infected with, or at 
increased risk for, HIV infection  
 
Inmates of correctional systems  People who have been in lockup, jail, prison, or a juvenile 
correctional facility for more than 72 consecutive hours in 
the preceding 12 months  
 
Persons who cannot be tested for HIV infection 
because of refusal, inadequate blood samples 
(e.g. hemodilution that could result in false-
negative tests), or any other reasons  
When a deceased potential organ donor’s blood specimen 
is hemodiluted, the donor should be considered at 
increased risk for HIV, HBV, and HCV infection because 
the donor’s risk for infection is unknown  
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In 1994, the Centers for Disease Control (CDC) developed guidelines for high-
risk behaviors to designate donors with an increased risk of transmitting HIV. In 2013 the 
CDC high-risk criteria were extended to include the screening of HBV and HCV in 
addition to HIV, and the U.S. PHS increased risk criteria was developed. PHS increased 
risk guidelines replaced the CDC high-risk guidelines.  
The Nucleic Acid Testing (NAT), which has a much shorter window that 
serological tests, is required to screen these high-risk donors. The aim of the CDC high-
risk and later of PHP increased risk designation was to inform candidates on the potential 
risk of HIV, HBV and HCV transmission from high-risk donors, recently infected, who 
tested negative on serologic testing or NAT but still potentially capable of transmitting 
these viral infections due to the window period between infection and seroconversion. 
PHP increased risk does not translate into donor quality. However, because of the 
designation, many of these organs are rejected with the perception that they can lead to 
poor survival. Acceptance practices vary by transplant program. Moreover, not all 
increase-risk donors have the same likelihood to transmit disease, but there is a wide 
variation: incarceration or sexual behaviors carry a much lower risk than intravenous 
drug use. However, because the risk of donor-derived HIV, HBV, or HCV transmission 
from a NAT negative donor is lower than 1%, often the risk of rejecting risk donors may 
be greater than the risk of accepting them.  
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Appendix C: Graphical Exploratory Analysis 
Variable Distributions of Categorical Variables  
Bar graphs visualize the frequency distribution of categorical variables and 
quantify the values within the categories of each variable to identify categories more 
frequents. (Describe). A review of the variable distributions revealed that only eight 
donors (or 0.2%) were HCV positive, and only two donors (or .06 %) were HBV Ag 
positive. Therefore, HCV and HBV were not considered in modeling and subsequent 
analyses because of the lack of predictive ability.  
 
Figure C1. Bar chars of donor gender, diabetes, hypertension, hypernatremia. 
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Figure C2. Bar chars of donor HCV, HBsAG, cause of death and DCD.
 
Figure C3. Bar chars of donor macrovascular steatosis, microvascular steatosis, recipient 
gender and ABO compatibility. 
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Distribution of Continuous Variables and Outlier Detection 
The distribution of continuous variables was depicted using histograms with 
density and boxplots, to examine the shape of the distribution and detect the presence of 
outliers. 
 
Figure C4. Histograms with density and boxplots o donor height and weight  
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Figure C5. Histograms with density and boxplots o donor BMI and BSA 
 
Figure C6. Histograms with density and boxplots of donor age and MDRD. 
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Figure C7. Histograms with density and boxplots of recipient BMI and age  
 
 
 
Figure C8. Histograms with density and boxplots of MELD score and cold ischemia 
time. 
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Figure C9. Histograms with density and boxplots of distance to transplant center and 
community health indicators. 
 
 
 
